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Abstract 
Background: Venous thromboembolism (VTE) in one of the leading causes of 
maternal morbidity and mortality in high income countries. However there is 
a surprising shortage of evidence which allows us to accurately predict which 
women are at high risk which has hindered prevention to date. Therefore the 
aim of this thesis is to measure the occurrence of and risk factors for VTE 
during the antepartum and postpartum periods. 
Methods: Electronic health records from women of childbearing age (15-44 
years) were identified from two separate databases; The Health Improvement 
Network (THIN) between 1995 and 2009 and the Clinical Practice Research 
Datalink (CPRD) linked to Hospital Episode Statistics (HES) between 1997 and 
2010. Five separate studies were then carried out to study the incidence and 
risk factors for VTE during antepartum and postpartum periods. In studies 1 
and 2 I used the THIN database to assess the Incidence of and risk factors for 
VTE during antepartum and postpartum periods separately. Studies 3, 4 and 
5 incorporated the CPRD-HES linked data which enabled me to get better 
ascertainment of VTE and its potential risk factors. Using these data I 
externally validated my VTE definition which was followed by investigating the 
impact of non-delivery related hospitalisations on the incidence of antepartum 
VTE. I also examined the risk factors for postpartum VTE using a conceptual 
hierarchical analysis approach along with their Impact on the timing of VTE 
during specific periods of postpartum. All results were presented in the form 
of absolute rates (AR) per 100,000 person-years and Incidence rate ratios 
(IRR) were calculated using Polsson regression with adjustment for relevant 
covariates. 
Results: In THIN, there were a total of 1.7 million women of which 280,451 
experienced 376,154 pregnancies resulting in live or stillbirths whereas the 
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CPRD-HES linked data contained information on over 240,000 pregnancies 
among 204,929 women. Overall VTE rates were highest in the first few weeks 
postpartum. Women in their third trimester of antepartum were at a 5 foid 
increased risk of first VTE compared to their time outside pregnancy whereas 
in the first and second trimesters this rate was only marginally higher. 
However the use of CPRD-HES linked database gave me estimates of VTE risk 
with better precision in and around pregnancy that were comparable to the 
existing literature. For my risk factor analysis I found that the strongest risk 
factor for VTE during the antepartum period was hospitalisation corresponding 
to a 17-fold increase (IRR=17.7 95%CI=7.7-39.6) compared to time outside 
hospital. The rate of VTE was also high during the 28 days post-discharge 
(IRR=5.9; 95%CI=3.5-10.0; AR=646). These factors were not confounded by 
pregnancy related characteristics and complications, pre-existing medical co-
morbiditles or demographic or life style related characteristics.! also found 
that postpartum, women whose pregnancies resulted in stillbirth were at a 6-
fold (IRR=6;" 95%CI 3.17-14.6; AR=2570) increased risk of VTE. Those with 
caesarean delivery (elective or emergency), pre-term birth or postpartum 
haemorrhage had a 2-fold or higher risk of postpartum VTE compared to their 
respective baseline (AR>600/100,000 person-years). These findings were 
consistent across both the THIN and CPRD-HES linked data bases with respect 
women's risk factors for VTE. Finally the risk of VTE remains conSistently high 
up to first six weeks postpartum (>700/100,000 person-years) for 
pregnancies of women complicated with BMI>30kg/m 2 or caesarean delivery 
whereas risk of VTE was only high in the first three weeks postpartum 
(>1300/100,000 person-years) In those with pre-term birth or postpartum 
haemorrhage. 
Conclusion: I have provided some of the most precise estimates of absolute 
rates of VTE In and around pregnancy for better understanding of risks. The 
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overall rate of antepartum VTE is substantially increased during non-delivery 
related hospitalisations and this increase is sustained in the 28 days post-
discharge. Postpartum, delivery associated characteristics and complications 
including, stillbirth, caesarean delivery, BMI>30Kg/m2 postpartum 
haemorrhage are important risk factors for VTE particularly during the first 
three weeks postpartum. My analysis provides valuable information to 
clinicians for better decision making in terms of identifying high risk pregnant 
and postpartum women who may require some form of thromboprophylaxis 
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1 Introduction 
1.1 Introduction to venous thromboembolism 
Thromboembolism is a detached intravascular mass mainly originating from 
some part of the detached thrombus that gets dislodged in the general 
circulation subsequently obstructing the blood flow in the vessels causing 
tissue and organ damage1• Deep vein thrombosis (DVT) and pulmonary 
embolism (PE) are the two main clinical manifestations of venous 
thromboembolism (VTE). It is estimated that VTE is responsible for 100,0002 
and 25,0003 annual deaths in United States and United Kingdom respectively 
many of which are potentially preventable. Data from primary care in the UK 
suggests that the short term mortality associated with DVT is 1.4% which 
increases to 23% when manifested as PE.4 Sudden death, heart failure or 
cardiovascular collapse may occur if more than 60% of the pulmonary 
circulation is obstructed. 1 While PE is more likely to be fatal than DVT, 
treatment for both conditions is quite similar.s The risk factors for VTE have 
been well documented in the general population (Table 1-1).6 For instance, 
those patients who undergo hip or knee replacement surgery or suffer a 
spinal cord Injury or any major trauma are more than 10 times more likely to 
develop VTE following surgery/Injury. For young women, pregnancy Is also 
considered to be a higher risk period for VTE. For Instance, the antepartum 
period Is considered to be a weak risk period for VTE (odds ratlo<2, compared 
to .non-pregnant women), whereas the postpartum period Is considered a 
moderate risk period (odds ratio 2-9). However, the evidence on which these 
estimates are based dates back to 1988 when diagnostic modalities were less 
prevalent potentially leading to underestimation VTE Incidence In general and 
in pregnancy. Additionally many previous studies only looked at fatal VTE 
(mainly PE) thus overlooking non-fatal DVT which is more frequent during 
pregnancy and is aSSOCiated with considerable morbidity. 
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Table 1-1: Risk factors for venous thromboembolisms as categorised 
by Anderson et al6 
Strong risk factors (odds ratio>10) 
Fracture (hip or leg) 
Hip or knee replacement 
Major general surgery 
Major trauma 
Spinal cord injury 
Moderate risk factor (odds ratio 2 - 9) 
Arthroscopic knee surgery 
Central venous lines 
Chemotherapy 
Congestive heart or respiratory failure 
Hormone replacement therapy 
Malignancy 
Oral contraceptive therapy 
Paralytic stroke 
Pregnancy/postpartum 
Previous venous thromboembolism 
Thrombophilia 
Weak risk factor (odds ratio <2) 
Bed rest 3 days 
Immobility due to sitting 
Increasing age 
Laparoscoplc surgery 
Obesity 
Pregnancy/ antepartum 
Varicose veins 
1.2 VTE in pregnancy: The medical burden 
Venous thromboembolism In one of the leading causes of maternal mortality 
In most developed countries causing around 1.17 deaths in the USA and 0.7 
deaths8 In the UK per 100,000 pregnancies. Whilst, the Centre for maternal 
and Child Enquiries (CMACE) report highlighted that annual maternal deaths 
from PE have significantly decreased from 33 (between 2003 and 2005) to 16 
(between 2006 and 2008)8 in the UK, the considerable morbidity associated 
with non-fatal VTE should not be overlooked. Overall previous evidence 
suggests that VTE occurs in 1-3 per 1000 full term pregnancies9• 10 with case 
fatality of 1.7-3% and 0.2% for PE and DVT respectively,11. 12 The reason 
behind the increased risk of VTE in pregnancy was described more than a 
century ago In the form of Virchow's trlad13 which describes the three main 
26 
factors which pre-dispose to thrombosis, namely a change in blood 
composition, venous stasis and changes in blood vessel structure. Pregnancy 
is associated with all of those factors starting from the alteration in clotting 
factors especially factor V and VIII. In some cases resistance to proteins C 
and S may also develop. Secondly, progesterone mediated venous stasis 
begins in early pregnancy and peaks during the 36th week of gestation. 
Thirdly, blood vessels are prone to get damaged during vaginal or caesarean 
delivery which can further increase the risk. 
1.3 Diagnosis of VTE in pregnancy 
Clinical assessment and diagnosis of VTE can be challenging as many of the 
signs and symptoms including leg oedema, dyspnoea and tachycardia of VTE 
often resemble to those of a normal pregnancy. 5 The incidence of isolated 
DVT Is more common In pregnancy which further complicates its diagnosis as 
it can mostly present as back and abdominal pain with or without oedema of 
the lower Iimbs. 5• 14 For DVT, the diagnostic gold standard historically has 
been contrast venography which was an invasive procedure and has now 
been replaced by ultrasonography. For suspected DVT, Doppler ultrasound is 
the preferred mode of investigation with 94% speciflclty and 97% 
sensitivity. 5. 15 For pulmonary embolism, a chest x-ray Is often non-conclusive 
and may pOint towards other potential causes of hypoxia and breathlessness. 
Depending on hospital policy and x-ray findings, various imaging techniques 
may be employed including CT pulmonary angiogram, echocardlogram and 
MRI each of which has varying degree of accuracy and exposure to radiatlon. 5 
These have largely replaced other tests such as the ventilatlon-perfuslon scan 
and Invasive pulmonary angiography which were previously used for PE 
diagnosis. 
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1.4 Treatment of VTE during pregnancy 
According to the Royal College of Obstetricians and Gynaecologists (RCOG)16 
guidelines on acute management of thrombosis, Low Molecular Weight 
Heparin (LMWH) is considered as the treatment of choice for management 
due to its proven safety and efficacy in pregnancy. In clinically suspected DVT 
or PE, treatment with LMWH should be initiated until the diagnosis is excluded 
by objective means, unless strongly contraindicated. For treatment of VTE 
during pregnancy, LMWH should be administered subcutaneously twice a day. 
'The dose should be titrated against the woman's weight. Due to the adverse 
effect on the foetus, the use of oral anticoagulants (eg. warfarin) is 
contraindicated during pregnancy. Therapeutic anticoagulant therapy should 
be continued for the remainder of the pregnancy and for at least 6 weeks 
postpartum until at least 3 months of treatment has been given in total. 
Women should be offered a choice of LMWH or oral anticoagulant for 
postnatal therapy after discussion about the need for regular blood tests for 
monitoring of warfarin, particularly during the first 10 days of treatment. 
Neither heparin nor warfarin is contraindicated in breast feeding therefore 
women may be converted from LMWH to warfaln 5-7 days after delivery. 
1.5 Thromboprophylaxis 
1.5.1 UK's thromboprophylaxis guideline In pregnancy and its impact 
on maternal mortality: The last 60 years 
The UK's thromboprophylaxis guidelines and its Impact on maternal mortality 
is summarised by Drife17 and the CMACE reports8, 18,19 (Table 1-2). The first 
advance in preventing deaths from venous thromboembolism in pregnant 
women was in the early 1960s when the Importance of early mobilization 
after normal delivery was recognized leading to the abolishment of enforced 
bed rest after childbirth. The use of anticoagulants was very poor at that 
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time and was considered as a matter of clinical judgement. For Instance only 
12 (9%) of the overall 129 deaths which occurred due to PE between 1961 
and 1963 were among women who received any form of anticoagulation. 
Overall deaths from pulmonary embolism have declined significantly between 
1952 and 1975 (from 138 to 38 maternal deaths) probably reflecting better 
case management and diagnostic procedures. After that time it was realised 
that risk factors (such as obesity, advanced maternal age and parity) play an 
Important role particularly In women who were put on bed rest during or after 
pregnancy due to existing co-morbidities and who underwent operative 
procedures. There was a further reduction in the overall deaths from PE 
between 1979 and 1981 (28 maternal deaths) which could reflect greater 
awareness of thromboembolism In pregnancy and wider use of anticoagulants 
In general. Furthermore the concept of thromboprophylaxis also emerged In 
those with a previous known history of deep vein thrombosis or pulmonary 
embolism. 
After 1991 VTE deaths preceding caesarean section became a major concern 
which led to the publication of R.oyal College of Obstetrician and 
Gynaecologists (RCOG) guidelines of thromboprophylaxis for operative 
procedures in 1995. The guidelines for the first time gave a clear risk 
assessment profile for thromboembolism in caesarean section which was 
based on stratifying risk groups as low, moderate and high based on certain 
factors. Furthermore, It also gave recommendations for thromboprophyJaxls 
during the antepartum and postpartum periods In those with a history for 
thromboembolism. However the guidelines were constrained to caesarean 
section and did not give recommendations for prophylaxis after vaginal 
delivery. This may have resulted In decreased mortality after caesarean 
section from 15 (1994-96) to 4 (1997-99) whereas death from VTE after 
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vaginal delivery remained constant during that time (10 maternal deaths). 
Deaths due to VTE once again increased between 2003 and 2005 with the rise 
in both antepartum and postpartum deaths which increased focus towards the 
publication of the RCOG's20 first comprehensive guidelines on 
thromboprophylaxis during pregnancy, labour and after vaginal delivery in 
2004. The guidelines not only recommended antepartum and postpartum 
thromboprophylaxis for women with previous thromboembolic disorders but 
also incorporated risk factors to identify the highest risk women for whom 
anticoagulants were recommended. They advised that all women should 
undergo routine assessment for thromboembolic disease ideally before or in 
early pregnancy and that antenatal anticoagulation should begin as soon as 
possible where required. A notable and statistically significant decrease in 
mortality from thromboembolism occurred between 2006 and 2008 when 
compared with the previous three-year period (2003-5) with venous 
thromboembolism being no longer the leading cause of maternal mortality in 
the most recent CMACE report.s This suggests that mortality associated with 
VTE can be prevented with better understanding of its risk factors and 
targeting of prophylaxis. However currently there is no evidence evaluating 
the overall incidence of VTE during the antepartum and postpartum periods 
before and after publication of RCOG guidelines for thromboprophylaxls. 
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Table 1-2: Maternal deaths and the use of anticoagulant for 
thromboprophylaxis in past 60 years. 
Year 
1952 
Maternal deaths'o 
Total VTE deaths: 138 
Antepartum death: 4 
Vaginal delivery deaths: 104 
C-sectlon deaths: 30 
1961 Total VTE deaths: 129 
Antepartum death : 36 
Vaginal delivery deaths: 66 
Interventions to reduce VTE associated deaths 
1963 Concept of early ambulation after delivery developed 
however the use of anticoagulant was still regarded as a 
matter of clinical judgement. No guideline or 
recommendation existed for the use of anticoagulants 
for thromboprophylaxis 
1973 Total VTE deaths: 38 
15 women were obese 
20% were on oestrogen 
1975 Risk factors such as age, parity and operative 
procedures were recognised as risk factors for VTE. No 
guideline or recommendation existed for the use of 
anticoagulants for thromboprophylaxiS 
1979 Total VTE deaths: 28 
1981 ROCG recommendation for thromboprophylaxis for those 
with previously proven DVT or PE 
1991 Total VTE deaths: 30 
Antepartum deaths: 12 
Vaginal delivery death: 13 
C-sectlon death: 4 
1993 
1996 
1999 
2002 
Total VTE deaths: 46 
Antepartum deaths: 15 
Vaginal delivery death: 10 
C-sectlon death: 15 
Total VTE deaths: 31 
Antepartum deaths: 13 
Vaginal delivery death: 10 
C-sectlon death: 4 
Total VTE deaths: 25 
Antepartum deaths: 4 
Vaginal delivery death: 7 
C-sectlon death: 9 
Total VTE deaths: 33 
Antepartum deaths: 11 
Vaginal delivery death: 8 
C-sectlon death: 7 
2005 Total VTE deaths: 16 
Antepartum deaths: 3 
Vaginal delivery death: 2 
C-sectlon death: 6 
Publication of RCOG recommendation of risk assessment 
and thromboprophylaxls In gynaecology and obstetrics. 
Only applied to C-sectlon and not to vaginal delivery 
The RCOG recommendations were publicised and the 
need for national guidelines on thromboprophylaxls after 
normal delivery were Identified 
The RCOG fIrst comprehensive guideline on the 
management of thromboembolic disease in pregnancy 
and puerperium (2001) 
The RCOG first comprehensive guideline on 
thromboprophylaxls during pregnancy, labour and after 
vaginal delivery (2004) 
2008 Updated RCOG guideline on thromboprophylaxls during 
pregnancy, labour and after vaginal delivery (2009) 
*Maternal deaths are derived from CMACE reports 
<>Stratlfied maternal deaths may not sum up to total maternal deaths as deaths associated with 
miscarriages/terminations were excluded or If the Information on deaths by antepartum and 
postpartum was not provided. 
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1.5.2 Thromboprophylaxis guidelines today 
In 2004 the first comprehensive guidelines20 issued by the RCOG on 
thromboprophylaxis during pregnancy and the postpartum were introduced 
which were updated in 2009 (Figure 1-1 and Figure 1-2). The guidelines 
suggest that the need for thromboprophylaxis should be assessed with 
regards to antepartum and postpartum separately and categorized pregnant 
and postpartum women as high, intermediate or low risk based on certain 
clinical risk factors. These guidelines recommend prophylaxis with low 
molecular weight heparin, for at least 6 weeks postpartum in the highest risk 
women and for 7 days in a much larger proportion of women considered to be 
at intermediate risk (those with 3 or more risk factors). Although a lower 
proportion of women will be considered at risk during the antepartum period 
(those with 2 or more risk factors or 3 if admitted to hospital) which may 
account for about 3-8% (for PE) of the total pregnant women ll, the advice for 
those who are at risk is to initiate thromboprophylaxis as early in pregnancy 
as practical and to continue throughout pregnancy.21 
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Figure 1-1: Current risk assessment and management of VTE in 
antenatal period 21 
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Figure 1-2: Current risk assessment and management of VTE during 
antenatal and postnatal period2 1 
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1.6 Agents used for thromboprophylaxis 
1.6.1 Low molecular weight heparin 
Despite the scarcity of supportive data from randomised controlled trials or 
large prospective observational studies, low molecular weight heparin (LMWH) 
is now commonly used for thromboprophylaxis during pregnancy instead of 
unfractionated heparin. 22 This change in practice is particularly based on large 
trials conducted in the non-pregnant population. It is considered as effective23 
as unfractionated heparin but more safe. For instance a systematic review by 
Sinson et al,24 evaluated the use of LMWH during pregnancy and reported a 
2.7% occurrence of minor bleed and no major haemorrhage episodes 
aSSOCiated with LMWH use. Another similar systematic review25 of 2,777 
pregnancies reported no episodes of heparin induced thrombocytopenia and a 
low Incidence of osteoporotic fractures (0.04%) and allergic skin reactions 
(1.8%). The study also reported the risk of major haemorrhage to be 2% 
which was primarily related to obstetric causes that could not be attributed to 
LMWH use. 
1.6.2 Unfractlonated heparin 
Unfractlonated heparin (UFH) Is used for both prevention and treatment of 
venous thromboembolism and has a shorter half-life than LMWH.22 It may be 
occaSionally be used during the time around delivery in cases where there is 
very high risk of thrombosis and when there Is reluctance to use LMWH 
(regional anaesthesla).21 The risk of major bleeding associated with the use of 
UFH among pregnant women is documented to be 2%. Compared to LMWH, 
the risk of heparin induced thrombocytopenia (HIT) is higher In those who 
receive UFH (0 versus 3%).26 Long term use of UFH has a/so been linked to 
Increased risk of osteoporosis and fracture. For Instance, previous studies 
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have highlighted vertebral fracture occurs in 2-3% of those receiving long 
term UFH therapy with a significant bone density reduction reported in up to 
30% of women.22, 27, 28 
1.6.3 Warfarin 
Warfarin use during pregnancy is only limited to the cases where the use of 
heparin is not suitable such as pregnant women with mechanical heart valves. 
This is due to the fact that warfarin crosses the placenta and has teratogenic 
potential. There is evidence of higher risk of complication associated with 
warfarin use including spontaneous miscarriages, stillbirths, maternal 
haemorrhage and congenital malformation. 21 
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1.7 Literature search 
Sections 1.8 to 1.12 provide a comprehensive overview of the current 
literature on Incidence of VTE and risk factors in and around pregnancy. In 
order to identify previous studies describing the incidence of VTE In and 
around pregnancy, I carried out a systematic literature review. I searched 
Medline and Embase for the period January 1960 to January 2013 to identify 
observational studies which estimated the rate of VTE among pregnant and 
puerperal women. Search terms to identify studies and those relating to VTE 
were adapted from a previous systematic review on the incidence of VTE in 
people with cancer29 These were combined with an adapted version of the 
Cochrane Pregnancy Group search strategy to identify studies relating to 
pregnancy.3D The final Medllne and Embase search terms are presented in 
Appendix 1 and Appendix 2 respectively (full results from a systematic review 
and meta-analysis of these studies are contained within chapter 4). A 
separate search strategy was carried out using the Medline database to 
Identify studies focussing on risk factors of VTE during pregnancy using terms 
such as "pregnancy", "risk factors" and "venous thromboembolism" between 
1960 and 2013. 
1.8 Incidence of VTE in and around pregnancy 
The Incidence of VTE in and around pregnancy varies considerably in the 
existing literature. Reported rates vary from 28 to 86 per 100,000 
pregnancies in the antepartum and 28-128 per 100,000 pregnancies in the 
postpartum period. The estimates from those studies are summarised In 
Table 1-3. These data also support the belief that VTE risk is highest around 
delivery and in the first two weeks postpartum.31-33 There is greater 
controversy surrounding the period of greatest antenatal risk with some 
studies reporting the highest risk In the first trimesters,34. 35 others have 
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reported an increased risk confined to the second and third trimester and a 
further study reporting a bimodal distribution where risks were highest in the 
first and third trimesters. 32 The wide variation in the estimates might be due 
to differences in the study designs and populations studied. Some limitations 
of previous studies are presented below: 
1.8.1 Use of number of pregnancies as the denominator 
Most studies have used number of pregnancies as the denominator when 
calculating the incidence rate instead of person-years. This approach does not 
take into account the difference in antepartum versus postpartum duration 
thus, making the risks in those respective periods non comparable. 
Theoretically, if we assume VTE effects 1 in every 1000 women during 
pregnancy and 1 In every 1000 women postpartum, periods which last for 
280 and 42 days respectively (as most studies assess up to six weeks 
postpartum), then this equates to a VTE rate of 133 per 100,000 person-
years during the antepartum and 800 per 100,000 person-years during the 
postpartum. Therefore assuming that the overall number of events was the 
same In both periods, the risk of VTE per unit of time would be much higher 
In the postpartum and using pregnancies as baseline does not capture this. 
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Table 1-3: Incidence of VTE in and around pregnancy per 100,000 pregnancies* presented in previous studies in order of publication 
Author Country Study Study design and methodology Number of Overall VTE Antepartum/postpartum Trimester 
period 
Sultan36 United Kingdom 1984-2004 
Vikrus37 Denmark 1995-2005 
O ' C o n n o o 8 8 United States 2003-2008 
liU12 Canada 1991-2006 
Jacobsen32 Norway 1990-2003 
Population based retrospective cohort. 
VTE cases were identified using primary 
care data validated by ev idence of 
anticoagulation 
Population based retrospective cohort. 
Pregnancies 
(birth outcome)* 
207,327 
(l ive birth only) 
819,751 
Cases were identified from a national (l ive birth, stillbirth 
patient reg istry using lCD-1O codes. VTE 
diagnoses in this reg istry have been 
previously val idated against medical 
records 
Cross sectional study. Cases were 
identif ied from a single hospital. Cases 
were objectively confirmed by diagnostic 
tests 
Cross sectional study . Cases were 
identif ied using hospital discharge 
database using !CD-I0 codes 
Cross sectional study . Cases were 
or miscarriages) 
33,311 
(not specified) 
3,852,569 
(live or stillbirths) 
613,847 
rate/l00,00 
pregnancies* 
101 
86 
222 
121 
100 
rates/l00,000 
pregnancies* 
Antepartum=45 
Postpartum=56 
Antepartum=59 
Postpa rtu m = 2 7 
Antepartum=108 
Postpartum=114 
Antepartum=56 
Peripartum=74 
Postpartum =46 
Antepartum=49 
Rate/l00,000 
pregnancies* 
First=6 
Second=9 
Third=30 
First=7 
Second=9 
Third=43 
First=30 
Second=27 
Third=51 
First= 10 
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Author Country Study Study design and methodology Number of Overall VTE Antepartum/postpartum Trimester 
period Pregnancies rate/IOO,OO rates/IOO,OOO Rate/IOO,OOO 
(birth outcome) * pregnancies* pregnancies* pregnancies* 
identified from patient and birth reg ister. (Pregnancies Postpartum=5 1 Second=10 
Cases were val idated for a subset of data reaching 23 weeks Third = 29 
by diagnostic tests of gestation) 
Lindqvist39 Sweden 1990-2005 Cross sectional study. Cases were 51,958 Postpa rtu m = 71 
identified from a single hospital. Cases (not specified) 
were objectively confirmed by diagnostic 
tests 
Sharma40 Austral ia 1999-2005 Cross sectional study. cases were 5,987 114 Antepartum=100 First=71 
identified from a single hospital. Not all (not specified) Postpa rtu m = 14 Third=28 
VTE cases were objectively confirmed. 
Included some probable and possible 
VTEs 
Larsen41 Denmark 1980-2001 Cross sectional study . cases were 71,729 179 Antepartum=85 
identif ied from a sin91e county. (l ive or stillbirths) Postpartum =94 
James7 United States 2000-2001 Cross-sectional study. Cases were 8,330,927 172 Antepartum=85 
ident if ied from national inpatient sample (live or stillb irths) Postpartum=85 
which covers around 100 hospitals using 
ICD-10 codes. 
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Author Country Study Study design and methodology Number of Overall VTE Antepartum/postpartum Trimester 
period Pregnancies rate/1OO,OO rates/1OO,OOO Rate/1OO,OOO 
(birth outcome) * pregnancies* pregnancies* pregnancies* 
Heit31 United States 1966-1995 Population based cohort. Potentially 50,080 199 Antepartum =71 Second=27 
fertile women were prospectively followed (Live or stillbirths) Postpartum=128 Third=40 
in a single county . Not all VTE cases were 
objectively confirmed. Included some 
probable and possible VTEs 
Haggaz9 Sudan 1999-2000 Cross sectional study. Cases were 14,210 380 Antepartum=56 
identified from a single hospital. Cases (not specified) Postpartum=323 
were objectively confirmed. 
Soomro42 Saudi Arab ia 1986- 1998 Cross sectional study. Cases were 39,757 125 Antepartum=42 First=17 
identified from a single hospital. Cases (not specified) Postpartum =83 Second=12 
were objectively confirmed . Third=12 
Chan43 China 1998-2000 Cross sectional study. Cases were 16,993 188 Antepartum=47 First =17 
identified from a single hosp ital. Cases (l ive, stillbirths or Postpartum=141 Second=17 
were objectively confirmed by diagnostic Third=l1 miscarriages) 
tests 
Ros33 Sweden 1987-1995 Population based retrospective cohort. 1,003,489 Postpartum = 28 Third=18 
Cases were identif ied using inpatient (Pregnancies 
reg istry using ICD-9 codes reaching 28 weeks 
of gestation) 
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Author Country Study Study design and methodology Number of Overall VTE Antepartum/postpartum Trimester 
period Pregnancies rate/l00,OO rates/l00,OOO Rate/l00,OOO 
( birth outcome) * pregnancies* pregnancies* pregnancies* 
Simpon 'o United Kingdom 1988-1997 Cross sectional study in wh ich cases were 395,335 90 Antepartum=26 
identified using ICD codes from hospital (live or st illbirths) Postpa rtu m = 64 
database 
Gherman34 United States 1978- 1996 Cross sectional study. Cases were 268,525 61 Antepartum=40 First=9 
identif ied from a single hospital. Cases (not specified) Postpartum=21 Second=22 
were objectively confirmed by d iagnost ic Third=10 
tests 
Lindqv ist44 Sweden 1990-1993 Cross sectional study. Cases were 479,422 BOb Antepartum=64 
identified from Swed ish birth and patient (Preg nancies Postpartum =62 
reg istry reaching 28 weeks 
of gestation) 
McColl4s United Kingdom 1985-1996 Cross sectional study. Cases were 72,201 85 Antepartum=56 
identif ied using national health service (l ive or stillbirths) Postpartum=29 
data. Cases were objectively confirmed 
by diagnostic tests 
Anderson46 Denmark 1984- 1994 Cross sectional study . Cases were 63,300 85 Antepartum=52 
identified using inpatient reg istry . Cases (not specified) Postpartum=33 
were obj ectively confi rmed by diagnostic 
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Author Country Study Study design and methodology Number of Overall VTE Antepartum/postpartum Trimester 
period Pregnancies rate/l00,00 rates/l00,000 Rate/l00,000 
(birth outcome) * pregnancies* pregnancies* pregnancies* 
tests 
Macklon47 United Kingdom 1981-1991 Cross sectional study where cases were 645,663 111 
identified from medical records at a single (live or stillbirths) 
hospital. Cases were objectively 
confi rmed by d iagnostic tests 
James48 United States 1989-1994 Cross sectional study. Cases were 30,040 53 Antepartum=26 
identified from a single un it wh ich were (Live births) Postpartum=16 
confirmed using diagnostic tests 
*birth outcome considered in the study population 
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1.8.2 Non-specification of type of pregnancy outcomes studied 
Most studies have only assessed risks in pregnancies that have ended in a live 
(or still) birth7, 10, 12, 49 and few studies have specified the length of gestation 
or whether only certain gestational lengths were included. 31, 44,50 In the most 
recent CMACE report, 2 of the 16 deaths from pulmonary embolism occurred 
in the 1 st t r i m e s t ~ r r following miscarriage.8 By only considering pregnancies 
which reach full term, these important and occasionally fatal events may be 
overlooked. In particular, it will not allow us to assess whether first trimester 
risks will differs for pregnancies that reach full term compared to those with 
non-live outcomes such as miscarriages, terminations or stillbirths. 
1.8.3 Reliance on International Classification of Disease (ICD) codes 
for defining VTE 
Studies solely reliant on ICD codes without any objective· confirmation or 
other source of validation might not provide accurate estimates. A code 
assigned for suspected VTE which was later not confirmed by objective means 
might lead to overestimation of the incidence especially In the third trimester 
of pregnancy as many VTE associated clinical symptoms overlap with changes 
associated with a normal pregnancy. These include pregnancy related 
changes of Increased Intra-abdominal pressure, obesity and decreased venous 
return associated with lower extremity oedema can be associated with a 
false-positive diagnosis of VTE.34 For Instance, of all studies conducted on VTE 
Incidence during the antepartum period that have utilised data up to or before 
2005, the studies where VTE outcome was not validated7, 31, 44 have reported 
the highest estimates ranging from 86 to 115 per 100,000 person-years. This 
Is higher than studies where VTE outcome was validated (53-76 per 100,000 
person-years during the same time period; later discussed In Chapter 4). 
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1.8.4 Ascertainment of VTE 
Both diagnosis and management of VTE have changed considerably over the 
course of time. Technology has improved in recent years allowing for more 
accurate diagnosis. This has been accompanied by the greater appreciation of 
prophylaxis measures in patients with increased risk of VTE. The first 
probably means that the older studies have a greater likelihood of 
misclassification of VTE, while the second means that there will be some 
expectation that rates might have decreased. The latter may also be 
countered by possibly more older mothers today than 30 years ago and 
perhaps also by increased prevalence of risk factors today (for example 
obesity51). This would make overall comparison of incidence estimates from 
previous studies less meaningful with today's rates. 
It is also important to note that changes in diagnostic modalities and case 
management over time might have lead to over diagnosis of VTE cases In 
more recent years. For Instance, Wiener et al. S2 in their time trend analYSis 
for pulmonary embolism in the USA concluded that with the introduction of 
new and improved diagnostic techniques there was an increase in the 
incidence of PE with reduction in PE associated mortality (8% reduction in 
mortality), suggesting over diagnosis of clinically Insignificant events; Despite 
the fact that this previous study had a number of limitations (reliance on 
death certificate for PE diagnosis, no Identifier to track Individual after 
hospital discharge and confounding by calendar year) this phenomenon might 
particularly affect pregnant women who are exposed to more frequent contact 
with health care professionals during and after their pregnancy compared to 
women in the general population. 
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Few recent studies (post 2005) have quantified the incidence of VTE during 
the antepartum and postpartum period where the VTE cases were either 
confirmed by objective means (diagnostic tests) or using a registry where VTE 
cases were previously validated. Whilst estimates from those studies are 
broadly similar for the antepartum (ranging from 95 to 144 per 100,000 
person-years), there are wide variations in the rate of VTE during the 
postpartum period (ranging from 124 to 969 per 100,000 person-years). Most 
of those estimates are based on small numbers which do not provide 
adequate precision when examining risk of VTE during the specific 
antepartum and postpartum periods. Moreover the wide variation in the 
reported rate of VTE during the postpartum may partially be explained by the 
thromboprophylaxis practice post-delivery, the duration and frequency of 
which may vary by country. For instance the UK's current RCOG 
thromboprophylaxis guidelines also extend to those women who have 
undergone normal vaginal delivery when accompanied by certain risk factors 
as opposed to US American College of Chest Physicians (ACCP) guidelines 
which are only restricted to post caesarean section women with additional risk 
factors. Secondly studies utilising data from a single centre may potentially 
miss out postpartum VTE (particularly DVT) diagnosed and managed solely in 
primary care or any other facility especially during the postpartum period. For 
Instance Vikrus et a/ l7 utilising data from an in-patient registry, quantified the 
incidence of VTE during the antepartum and postpartum periods and reported 
the rate of VTE to be 107 and 304 per 100,000 person-years respectively. 
Despite the fact that their study utilised prospectively collected data with 
large follow-up where VTE diagnosis was previously validated, the use of 
hospital admission date as the date of diagnosis may have potentially caused 
misclassification between antepartum and postpartum VTE events around the 
time of delivery for maternity admissions taking place before delivery which 
were also complicated by VTE during the postpartum period. This may have 
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led to slight underestimation of postpartum VTE incidence with the added 
potential of missing out DVTs diagnosed and managed in primary care. 
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1.9 Risk factors for VTE in and around pregnancy 
Many of the recent UK guidelines are hampered by the lack of contemporary; 
UK-population based estimates from the studies of sufficient size leading to 
wide variation in the absolute and relative risks of VTE. Moreover, studies 
exploring risk factors for VTE such as age, parity, BMI, smoking provide 
inconsistent estimates, There are few important pOints to consider about the 
evidence surrounding the risk factors of VTE: 
1.9.1 Type of evidence 
To date there have been number of studies which have explored risk factors 
for VTE in the pregnant population. Risk factors highlighted in previous 
studies are summarised as Table 1-4, Table 1-5 and Table 1-6. Most of those 
studies can broadly be categorised as either registry based, or hospital based 
studies. Registry based studies analyse information collected from more than 
one centre over time. Whilst such studies are based on large sample size, 
they often suffer from VTE validation issues (previously highlighted) and are 
only able to analyse a few risk factors simultaneously. This is because the 
information recorded on anyone patient Is limited. For Instance, Llndqvlst et 
al44 in their registry based study analysed more than 470,000 pregnancies 
and found that caesarean section deliveries were associated with a 5 fold 
increased risk compared to normal vaginal deliveries during the postpartum. 
However they were not able to analyse other important risk factors such as 
BMI, birth outcome, length of gestation and pre-exlsting medical co-
morbldities which may have confounded their association to a certain extent. 
Furthermore, most of the previous registry based studies have lumped 
antepartum and postpartum VTE together for their risk factor analysis despite 
evidence of differences in overall level of risk and risk factor profiles in these 
two periods (Table 1-4). On the other hand hospital based studies provide 
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more in-depth information on VTE outcomes and potential risk factors but are 
based on insufficient statistical power to provide meaningful estimates. For 
instance Chan et al43 looked a wide range of pregnancy related factors which 
were individually scrutinised but their analysis was based on only 25 VTE 
events which may have potentially led to type 2 error (i.e. failure to reject a 
false null hypothesis. 
1.9.2 Lack of contemporary UK based evidence 
Whilst there is lack of contemporary UK based studies on the VTE risk factors 
in and around pregnancy, Jacobsen et al s3 addressed some of the limitations 
of previously highlighted registry and hospital based studies by conducting a 
case-control study in Norway where cases where recruited from 18 different 
hospitals through a Norwegian Patient Register. These were when Individually 
scrutinised for wide range of potential risk factors and were compared to their 
respective controls. However, their controls (recruited from a single hospital) 
were systematically different from the general population (with respect to 
mode of delivery, pre-eclampsia, multiple pregnancies and other factors) 
which may have biased their estimates. For instance their controls had more 
emergency and planned caesarean sections than the general population which 
may have biased their estimates towards the null as evident by there being 
no statistically significant association between elective caesarean section and 
VTE. Despite of the above stated limitations, studies highlighted in Table 1-5 
and Table 1-6 provide the best available evidence of the risk factors of VTE in 
pregnant and postpartum women. However, most of them utilise data up to 
2004 which also has its implications (Section 1.8.4). Therefore in general 
there is a lack of contemporary studies especially from the UK 
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1.9.3 Implications for the thromboprophylaxis guidelines 
1.9.3.1 Reliance on CMACE report 
The current guidance for thromboprophylaxls is reliant on expert consensus 
and CMACE reports.s Whilst CMACE reports are useful in that they provide 
information on the most serious VTEs occurring among women from the UK, 
as they only consider fatal events they cannot be a good source of evidence· 
for identifying risk factors for VTE. For instance, these reports have 
consistently identified that the women who die from VTE are either ~ 3 5 5 years 
of age, have high BMI or are immobile as reflected in the current prophylaxis 
guidelines. This does not indicate independent or causal associations as these 
findings could be due to chance (as they were based on only handful of cases) 
or confounding. These gaps in knowledge might lead to exaggeration of the 
Impact of the risk factor leading to un-necessarily high use of anticoagulants 
(which is expensive, inconvenient and uncomfortable to administer54) in the 
large number of women who will exhibit one or more of these factors. It may 
also underestimate the relative importance of other risk factors. 
:1.9.3.2 Unknown risk factors 
There might also be some unknown factors influencing the risk of VTE. For 
instance, a population-based case-control study exploring risk factors for 
antepartum PE in the UK concluded that two thirds of the women with 
confirmed PE had no known risk factors according to the current guldellnes. ll 
This finding is consistent with another hospital based cross sectional study in 
which 36% of the women with VTE during the antepartum/postpartum 
periods had no clinical risk factors.45 This either indicates that these VTE risk 
factors are being under recorded or there is still room for targeted 
thromboprophylaxis. However there Is a strong possibility that the latter may 
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be true as information on risk factors in both previous studies was collected 
via structured questionnaire. 
1.9.3.3 Reliance on relative risk 
Whilst odds ratios and rate ratios present measures of effect for each risk 
factor during pregnancy, it is also important to consider the absolute risks 
associated with those risk factors when considering thromboprophylaxis. For 
instance, factor "X" maybe associated with a 5-fold increased risk of VTE 
during the antepartum period, which in relative terms is evidence of a strong 
association. However hypothetically if the risk of VTE associated with not 
having factor "X" is less than 0.001%, in absolute terms the additional risk 
associated is still only 0.005% which is not so alarming considering the 
number needed to treat. However currently there is a lack of studies 
estimating the risk factors of VTE in absolute terms. 
Some of the risk factors from previous studies are summarised below which 
can be broadly categorised as demographic risk factors, pregnancy related 
characteristics, delivery related characteristics and complications and pre-
existing medical co-morbiditles (Table 1-4). 
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Table 1-4: Risk factors for VTE during pregnancy/postpartum with their respective odds ratios presented in previous 
studies (either where risk factors for Antepartum and Postpartum periods could not be distinguished or where combined 
results have been presented in addition to the separate antepartum/postpartum results). 
Risk factors 
Obesity (BMI>30 Kg/m2 ) 
A g e ~ 3 5 5
Smoking/current 
smoking/tobacco use 
Pa rity 
2 
3 or more 
Mode of delivery 
Any caesarean 
Emergency caesarean 
Elective caesarean 
Multiple gestation 
Pre eclampsia 
Obstetric haemorrhage 
Hyperemesis 
Pre-term birth 
Stillbirth 
Postpartum haemorrhage 
Antepartum haemorrhage 
Danileko-Dixon55 et Lindqv ist et al.44 Liu et al.12 l a mes et al.7 
al. (VTE)* ( VTE) * (PE) * (VTE) * 
Demographic and life style related factors 
0 .77 (0.22-2.72)" 2 .7 (1.6-4.4)' 4.4 (3.4-5.7) + 
1.01 (0 .94-1.07)1 1.3 (1.0-1.7)d 1.0 (0 .8 -1.3)' 
2 .37 (1.18-4.78)b 1.4 (1. 1-1.9)2.b 1.5 (0.6-3.7)+ 1.7 (1.4-2 .1)b 
Pregnancy and delivery related characteristics and complications 
1.17 (0 .39-3.47t 
7.00 (0.36-135 )+ 
1.00 (0.14 -7 .10)+ 
9.00 (1.14 -71.0 )+ 
4.50 (0 .97-20.8t 
1.5 (1.1-1.9)" 
2.4 (1.8-3.1)" 
3.6 (3.0-4 .3)+ 
1.8 (Ll -3 .0), 
2.9 (2 .1 -3 .9)+ 
2.9 (2.4-3.5 )+ 2.1 (1.8-24 )< 
1.3 (0 .9-1.9)' 1.6 (1.2-2.1t 
1.2 (0.8 -1.8)' 0 .9 (0.7-1.0) + 
2.2 (0.6-7.3) + 2.5 (2.0-3.2) + 
2.1 (1. 6-2 .6 ), 
1.3 (1.0-1.7) + 1.3 (1.1 -1.6)+ 
1.0 (0.3 -4.4)+ 2 .3 (1.8 -2 .8)+ 
Ros et al.5O 
(PE) * 
1.6 (1.1-2.2)1 
1.4 (1.1-1.9) + 
1.8 (1.1-2.8) 
1.4 (1.1-1.9)' 
2.3 (1.1-4.6)' 
4.8 (2 .7-8.6)3+ 
Haggaz et al.' 
(VTE) * 
0 .22 (0.05 -0.95), 
2.84 (1.05-7.6)' 
0 .15 (0.0 2-0.77) + 
Chan et al.43 
(VTE) * 
11.7 (3 .7-37 .0)< 
11.2 (4.5 -27.4)< 
1.8 (0.2-13 .5t 
5.1 (1. 2-21.7 )+ 
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Risk factors 
Infection 
Varicose veins 
Diabetes 
Hypertension 
Thrombophilia 
Cardiac disease 
Lupus 
Danileko-Dixonss et 
al. (VTE)* 
2.15 (0.90-5.10)+ 
Lindqvist et al.44 
(VTE)* 
' Age per 10 years, 2>10 Cigarette/day, 3Severe eclampsia 
Liu et al.12 
(PE)* 
4.1 (3.0-5.6) 
lames et al/ 
(VTE)* 
4.1 (2.9-5.7)+ 
Medical co-morbidities 
1.4 (1.0-1.Bt 
1.2 (0.9-1.B)+ 
2.4 (1.1-5 .0)+ 
43.4 (35.0 -53.9 )+ 
2.0 (1.4-2.7)+ 
loB (1.4-2.3)+ 
51.B (3B.7-69.2)+ 
7 .1 (6.2-B.3)+ 
B.7 (5.B-13.0t 
Ros et al.so 
(PE)* 
2.7 (1.3 -5.4t 
Haggaz et al.9 
(VTE)* 
Chan et al.43 
(VTE)* 
• Compared to normal BMI , b Compared to Never smoker, C Compared to spontaneous vaginal delivery, d Compared to age 20-24 years, e Compared to parity 1, f Age<30 
years 
+Compared to women without the risk factor under study, * Preference g iven to the most fully adjusted results presented in the study 
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Table 1-5: Risk factors for VTE during the antepartum period with their respective odds ratios presented in previous studies 
Risk factors 
Obes ity (BMI>30Kg/m2) 
A g e ~ 3 5 5
Smoking/current smoking/tobacco use 
Parity 
2 
>3 
Multiple gestation 
Assisted reproduction 
Gestational diabetes 
Premature rupture of membrane 
Simpson et al. iO 
(VTE)* 
Lindqvist et al.·· 
(VTE)* 
Jacobsen et al.32, 53 
(VTE) * 
Demographic and life style related factors 
1.4 (0 .7-2. 5)" 1.8 (1.3-2.4)"b 
1.0 (0.7-1.4)4,f 1.5 (1.1 -2.2)2,C 
1.1 (0.8-2.0)5.' 2.1 (1.3-3.4)3 .• 
Pregnancy related characteristics and complications 
4.2 (1.8 -9.7)+ 
1.3 (0 .8-2.0)d 
2.8 (1.8 -4.4)d 
2.1 (1.0 -4.6)+ 
0.8 (0. 5-1.2)d 
1.0 (0.6-1.8)d 
2.7 (1.6-4.5)+ 
4.4 (2.6-7.5t 
4.1 (2.0-7.5)+ 
0.2 (0 .1-1.0r 
Pre-eclampsia 0.8 (0.4-1.7) 0.5 (0 .2-1.2) 
'SMl >25, 2Age 35-54 years, 310-30 cigarettes per day, 4 A g e ~ 3 5 5 years, 5 ~ 1 0 0 Cigarettes per day, 
Larsen et al.41 
(VTE)* 
9.7 (3.1-30.8)h 
5.7 (2.5-13 .2)' 
Knight et al.ll 
(PE)* 
2.65 (1.09-4.45)h 
0 .90 (0.42-1.90)1 
0 .89 (0.40-1.95)" 
4.03 (1.60-9 .84)J 
• Compared to normal BMl, b Compared to BMl<20Kg/ m2, C Compared to age 25-29 years, d Compared to parity 1, ' Compared to non smokers, f Compared to Ages19 
years, hCompared to BMI<25 Kg/m2, ICompared to age<35 years, JCompared to parity O. 
·Compared to women without the risk factor under study 
*Preference given to the most fully adjusted results presented in the study 
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Table 1-6: Risk factors for VTE during the postpartum period with their respective odds ratios presented in previous studies 
Risk factors 
Obesity (BMI>30Kg/ m 2) 
A g e ~ 3 5 5
Smoking/current 
smoking/tobacco use 
Simpson et al.'O 
(VTE) 
1. 7 (1.2-2.4)" 
1.4 ( 1.0-2.0)b 
Lindqvist et al!· 
(VTE) 
Jacobsen et al.32, 53 
(VTE) 
lindqvist et al.39 
Demographic and life style related factors 
1.2 (0 .9-1.6)9 
1.2 (0.8 -1. 7)5.f 
2.4 (1.7-2.3)1.. 2.3 (1.0-4.8)6.h 
0.8 (0.5-1.1)2." 2.5 (0.3-18.9) 7.' 
3.4 (2.0 -5 .5)3.f 
Larsen et al.41 
(VTE) 
2.8 (0.8-9.8)J 
1.3 (0.6-2.7) f 
Pregnancy related characteristics, complications and medical co-morbidities 
Parity 
2 
>3 
Mode of delivery 
Any caesarean 
Emergency caesarean 
Elective caesarean 
Multiple gestation 
Eclampsia 
Pre eclamps ia 
Obstetric haemorrhage 
Pre-term birth 
Stillbirth 
2.6 ( 1.5-2.7)' 
2.4 ( 1.6-3.5)d 
Card iac disease 5.4 (2.6-11.3)' 
1. 7 (1.2-2.4 )k 
1.8 (1.2-2.9 )k 
4.9 (3.8-6.3 )' 
0 .6 (0 .2-1.4)" 
3 .0 (2.4-4.4)" 
1.2 (0 .9-1.8)k 
1.9 (1.2-3.0)k 
4 .0 (3.0-5.3)' 
2 .7 (1.8 -4.0)' 
4.4 ( 1.4-14.2)" 
2.8 (2.8-5 .1)" 
4 .1 (2 .3-7.3)4." 
6.8 (3.4-13.2)' 
11.6 (4.6-29.5)' 
Morris et al.56 
(PE) 
1.67 (1.01-2.76)7" 
1.17 (0 .83-1.65)f 
1.49 (1.02 -2 .20)' 
3.11 (2.22-4.30) 
2.18 ( 1.54-3 .09) 
5.9(3.0-11.6) 
1 B M M > 2 2 K g / m ~ I I - a t e r n a ( a g e e 35-54 years, 310-30 cigarettes per day, 4> 1000 ml blood loss, 5 ~ 1 0 0 cigarette per day, 6BMI<28Kg/m2 7Age>40 years, 
"Compared to age 25-34 years, bCompared to normal BMI , 'Compared to spontaneous vag inal del ivery, dCompared to normal gestation, ·Compared to BMI<20Kg/m2, 
fCompared to non-smoker, 9Compared to ageS19 years, hCompared to B M I ~ 2 8 K g / / 2 2 'Compared to age s40 years, JCompared to BMI<25Kg/mH Compared to parity 1 
·Compared to women wi thout the risk factor under study, * Preference g iven to the most fully adjusted results presented in the study 
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1.9.4 Basic and demographic risk factors 
1.9.4.1 Body mass index 
A high BMI has been shown to be associated with many adverse outcomes 
Including cardiac disease, atherothrombosis disease and VTE in general 
medical patients. 57 A literature review by Duhl et al. 57 suggested that many 
aspects of obesity aggravate prothrombotic risk in pregnancy. Moreover the 
fibrinolytic process is also decreased. There Is also a high incidence of Insulin 
resistance syndrome also known as metabolic syndrome which Inhibits the 
fibrinolytic process. A cross-sectional study by Sebire et al58 highlighted that 
obese women are more likely to develop gestational diabetes, proteinurlc pre-
eclampsia, postpartum haemorrhage, genital tract Infection, wound Infection 
and are more likely to have caesarean section which may further add to the 
Increased risk of VTE associated with obesity. To date there are many cross 
sectional studies conducted exploring the association between high BMI and 
VTE during pregnancy with most studies suggesting an increased risk of 
around 2-fold compared to women with normal BMI (20-24.9 kg/m2) (Table 
1-4 to Table 1-6). The current RCOG guideline for thromboprophylaxls21 has 
assumed much higher risk of VTE in women who are morbidly obese 
(BMI>40kg/m2) and Is reflected as a separate category which is based on 
expert opinion. Additionally, there is a lack of evidence on how the effect of 
high BMI (>30Kg/m2) on the risk of VTE is mediated by pregnancy associated 
complications (postpartum haemorrhage, mode of delivery etc.) and other 
medical co-morbldlties (diabetes, hypertension etc.) by showing variation In 
the effect size when adjusted for those factors. 
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1.9.4.2 Maternal age and smoking status 
The risk of VTE increases with age in the general population where an 
exponential increase in the risk of VTE takes place after 45 years6 (Figure 
1-3). Whilst a g e ~ 3 S S is considered a risk factor in the current RCOG 
guidelines, current evidence from primary care in the UK36 suggests no 
association between a g e ~ 3 5 5 years and VTE during the antepartum and a 
70% increase in the risk during the postpartum period compared to those 
aged 25-34 years. This finding Is In concordance with other studies 10, 11,44,53, 
56 that also failed to find a strong association of VTE with age at pregnancy. 
The thrombogenic potential of tobacco smoking has been recognised for more 
than 30 years. Early studies were poorly designed and gave inconsistent 
evidence however recent evidence supports this relationship in the general 
population.59 There are still controversies surrounding cigarette smoking and 
the risk VTE during pregnancy. For instance, a population based case control 
study conducted by Danilenko-Dixon et al., found a 2.5 fold Increased risk of 
VTE during pregnancy among cigarette smokers. 55 These findings contradict 
those presented by Llu et al.12 in a large cross-sectional hospital based study 
that showed no association of tobacco use with either PE or DVT. Furthermore 
a cross-sectional study by Larsen et al.41 showed no association between 
smoking and VTE during the antepartum but a 7-fold Increased risk during 
the postpartum period. The wide variation In the estimates may partially be 
explained by the fact that most studies on the subject use hospital discharge 
data where smoking status is liable to be poorly recorded or not recorded at 
all. 
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Figure 1-3: Association between age and VTE60 
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1.10 Delivery associated characteristics and complications 
1.10.1 Adverse pregnancy outcomes 
Several adverse pregnancy outcomes have been linked to increased risk of 
both antenatal and postnatal VTE. For instance, pre-term birth which occurs 
in 7%61 of all deliveries is known to be associated with a more than 2-fold lO 
higher risk of postnatal VTE compared to pregnancies with normal gestational 
length . Similarly Morris et al. 56 found a 6 fold increase in the risk postpartum 
PE in those with stillbirths compared to pregnancies resulting in live births . To 
date these factors have received limited attention and are not incorporated in 
the current UK guidelines for thromboprophylaxis. This could be due the pre -
conceived notion that the augmented risk associated with sti llbirth and pre-
term birth may be mediated by pre -eclampsia. While this may partially be 
true, 50% of stillbirths are unexplained62 and 80% of pre -terms births occur 
in pregnancies not complicated by pre -eclampsia 63 which highlights the 
potential importance of those risk factors by themselves. 
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1.10.2 Caesarean mode of delivery 
The need for VTE risk assessment and thromboprophylaxis in women post 
caesarean section has been recognised since the early 90s. Previous studies 
have consistently reported higher risks of VTE among women delivering by 
caesarean section (estimates ranging from a 17% to an ll-fold Increased 
risk; Table 1-4 and Table 1-5) with only few studies32• 43 going into greater 
detail of separating elective versus emergency caesarean. 43• 53 The impact of 
elective and emergency caesarean mode of delivery on VTE is also debatable. 
The wide variation In the reported rates may be due the difference In the 
study populations and data sources used. For Instance Chan et al. (China) In 
their cross-sectional analysis of hospital discharge record from a single centre 
reported 11-fold Increased risk of VTE for both elective and emergency 
caesarean section whereas Jacobsen et al. (Norway) using patient registry 
data reported relative risk to be 2.7-fold and 4-fold respectively. The 
incoherence In the reported estimates may also be due to the difference in 
the country's health care system and opinion about offering 
thromboprophylaxis to women post caesarean delivery (later discussed In 
chapter 4). Despite the absence of randomized controlled trials assessing the 
effectiveness of offering thromboprophylaxls to women post caesarean 
section, many guldellnes21• 64 support the use of thromboprophylaxls among 
those women. Finally the current RCOG guidelines for thromboprophylaxls21 
suggest 7 days thromboprophylaxls with LMWH for those who had emergency 
caesarean section whereas pharmacological thromboprophylaxls Is only 
recommended for those who had elective caesarean section If accompanied 
by one or more additional risk factors. However these recommendations are 
based on scarce eVidence as most prior studies fail to separate elective from 
emergency caesarean section. 
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1.10.3 Postpartum haemorrhage 
Postpartum haemorrhage which affects around 10% of all pregnancies Is also 
associated with a high relative rate of VTE. Most studies that have examined 
this association relied on hospital discharge data where information on both 
haemorrhage and VTE was extracted using ICO-l0 codes around the time of 
delivery. Given the increased used LMWH for thromboprophylaxis during the 
postpartum period where the risk of postpartum haemorrhage Is 1%2s, there 
may be particular concerns over establishing the temporal relationship of 
severe postpartum haemorrhage (affect 1% of all pregnancies) and VTE if 
they both took place during the same hospital admission. Moreover, the risk 
of VTE associated with postpartum haemorrhage may be the function of blood 
transfusion. 7 
1.11 Pregnancy related characteristics and complications 
1.11.1 Parity 
Parity is another established risk factor of VTE and Is Incorporated In the 
current RCOG guidelines for thromboprophylaxls. A cross sectional study by 
Lindqvist et al.44 found 3-fold and 70% Increased risks of VTE In those with 
parity 3 or more during the antepartum and postpartum periods respectively. 
Furthermore, a population based case-control study by Knight et al. 11 
reported a 4-fold Increased risk of PE even among pregnant women with 
p a r i t y ~ l l during the antepartum period. In contrast Jacobsen at.al s3 found no 
association between multiparous women and VTE during the antepartum 
period but a 70% increased risk of VTE In those with p a r t y ~ 2 2 during 
postpartum. Whilst the strong positive assoCiation between parity and 
postnatal VTE is not clear, the wide variation In the reported estimates In 
previous studies may partially be explained by the characteristics of previous 
studies. For Instance, the definition of parity differs by country and on 
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gestational thresholds. In the UK parity is defined as number of previous 
pregnancies reaching 24 weeks whereas in the US this cut off is 20 weeks. 
Additionally a survey conducted in the England demonstrated that clinicians 
and midwives often apply the term "parity" incorrectly.6s Moreover, the study 
by Lindqvist et al.44 only included pregnancies reaching a gestational age of 
24 weeks or more in their analysis whereas Knight et alll only looked at PE. 
1.11.2 Pre-eclampsia/eclampsia 
Currently RCOG guideline on thromboprophylaxis considers pre-eclampsia and 
eclampsia as both antenatal and postnatal period risk factors. This is based 
on the evidence that does not allow separation between antepartum and 
postpartum periods. For instance, Jacobson et al.s3 in their case control study 
reported pre-eclampsia to be a significant postnatal risk factor (associated 
with 4-fold higher risk) as opposed to antenatal risk factor. The non-
statistically significant aSSOCiation between antenatal VTE and pre-eclampsia 
may be due to the fairly small follow-up time period between the date of pre-
eclampsia and delivery. The early onset pre-eclampsia may have different 
pathology than the more serious late onset of the disease as the former may 
be linked to prolonged Immobilisation prior to delivery. 
1.11.3 Hyperemesis 
Hyperemesis gravidarum (HG) is defined as vomiting in pregnancy that Is 
'pernlclous enough to cause weight loss, dehydration and electrolyte 
Imbalance.66 Estimates of severe nausea and vomiting of pregnancy vary 
greatly and range from 0.3% (Sweden) to 10% (China) of all pregnancles.67 
It Is regarded as a risk factor for VTE In both the antepartum and postpartum 
periods according to the RCOG guideline for thromboprophylaxls. Dehydration 
and vasospasm Is largely considered to be the pathogenesis behind Its 
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increased risk associated with VTE. For instance North American cross-
sectional studies7• 12 have found a 2.5 to 4 fold increased risk of VTE 
associated with HG during antepartum/postpartum periods. However these 
estimates are based on hospital based studies which are more likely to 
capture pregnant women with severe forms of HG warranting hospitalisation. 
Secondly, it is not known whether its impact differs during the antepartum 
versus the postpartum period. 
1.11.4 Acute systemic infection 
Inflammation is the key determinant of endothelial function in both arteries 
and veins and the link between Infection and venous thrombosis via 
endothelial activation has been suggested.68 A self-controlled case series by 
Smeeth et al68 using primary care data revealed a transient increased risk of 
VTE during the initial weeks following both urinary and respiratory Infection. 
Similarly puerperal Infection which occurs In 1-8% of pregnancies has also 
shown to Increase the risk of VTE by 4 to 5-fold,1· 12 However this evidence 
comes from hospital-based cross-sectional studies which most likely presents 
only the severe form of infection requiring hospitalisation and there is also a 
potential of missing out non-severe infection diagnosed in primary care. 
1.12 Medical co-morbidities 
1.12.1 Hospitalisation 
Hospitalisation Is considered an Important risk factor In the general non-
pregnant population. According to the Department of Health, each year over 
25,000 people die In England from VTE as a consequence of hospital stay.3 
The All-Party Parliamentary Thrombosis Group69 working on the prevention of 
VTE has recommended mandatory risk assessment for all patients admitted to 
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hospital. 21 The risk of VTE is not only dependent on the reason for admission 
but also on co-existing patient related factors and therefore the decision of 
whether a patient should be offered thromboprophylaxls is currently 
dependent on the balance between the absolute rate of thrombosis and the 
risk of bleeding. As most previous studies on VTE in pregnancy rely on 
hospital discharge data both to determine exposures and outcome it will 
simply not be possible to look at hospitalisation as a risk factor in its own. 
However, Heit et al.7° in their population based cohort study estimated the 
incidence rate of VTE among hospitalised patients and compared it to non-
hospitalised community residents. Overall the age and sex adjusted absolute 
rate of VTE among hospitalised patient was calculated to be 960 per 100,000 
person-years which was more than 100 times greater than the rate in non-
hospitalised community residents (incidence rate=71 per 100,000 person-
years). It is not clear if a similar increase risk would be observed among 
pregnant women who are younger and would on average have a better health 
prognosis. To date there have been no studies evaluating the impact of 
hospitalisation or post-hospitalisation on VTE during pregnancy. 
1.12.2 Previous VTE 
There are number of studies suggesting increased risk of VTE during 
pregnancy in those with history of thrombosis. The rate of recurrence is 
reported between 2.4% and 10.9%71-75 whereas rate of recurrence VTE In 
women who receive anticoagulation is reported to range between 0 and 
2.4%.49 Whilst a previous VTE either during or outside of pregnancy is 
considered an important risk factor in the current RCOG guidelines for 
thromboprophylaxis, most are first events which can be prevented through 
better understanding of its occurrence and risk factors. Additionally recurrent 
VTE occurs in a small proportion of pregnant women who will very likely be 
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cared for differently than those without a history of VTE. Furthermore the use 
of anticoagulants as thromboprophylaxis in those with prior history of 
thrombosis is arguably less controversial in the UK and therefore less relevant 
to current practices. 
1.12.3 Thrombophilia and other inherited conditions 
Thrombophilia, a condition where the blood has an increased tendency to clot 
is another well recognised risk factor for VTE. lames et al.1 in their cross 
sectional analysis of hospital discharge records found that those diagnosed 
with thrombophilia were 51 (95%CI 38.7-69.2) times more likely to have a 
VTE diagnosis during pregnancy compared to those without the condition. 
However Liu et al 12 found a 2 fold and 15 fold increased risk of PE and DVT 
respectively associated with thrombophilia. The difference in the estimates 
may be due to the fact that the former study failed to separate first from 
recurrent VTE events as the majority of thrombophilias may be diagnosed 
after the first VTE event. It is also important to note that a diagnosis of 
thrombophilia cannot be used to predict VTE as routine thrombophilia 
screening is not recommended for pregnant women. Furthermore, in practice 
testing for thrombophilia does not usually influence thromboprophylaxis in 
current pregnancy unless detected in a woman with a prior VTE related to a 
temporary risk factor who would not otherwise receive thromboprophylaxis. 21 
Evidence also suggests that prior diagnosis of varicose veins, cardiac disease, 
diabetes, inflammatory bowel disease, hypertension lupus have a" been 
associated with increased rIsk of VTE and most of these are incorporated in 
the current RCOG guideline. However the absolute risks associated with these 
risk factors have not been studied. 
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1.13 Project justification 
VTE is one of the leading causes of maternal mortality in high income 
countries and is associated with a considerable health and social economic 
burden. There are no up-to-date estimates of the incidence of first VTE in and 
around pregnancy available at a population level from the UK and data from 
other countries are limited. While numerous attempts have been made to 
understand VTE risk factors among pregnant women, there is still 
inconsistency and disagreement concerning which women are at highest risk 
of developing a first VTE during pregnancy and in the postpartum separately 
with limited focus on crucial risk factors such as hospitalisation and stillbirth. 
Most of the studies on the subject are hospital-based cross-sectional studies 
with no population-based cohort studies from the UK. This is combined with a 
lack of both national and international data about the relative impact of those 
risk factors with respect to the absolute risk of VTE. Only a few studies 
comprehensively examine factors occurring before, during and after childbirth 
and their impact on postpartum VTE while adequately adjusting for other 
confounding factors and have examined the interrelationship between factors. 
Additionally none of the previous studies have assessed the Impact of risk 
factors on the incidence of VTE during specific periods of postpartum. 
Knowledge of the absolute risks of VTE in pregnancy and following childbirth 
and how recognised risk factors influence these is therefore crucial In 
identifying pregnant women who are most likely to benefit from 
thromboprophylaxis. However due to the relatively low incidence of VTE 
among pregnant women and uncertainties over VTE risk factors bespoke 
cohort studies may not be cost effective In providing robust evidence. 
Therefore it is more appropriate to use large routinely collected data that 
contain information on both exposure and outcome and can provide 
generalisable population based estimates. The data sources used in the work 
presented In this thesis provide contemporary clinical information that is 
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relevant to the UK population. Furthermore it will also provide international 
leading evidence on the absolute and relative risks of factors associated with 
VTE in and around pregnancy. 
1. 13.10bjectives 
The objectives for this thesis are: 
• To determine the incidence of VTE in and around pregnancy and 
compare it to time outside pregnancy utilising primary care data from 
the UK. 
• To determine the risk factors of antepartum and postpartum VTE using 
primary care data from the UK. 
• To use the recent linkage of electronic primary and secondary care 
data to comprehensively assess VTE occurrence and determine which 
definition(s) of VTE in women of childbearing age provide estimates 
which are most consistent with existing literature 
• To assess the impact of hospitalisation and other risk factors on the 
incidence of VTE during the antepartum period using linked primary 
and secondary care data. 
• To determine the risk factors for postpartum VTE and to assess their 
impact on VTE in specific windows of time following delivery using 
linked primary and secondary care data. 
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1.14 Thesis outline 
The subsequent chapters of this thesis contain results from five studies that 
were carried out to address the main research objectives of this thesis. The 
outline below briefly summarises the main content of each chapter. Each of 
the following chapters has its own background followed by methods, results, 
discussion and conclusion. 
Chapter 2: This chapter describes the Incidence of VTE in and around 
pregnancy utilizing The Health Improvement Network (THIN) which is a 
computerised primary care database from the United Kingdom. It also 
compares the rate of VTE during pregnancy and postpartum to that outside 
pregnancy. 
Chapter 3: This chapter uses the same database to Identify risk factors for 
VTE during the antepartum and postpartum periods separately In terms of 
absolute and relative risk. 
Chapter 4: This chapter introduces and describes the recent linkage of 
electronic primary care records (Clinical Practice Research Datallnk) with the 
English Hospital Episode StatistiCS database (HES) to comprehensively assess 
VTE occurrence and the best way of defining VTE In and around pregnancy. 
Chapter 5: This chapter looks at the Impact of hospitalisation and post-
hospitalisation on the Incidence of antepartum VTE using linked primary and 
secondary care data. 
Chapter 6: This chapter Identifies risk factors for VTE during the postpartum 
period utilising the linked primary and secondary care data. Additionally, it 
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evaluates the impact of those risk factors on the timing of VTE during the 
time around delivery and specific periods of postpartum. 
Chapter 7: This chapter summarises the main findings of this thesis and 
suggests clinical recommendations and direction for future research. 
1.lS Role of candidate 
The initial idea for this PhD was conceived by Dr. Matthew J Grainge along 
with Dr. Joe West and Dr. Laila Jal Tata which followed on from a work 
initially started as an MSc project. 36 The candidate continued to further 
develop the project by carrying out a detailed literature review and 
formulating specific research questions with continuous guidance from all 
three supervisors. The THIN dataset used In the chapter 2 and 3 was Initially 
processed by Mr Chris Smith. Dr. Llnda Fiaschi extracted the information on 
potentially fertile women and created the pregnancy cohort. The pregnancy 
and patient cohort using the linked primary (CPRD) and secondary care (HES) 
used In chapter 4, 5 and 6 was created by the candidate. The candidate did 
an -extensive literature review, also extracted Information on exposure and 
outcomes from all three data sources, did the necessary data management 
and formulated and conducted statistical analyses for each chapter. 
Furthermore, the candidate generated all tables and figures and wrote the 
thesis which was read and approved by all three supervisors. 
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2 Incidence of VTE in and around pregnancy: An updated 
population based cohort study from the United Kingdom 
This chapter describes the incidence of VTE in and around pregnancy utilizing 
The Health Improvement Network (THIN) which is a computerised primary 
care database from the United Kingdom. It also compares the rates of VTE 
during pregnancy and the postpartum to that outside pregnancy. This chapter 
provides an updated analysis of a study which I previously published using 
THIN data up to 2004. 36 
2.1 Introduction 
The knowledge of the absolute and relative risk of VTE at different times 
around pregnancy Is of crucial Importance In Identifying pregnant women or 
those who have recently delivered, who would benefit most from 
anticoagulant thromboprophylaxls which Is known to be generally safe and 
highly effective 25, 76. Equally by determining low risk periods, unnecessary 
thromboprophylaxls and Its potential harms to both the mother and foetus 
could be avoided. However, clinical 'guidelines developed by the American 
College of Chest Physicians 22, the UK Royal College of Obstetricians and 
Gynaecologists 21, and the Society of Obstetricians and Gynecologlsts of 
Canada77 are all limited by both the quality and quantity of the current 
evidence base and understandably have had to rely upon expert consensus 
opinion In formulating the recommendations made. One example of the 
existing scarcity of evidence Is the lack of precise and consistent estimates of 
the absolute risk of VTE In and around pregnancy. Reported rates vary 
considerably from 28-86 per 100,000 pregnancies during the antepartum and 
28-128 per 100,000 during the postpartum period 7,10,12,31,32,34,37,43-46,78. 
Inconsistencies also surround the trimester of pregnancy and weeks 
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postpartum during which a woman is at highest risk of VTE and the extent to 
which age affects these risks.31, 32, 35, 79 Fewer studies have specifically 
compared rates of VTE around pregnancy either with those outside of 
pregnancy or with those in non-pregnant women, and the evidence from 
these is inconsistent.31, 37, 79 For example a case-control study by Pomp et al. 
demonstrated a 5 and 60-fold increased risk of VTE associated with 
antepartum and postpartum period respectively compared to non-pregnant 
women. However Vikrus et al. in their population-based cohort study 
demonstrated a 3.5 and 8-fold Increased risk of VTE during the antepartum 
and postpartum periods when similar comparisons were made. 
2.1.1 Study justification and aim 
Accurate estimates of rates of VTE that are generalisable to the majority of 
pregnancies will aid both women and practitioners In their decision making 
surrounding the prevention of VTE. I therefore aimed to determine the 
absolute and relative risks of VTE In women of child bearing age around 
pregnancy with the primary objective of Informing revisions to existing clinical 
guidelines. 
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2.2 Method 
2.2.1 Data source used 
The dataset used to for this study comes from The Health Improvement 
Network (THIN). It is a computerised primary health care database containing 
medical, prescription, lifestyle and socio-demographic Information from 
individual anonymised patients from across the UK. It was Initiated as a 
collaboration between two companies with established names In primary care 
computing; EPIC, an expert in the provision of the primary care patient data 
that is used for medical research and In Practice System (InPS) who 
developed and provide the widely used Vision general practice computing 
system. The anonymised patient data are collected from the primary care 
practice's ViSion clinical system on a regular basis without interruption to the 
running general GP's system and sent to EPIC who supplies the THIN data to 
researchers. The baSic aims of THIN are; 
• To help those practices that have joined THIN Improve the quality of 
their clinical data recording by offering training and analysis of the 
practice's anonymised patient data 
• Create a database of anonymlsed primary care data to be used by 
academics, commercial and other research organisations to undertake 
studies in epidemiology, drug safety and the treatment and 
prevention of disease. 
The version of THIN used for the second and third chapter of this thesis 
contained data from 429 practices with a total of 7.7 million patients of which 
3 million patients were actively registered and could be prospectively 
followed. 
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2.2.2 Information contained within THIN 
Upon data collection, patient's identifying Information such as name, exact 
date of birth and National Health Service (NHS) number are removed. 
Although identifying information is not available to THIN, each patient in the 
database is assigned a new unique identifier to be used by the researcher to 
identify individual patients. Additional demographic information such as age 
and gender are also collected. THIN also contains life style related 
information such as smoking status and alcohol consumption recorded by the 
general practitioner during the course of clinical consultation. The medical and 
prescription records in THIN have been previously validated for pharmaco-
epidemiological research.8o-82 For instance Lewis et al82 carried out series of 
studies using THIN found the expected positive associations of stoke with 
diabetes and hypertension; of myocardial Infarction with hypertension, 
hypercholesterolemia, obesity and smoking and of peptic ulcer with aspirin, 
NSAIDs and potassium. Furthermore the group also confirmed the negative 
association of colorectal cancer with aspirin, NSAIDs and Cox-2 inhibitors. 
All medical conditions and symptoms reported by patients to the GP are 
recorded on the computer during a consultation. These build up a complete 
computerised medical history for each patient. All medical conditions In THIN 
are recorded in the form of Read codes. These use a hlerarchal system 
allowing cross-referencing of the codes to International Classification of 
Disease (ICD-lD) headlngs.83 Information on secondary care referrals are also 
recorded in the database. Similarly, secondary care information Including 
hospital admissions, diagnosis, and outpatient consultations is received by 
primary care practices and also retrospectively recorded. 
Prescriptions In primary care are very well recorded as the computerised 
system used by GPs to enter medication Is also used to print paper copies of 
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the prescription to be presented at the pharmacy by the patients. The 
computerised prescribing creates therapy records for each patient using the 
Multilex coding system which can be linked to the relevant chapter of the 
British National formulary (BNF). Prescriptions not issued from the computer, 
such as controlled drugs, immunisations, private prescriptions and drugs 
prescribed during the home visits should all be entered. However there is a 
possibility of under recording. Additionally drugs prescribed in secondary care 
or by other specialists will not appear in the THIN data unless the treatment 
is continued after the patient is discharged. Due to the constraints of 
specialist and hospital prescribing budgets many prescriptions Issued outside 
of the GP practice will usually be enough to cover only the first 7 to 14 days. 
Each THIN practice has data split into four raw standard data files from which 
the researcher can extract the relevant Information. These can be linked 
together by a unique patient Identifier. Table 2-1 presents the overall file 
structure of THIN. 
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Table 2-1: File structure of the data file contained In THIN 
Files 
Patient 
Clinical 
Therapy 
Additional data 
Information contained 
Year of birth, gender, death date, transfer out date, 
date of registration, registration status etc. 
Event date, Read code for medical disease diagnosis, 
symptoms, procedure and investigations, referral 
I nformation etc. 
Date of prescription, drug code using Multilex coding 
system, dose, number of prescriptions, duration of 
prescription etc. 
This file contains additional patient Information 
including life style related characteristiCS including 
smoking status, alcohol consumption etc. 
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2.2.3 Date information 
The patient file contains a computerization date, Vision date and Acceptable 
Mortality Reporting (AMR) date. The computerization date is calculated as the 
date when a practice started using computerized prescriptions every day for 
certain consecutive months whereas the Vision date is the date when a 
practice switched to Vision practice management software to record 
consultations. 
The AMR date represents the date from which a practice Is expected to be 
reporting all-cause mortality In accordance with those derived from the Office 
for National Statistics (ONS) as age and sex standardised to the local 
practice's population. The application of this date aims to ensure that no 
immortal time periods are present in the data. For instance such periods may 
occur when a practice switches to another system and doesn't remove all 
deceased patients or if a practice Is split some deceased as well as alive 
patients are transferred to the new practice. 
2.2.4 Justification of using THIN 
Advantage and disadvantages of using THIN 
(With specific reference to VTE In pregnancy studies) 
THIN is an incredible data source which is now widely used for epidemiological 
studies. However like all data sources there are certain limitations which 
should be kept in mind. The following section mentions some of the strengths 
and limitations of THIN and their consideration to certain extent underpins the 
design of studies presented In the following chapters. 
75 
Size 
One of the biggest strengths of this primary care database is its size. With 
data on millions of patient records, it is possible to study rare diseases like 
VTE in pregnancy for which bespoke cohorts may not be cost effective. The 
large sample does not only give more precision and power to look at the 
incidence of VTE in narrow windows of time (e.g. trimester of antepartum) 
but also provides the opportunity to look at rare risk factors for VTE (e.g. 
postpartum haemorrhage, cardiac disease, Inflammatory Bowel Disease 
(IBD» which are highlighted in subsequent chapters. 
Representativeness 
Whilst general practices registered with THIN are self-selected from various 
different areas of the UK, it's population is highly comparable to the UK 
population in terms of age and sex structure level at regional levels.8o 
Therefore it is reasonable to assume that the study findings using THIN are 
generalisable to the whole of the UK population. One limitation to this 
generallsability is that THIN marginally under represents those practices 
serving more deprived populations.84 However the Impact of this may be 
trivial as no association has been found between PE and socio-economlc 
status among pregnant women. ll 
Prospectively collected 
For each patient registered with THIN, there is a start date which ascertains 
which data are prospectively or retrospectively recorded. This Is of particular 
Importance for studies where exposure recall may be biased. For Instance 
pregnant women with VTE may be more likely to recall their history of VTE 
risk factors (e.g. hyperemesis, pre-pregnancy BMI, history of medical 
conditions) more accurately than those without thrombosis. This also gives 
more precise timing of both exposure and outcome. 
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Validated 
Although THIN uses strict measures to ensure the quality of data is of the 
highest standard, information recorded on specific diseases can also be 
externally validated by third parties. The process involves requesting 
anonymised paper records or asking the GPs of relevant practices to fill out a 
questionnaire to validate medical Information recorded In the electronic data. 
The diagnosis of VTE has been validated by this process with a positive 
predicted value (PPV) of 84%85 in a similar primary care database (Clinical 
Practice Research Database (CPRD), some of whose practices also contribute 
to THIN. Similarly, fertility rates estimated from THIN are comparable to the 
national figures. 81 
Contemporary 
The changes In diagnostic modalities over time have led to better clinical 
ascertainment of VTE diagnosis in the UK and in most high income countries. 
This Is In addition to the Increasing prevalence of certain VTE risk factors (e.g. 
body mass Index) which may contribute towards the Increase In the incidence 
of VTE. Most studies on the Incidence and risk factors of VTE have used data 
up to 2005 which may not reflect the true incidence of VTE In more recent 
years since UK21 and US64 guidelines on thromboprophylaxls have been more 
comprehensively disseminated after 2004. Hence THIN provides a large 
component of follow-up time from more recent years which may be 
generalisable to the current rather than the historical clinical setting. One 
drawback Is the Increased potential for ascertainment bias which will be 
discussed later In this chapter. 
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Short duration of individual women follow-up 
It is Important to note that in THIN the duration of follow-up for each 
individual patient is short. For instance the median follow-up (of acceptable 
quality prospectively recorded clinical data) for potentially fertile women In 
THIN Is approximately 3.2 years and there are no prospectively recorded data 
before 1987. This means that there is a potential of missing pregnancies prior 
1987 which may result in incorrect information on parity and gravidity of 
women who do not have such data starting at the beginning of their 
reproductive years. 
Incomplete recording 
As with any routinely collected data, there is a concern that what is recorded 
Is not determined by protocols designed for research. This means that 
recording of Information In THIN is purely driven by a GP's and other health 
professionals' assessment and care of the patient in primary care. Hence the 
recording of data Is not only Incomplete but it Is likely there Is bias as to 
which data are missing. For instance, it Is likely that a GP will record "a 
patient smokes heavily" If they know, as this may adversely affect health. 
However It is less likely that they would record the Information that a patient 
Is non-smoker unless they suffered from condition which might be 
attributable to smoking. This limitation may have been addressed to a certain 
extent In recent years with the introduction of Quality Outcome Framework 
(QOF) which is an Incentive program for all general practices In the UK.86 It 
rewards GPs for how well patients are cared for based on their completeness 
of certain clinical Indicators of clinical practice quality. The QOF contains 
certain indicators for which a practice scores points according to their level of 
achievement. These Indicators include cancer, cardiovascular diseases and 
respiratory disease. This presumably may have an Impact on the 
completeness of recording of medical conditions. However the evidence on 
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whether it improves the quality of care of the patient is weakY Currently, 
however there are no indicators for antenatal care so the extent to which 
biases may operate in recording around pregnancy are unknown. 
2.2.5 Study population 
The study time period was defined between April 1995 and July 2009 during 
which all women between the ages of 15 and 44 years registered with THIN 
were identified. All women with a medical code for VTE before the start of the 
observation period (history of VTE) were excluded. The study start date was 
defined as the latest of the woman's registration date with THIN, the 
practice's AMR date, first day of 1995 and the date of the women's 15th 
birthday. However for some practices, the Vision date was used Instead of 
AMR date if it was recorded earlier than the latter date as It Implied that 
information recorded in Vision is recorded in a stable and reliable way. The 
end date of the study was defined as the earliest date of the transfer out 
date, date of death, date of first VTE, date of last data collection from the 
practice and the woman's 45th birthday. 
2.2.6 Study design 
An open historic cohort design was used In the study where women between 
the ages of 15 and 44 years could enter and exit study at different points In 
time (Figure 2-1). A woman stopped contributing person time If she 
developed VTE, died, or was transferred out of a participating practice. 
2.2.7 Exposure 
The exposure in this study was defined as pregnancy including the 
postpartum period. Pregnancies were defined using Read codes for 
delivery/pregnancy which were categorised by pregnancy outcome (live birth, 
79 
stillbirth, miscarriage or termination). The total person time for each woman 
was divided into antepartum postpartum and time outside of pregnancy. 
Exposure and baseline time periods were defined as follows: 
2.2.7.1 Antepartum 
The antepartum period was defined as the date of the woman's last recorded 
menstrual period until the date of delivery. For women with no information on 
the gestational age at delivery, antepartum was defined as 280 days (40 
weeks) prior to the date of delivery. This was subsequently divided Into 
trimesters which were defined as follows: 
First trimester: Date of conception until 90 days after conception 
Second trimester: 90 days after conception until 180 days after conception 
Third trimester: 180 days from conception until the date of delivery. 
2.2.7.2 Postpartum 
The postpartum period was defined as up to 12 weeks (84 days) following 
delivery and was divided as follows: 
Early postpartum: The first 6 weeks (42 days) following delivery 
Late postpartum: The second 6 weeks (43-84 days) following delivery. The 
overall postpartum period was also divided Into Individual weeks. 
For pregnancies resulting In miscarriages and terminations, this time period 
was defined as the first 6 weeks following a miscarriage or termination. 
2.2.7.3 Baseline period 
To calculate baseline rates I used the cohort time spent outside pregnancy 
(including the first 12 weeks postpartum) during their registration with the 
general practice. For women with no recorded pregnancies this included their 
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entire registration during the study period between which they were 15 and 
44 years of age. This time period will be referred to henceforth as "time 
outside pregnancy". 
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Figure 2-1: Study design 
April 1995 Pregnancy 
1 
.- , 
Antepartwn 
July 2009 
VTE eventl Transferred out/Death 
Person time 
TIE event/ Transferred out/Death 
• 
Postpartwn 
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2.2.S Outcome 
The outcome for this study was defined as the first venous thromboembolism 
(VTE) including pulmonary embolism (PE) or deep vein thrombosis (DVT) 
experienced by a woman more than a month after her study start date. Cases 
and person time occurring within one month of the study start date were 
excluded to avoid any prevalent cases being included as Incident which is a 
potential limitation of the data used. la The one month cut-off was also based on 
an initial examination of the dataset which revealed higher Incidence of VTE 
during the first month of women's registration with the practice (Appendix 3). 
Diagnosis of VTE was based on a recorded medical code assigned by a physician 
(Appendix 4) supplemented by having either a recorded anticoagulant 
prescription (either unfractlonated heparin, warfarin or low molecular weight 
heparin) in the 90 days following the event (Appendix 5), a medical diagnosis 
indicating an anticoagulant prescription which took place In the 90 days following 
the event (Appendix 6), death within 30 days of the event (see Appendix 7 for 
derivation of the date of death). Based on this, 84% of VTE cases were validated 
in a previous study using similar electronic primary care data (CPRD).85 
2.2.9 Statistical analysis 
2.2.9.1 Descriptive statistics 
All data management and analysis was carried out using Stata version 11. The 
study population was described using frequencies and percentages Including how 
different ways of validating VTE might Influence Incidence rates. Total person 
time In the study was divided Into antepartum, postpartum and time outside 
pregnancy. The median follow up time along with the Inter-quartile range (IQR) 
was also presented. 
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2.2.9.2 Calculation of Incidence 
Incidence rates and 95% Cls were calculated In the antepartum, postpartum and 
time outside pregnancy per 100,000 person years. This was done by dividing 
total number of VTE events in the antepartum and postpartum period and time 
outside pregnancy by person-years of follow up in those respective time periods. 
Similarly rates per 100,000 person-years were also calculated for each trimester 
of the antepartum period and different periods of postpartum time (early, late, 
and by weeks). The calculated incidence rates were also stratified by calendar 
time (before and after 2004). The calendar year cut-off was based on the 
publication of the first RCOG comprehensive guideline for thromboprophylaxls. 2o 
2.2.9.3 Calculation of Incidence rate ratios 
To assess the increase in the risk of VTE antepartum and postpartum, Incidence 
rate ratios (IRR) were calculated in those respective time periods compared to 
time outside pregnancy using a Poisson regression model. The same baseline 
was used when calculating IRRs for each trimester of antepartum and different 
periods of postpartum compared to time outside pregnancy. The incidence rate 
ratios were adjusted for age and calendar year. Additionally an Interaction term 
between pregnancy status (antepartum, postpartum and time outside 
pregnancy) and age group was fitted to formally test for Interaction between 
these terms. 
2.2.9.4 Sensitivity analysIs 
Due to specific limitations of the dataset used as previously highlighted, the 
following sensitivity analyses were performed. 
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2.2.9.4.1 Restricting the outcome definition 
One limitation of using the VTE outcome definition In pregnancy In particular Is 
the potential overestimation of some of the VTEs especially in the antepartum 
period where low molecular weight heparin (LMWH) can be used both as 
prophylaxis and therapeutically. A sensitivity analysis was therefore performed 
by restricting all analyses to include only those women who were prescribed 
either warfarin or related drugs (Fondaparinux, Lepiradin, Phenldione and 
Acenocoumorol) or had a medical code indicating anticoagulant therapy (but 
who did not have LMWH prescribed) within 90 days of the event or death within 
30 days of the event. Absolute and relative rates of VTE for periods of 
antepartum and postpartum were calculated using methods identical to before. 
2.2.9.4.2 Oyer diagnosis and ascertainment bias due to change in practice 
Since the publication of the first comprehensive guidelines on the use of 
thromboprophylaxls during pregnancy and postpartum in 200420 it is plausible 
that pregnant women might be more likely to get over diagnosed (ascertainment 
bias) with VTE due to increased clinical awareness compared to before the 
guidelines. In order to assess the impact of any changes in practice relating to 
the diagnosis of VTE, IRRs were calculated to compare antepartum and 
postpartum risks with those outside pregnancy, but with results stratified by 
calendar time (before and after 2004). 
2.2.9.4.3 Over diagnosis In pregnant women during the third trimester 
It is also possible that VTE may be particularly prone to over diagnosis In the 
third trimester of pregnancy where pregnant women are more likely to visit 
cliniCians. Since there is no information on the severity of disease and cause of 
death In the current dataset the analyses mentioned In Section 2.2.9.2 and 
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Section 2.2.9.3 were repeated restricted to pulmonary embolism, where over-
diagnosis is assumed to be less likely 
2.2.10 Ethics approval 
This study conducted in this and following chapter was approved by the THIN 
scientific advisory committee (reference number lO-002R) 
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2.3 Results 
2.3.1 Study population 
Figure 2-2 presents the basic characteristics of the study population. The study 
population consisted of 1,720,839 potentially fertile women (aged 15-44 years) 
of whom 20% experienced at least one pregnancy. There were a total of 
497,351 pregnancies during the study period of which 75% ended In live births 
whereas 0.2% (1,152), 13% (64,167) and 11% (57,030) resulted In stillbirth, 
termination and miscarriage respectively. The study Included over 7.8 million 
person-years of follow up. Around 5% of this time was associated with 
pregnancy which was divided into 279,231 and 97,981 person-years for 
antepartum and postpartum periods respectively. A total of 7.4 million person-
years were associated with time outside pregnancy which Included non-pregnant 
time periods for women experiencing at least one pregnancy and the whole 
period of observation for women with no recorded pregnancy during the study 
period. The median follow up time for each woman was 3.2 (IQR= 1.2 - 6.S) 
years. 
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Figure 2-2: Basic characteristics of the study population 
Exposure 
Total women In study -1,720,8'9 
Total prelfUlnt women-335,999 
Total prelfUlnc:Ie.- 497,351 
Medl.n follow up (IQR). 3.2 (1.2-6.5) 
Women durllll potentially fertile period 
(Ale - 15 - 44 years) 
Person ye.rs - 7,824,026 
I 
nme period .ssoclated 
with prelf1anc:y 
Person years. 377,212 
I 
I I 
Exposure Baseline 
Total Ante partum period 
In person yea,. -279,231 
Live blrths==2SS,292 
Stlllblrths=6SS 
Mlsc.rrlages=l1,188 
Terrnlnatlons=12,096 
Total Postpartum period 
In person yea ... - 97,981 
live blrths=84,12S 
Stlllblrths=24S 
Mlscarrtaze=6,321 
Total outside prepanc:y time 
Person ye ..... 7,446,814 
T errnlnatlons=7,288 
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2.3.2 VTE Case Confirmation 
Figure 2-3 presents the total number of cases confirmed using different sources 
of validation. There was a total of 4,456 potential cases of VTE identified during 
the study period of which only 59% (2,668) were confirmed by the definition in 
Section 2.2.8 and met my criteria for an outcome event. Of the total cases 
confirmed, the majority (95%) were validated by a prescription of 
anticoagulants (80% warfarin and related drugs and 15% heparin) within 90 
days of the event. An additional 3% of the cases were confirmed by medical 
codes for anticoagulant therapy for heparin or warfarin recorded within 90 days 
of the VTE event. Around 1 % of additional VTE cases were confirmed by death 
recorded within 30 days of the event, the majority of which followed a PE event. 
Table 2-2 presents the number of confirmed cases at different times during 
antepartum and postpartum periods by mode of confirmation. More than half of 
the antepartum VTEs were confirmed by a heparin prescription, with the highest 
proportions confirmed by heparin in the first and second trimesters. However in 
the postpartum 84% of the cases were confirmed by warfarin or related drugs 
whereas only 12% were confirmed by heparin. Other sources of confirmation 
Including deaths and anticoagulant clinics codes were responsible for only a 
small number of additional case confirmations. 
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Figure 2-3: Number of cases confirmed using different sources of 
validation presented in a hierarchical manner 
Total VTE cases 
2,668 
, 
Anticoagulant prescription 
confirmed 
warfarin=2,134 (80%) 
Heparin=409(15%) 
Additional cases confirmed by 
anticoagulant medica' code 
89(3.4%) 
, 
Additional cases confirm ed by 
death 
36(1.3%) 
Table 2-2: Number of cases confirmed In specific time periods (number 
of additional cases confirmed In a hierarchical manner from left to right) 
Variable Anticoagulant Anticoagulant Death Total n(%) 
prescription n(%) clinic n(%) n(%) 
Warfarin Heparin 
Antepartum 49(22) 163(73) 12(5) 0(0) 224(100) 
First trimester 8 (16) 39(78) 3(6) 0(0) 50(100) 
Second trimester 3(6) 40(85) 4(9) 0(0) 47(100) 
Third trimester 38(30) 84(66) 5(4) 0(0) 127(100) 
Postpartum 259(84) 36(12) 10(3) 1(0.3) 306(100) 
Early postpartum 218(83) 33(13) 9(3) 1(0.4) 261(100) 
Late postpartum 41(91) 3(7) 1(2) 0(0) 45(100) 
Time outside 1,826 (85) 210 (10) 67 (3) 35 (2) 2,138 (100) 
pregnancy 
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2.3.3 Risks of VTE in pregnancy overall and by age 
Table 2-3 presents the absolute rate of VTE per 100,000 person-years In and 
around pregnancy and outside pregnancy by age. Among all women, the rate of 
VTE ranged from 28 per 100,000 person years outside pregnancy (95% Cl, 27-
29) to 337 per 100,000 person years during the postpartum period (95% Cl, 
300-379). The overall rate of VTE for pregnancies resulting In live or stillbirth In 
and around pregnancy (Including both antepartum and postpartum periods) was 
146 per 100,000 person years (95% Cl 134-160 per 100,000 person years). 
Women in the oldest age band (35-44 years) had a 38% higher rate of VTE than 
women aged 25-34 years during the time outside pregnancy (absolute excess 
risk of 0.1 per 1000 person-years). Additionally there was a 41% and 57% 
Increased risk during antepartum and postpartum periods respectively among 
women a g e d ~ 3 S S years compared to baseline. For the time period associated 
with miscarriages the risk of VTE was calculated to be 3S and 126 per 100,000 
person-years for antepartum and postpartum respectively. Similarly, antepartum 
and postpartum risks of VTE for pregnancies resulting In termination were 
calculated to be 41 and 178 per 100,000 person-years respectively. 
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Table 2-3: Rate of VTE by age and pregnancy status. 
Variable N Rate (95%CI) IRR (95%CI) 
Time outside pregnancy 
All ages 
15-24 years 
25-34 years 
35-44 years 
Antepartum 
All ages 
15-24 years 
25-34 years 
35-44 years 
Postpartum 
All ages 
15-24 years 
25-34 years 
35-44 years 
Antepartum (all ages) 
Postpartum (all ages) 
Antepartum (all ages) 
Postpartum (all ages) 
Pregnancies ending in live or stillbirth 
2138 
295 
711 
1132 
215 
45 
120 
50 
28 (27-29) 
14 (13-16) 
28 (26-30) 
38 (36-41) 
84 (73-96) 
73 (54-98) 
79 (60-95) 
113 (85-148) 
337 (300-379) 
0.51 (0.45-0.59) 
1.00 
1.38 (1.26-1.52) 
0.91 (0.65-1.29) 
1.00 
1.41 (1.01-1.96) 
285 
48 
156 
81 
255 (192-339) 0.80 (0.58-1.11) 
316 (270-370) 
497 (399-618) 
1.00 
1.57 (1.20-2.05) 
Pregnancies resulting In miscarriages 
4 35 (13-95) 
8 126 (63-253) 
Pregnancies resulting In terminations 
5 41 (17-99) 
13 178 (103-307) 
*per 100,000 person years 
'Increase In the risk compared to 15-25 years 
t Increase In the risk compared to 25-34 years 
IRR Incidence rate ratio, Cl confidence Interval, VTE venous thromboembolism 
RD Risk difference 
RD (95%CI) 
13 (10 to16)¥ 
10 (7 to 13)t 
6 (-19 to .3)' 
3 (-1 to 6)t 
60 (-27 to 148)· 
180 (61 to 300)t 
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2.3.4 Incidence rate ratios In and around pregnancy 
Overall for pregnancies resulting in live or stillbirths a 2.9 fold (95% Cl 2.53-
3.36) and 11.6 fold (95% Cl 10.3-13.2) increase in risk of VTE was observed 
during the antepartum and postpartum periods respectively compared to outside 
pregnancy (Table 2 4). These IRRs remained similar when stratified according to 
age. This was confirmed by a non-significant test for interaction between age 
and pregnancy status (p=0.40). 
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Table 2-4: Overall and age-specific Incidence Rate ratios of VTE in ante 
and postpartum compared to outside pregnancy 
Variable Incidence rate 95%CI Incidence rate 95%CJ 
ratio ratio 
(Unadjusted) (Adjusted) 
Pregnancies resulting in live or stillbirths 
All ages 
Time outside pregnancy 1.00 1.00 
Antepartum 2.9 2.54 - 3.66 2.92 2.53 - 3.36 
Postpartum 11.7 10.3 - 13.3 11.6 10.3 - 13.2 
15-24 years 
Time outside pregnancy 1.00 1.00 
Antepartum 5.00 3.65 - 6.85 5.02 3.66 - 6.87 
Postpartum 17.4 12.8 - 23.6 17.4 12.8 - 23.6 
25-34 years 
Time outside pregnancy 1.00 1.00 
Antepartum 2.83 2.34 - 3.44 2.82 2.33 - 3.43 
Postpartum 11.2 9.46 - 13.3 11.1 9.38 - 13.2 
35-44 years 
Time outside pregnancy 1.00 1.00 
Antepartum 2.89 2.18 - 3.84 2.86 2.15 - 3.80 
Postpartum 12.7 10.1 - 15.8 12.5 10.0 - 15.7 
Pregnancies resulting In miscarriages 
All ages 
Time outside pregnancy 1.00 1.00 
Antepartum 1.24 0.46 - 3.32 1.25 0.46 - 3.33 
Postpartum 4.40 2.20 - 8.82 4.39 2.19 - 8.80 
Pregnancies resulting In terminations 
All ages 
Time outSide pregnancy 1.00 1.00 
Antepartum 1.43 0.59 - 3.46 1.75 0.73 - 4.23 
Postpartum 6.21 3.60 - 10.7 7.5 4.38 - 13.0 
*adjusted for age and calendar year 
Cl confidence Interval 
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2.3.5 Risks by trimester and weeks postpartum 
Absolute rates of VTE were roughly similar in the first and second trimester with 
incidence rates of 53 and 55 per 100,000 person years respectively (Table 2-5). 
The rate of VTE was higher in the third trimester (133 per 100,000 person-
years; 5-fold increase in risk) and peaked in the early postpartum period (561 
per 100,000 person years; 20-fold increase In risk compared to time outside 
pregnancy). The rate of VTE was also slightly high in the late postpartum period 
with an absolute rate of 108 per 100,000 person-years (3-fold increased risk). 
Figure 2-4 shows the rate of VTE per 100,000 person-years by weeks of 
antepartum and postpartum time showing that the rate of VTE Is much higher in 
the first five weeks postpartum compared to the weeks immediately preceding 
delivery. However, the rate of VTE sharply declined from the fifth week onwards 
in the postpartum period. 
Table 2-5: Rate of VTE per 100,000 person years during different time 
periods of pregnancy and postpartum (live or stillbirths) compared to 
time outside pregnancy 
Variable Rate (95%CI) IRR (95% Cl) IRR (95% Cl) 
(unadjusted) (Adjusted)· 
Outside pregnancy 28 (27-29) 1.00 1.00 
Antepartum 
First trimester 53 (39-72) 1.86 (1.36-2.53) 2.01 (1.47-2.74) 
Second trimester 55 (41-74) 1.94 (1.45-2.59) 2.08 (1.55-2.77) 
Third trimester 133 (112-159) 4.65 (3.89-5.56) 4.95 (4.13-5.93) 
Postpartum 
Early postpartum 561 (494-636) 19.5 (17.1-22.3) 20.6 (18.0-23.6) 
Late postpartum 108 (80-144) 3.76 (2.80-5.06) 3.95 (2.93-5.31) 
*Adjusted for age and calendar year 
Cl: Confidence Interval 
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Figure 2-4 Rate of venous thromboembolism per 100,000 person-years in weeks of antepartum and postpartum (live or 
stillbirths only) 
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2.3.6 Rate of VTE stratified by calendar year 
Figure 2-5 presents the overall rate of VTE at different time periods around 
pregnancy and outside pregnancy before and after 2004. Over(3I1, the rate of 
VTE remained roughly similar for outside pregnancy and the three trimesters 
of antepartum when stratified by calendar year. However the rate of VTE 
more than doubled in the late postpartum from 69 per 100,000 person years 
(95%CI 33-99) before 2004 to 149 per 100,000 person years (95% Cl 89-
190) after 2004. However this difference was not statistically significant. 
Figure 2-5: Rate of VTE stratified by calendar year (pregnancies of 
women resulting in live or stillbirths only) 
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2.3.7 Sensitivity analysis 
2.3.7.1 Rate of VTE using restrictive definition (pregnancies of 
women resulting In live or stillbirths onlv) 
Around 84% of VTE cases were confirmed based on warfarin or related drugs 
(Fondaparinux, Lepiradin, Phenidione and Acenocoumarol) prescribed in 
primary care or a medical code Indicating anticoagulant therapy within 90 
days of the event occurring or death within 30 days of the event. For those 
events that occurred in the 1st and 2nd trimester this proportion was far lower 
(7 of 88= 8%) increasing to 33% In the third trimester and 87% in the 
postpartum. Therefore my results remained broadly unchanged during time 
outside pregnancy, third trimester of antepartum and postpartum when using 
this restricted definition (Table 2-6). However my calculated estimates were 
much lower in the 1st and 2nd trimesters corresponding to the absolute rates 
of 5 and 3 per 100,000 person-years respectively. 
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Table 2-6 Rate and rate ratio of VTE using restrictive definition 
(pregnancies of women resulting in live or stillbirths only) 
Time period N Rate (9S%CI) IRR (9S%CI) 
Time outside pregnancy 1904 25 (24-26) 1.00 
Antepartum overall 49 19 (14-25) 0.81 (0.61-1.07) 
Trimester 1 4 5 (1-13) 0.22 (0.08-0.59) 
Trimester 2 3 3 (1-11) 0.15 (0.04-0.46) 
Trimester 3 42 44 (32-59) 1.85 (1.36-2.51) 
Postpartum overall 248 293 (259-332) 12.2 (10.6-13.9) 
Early postpartum 206 481 (420-552) 20.0 (17.3-23.2) 
Week 1 . 32 445 (314-629) 18.6 (13.1-26.4) 
Week 2 37 515 (373-711) 21.5 (15.5-29.8) 
Week 3 45 629 (470-843) 26.2 (19.5-35.3) 
Week 4 37 520 (366-704) 21.6 (15.6-30.0) 
Week 5 36 508 (366-704) 21.1 (15.2-29.4) 
Week 6 19 262 (171-422) 11.2 (7.12-17.6) 
Late postpartum 42 100 (74-136) 4.18 (1.00-1.18) 
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2.3.7.2 Incidence rate ratio stratified by calendar year 
The rate of VTE slightly increased after 2004 for both antepartum and 
postpartum periods (Table 2-7). The absolute rate increased from 66 per 
100,000 person-years before 2004 to 96 per 100,000 person years after 2004 
for antepartum. Similarly, for postpartum, the absolute rate was calculated to 
be 291 per 100,000 person years and 334 per 100,000 person years for 
before and after 2004 respectively. However the relative increase in the risk 
for antepartum and postpartum periods compared to outside pregnancy 
remained roughly similar when stratified by calendar year as rates outside of 
pregnancy also increased over this time period. 
Table 2-7: Rate and rate ratios stratified by calendar year 
(pregnancies of women resulting in live or stillbirths only) 
Time period N Rate (950/0CI) IRR (950/0CI) 
Time outside pregnancy 
Antepartum (overall) 
Postpartum (overall) 
Time outside pregnancy 
Antepartum (overall) 
Postpartum (overall) 
Before 2004 
1085 26 (24-28) 
100 66 (54-80) 
148 291 (248-343) 
After 2004 
1053 31 (29-33) 
124 96 (81-115) 
158 334 (285-390) 
1.00 
2.73 (2.22-3.36) 
11.9 (9.99-14.1) 
1.00 
3.26 (2.27-3.96) 
11.2 (9.46-13.2) 
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2.3.7.3 Only restricting analysis to pulmonary embolism 
Table 2-8 presents the absolute and relative risk of PE during different time 
periods of antepartum and postpartum compared to outside pregnancy. 
Around 36% of VTEs were categorized as PE based on medical codes. Of the 
65 PE cases diagnosed during the antepartum period 62% occurred during 
the third trimester. The absolute rate of PE was lower In the first and second 
trimester. During the third trimester and early postpartum period the relative 
risk Increased to 4.1 fold (95% Cl 3.0-5.7) and 21.4 fold (95%CI 17.2-26.7) 
respectively compared to time outside pregnancy. 
Table 2-8 Absolute rate and incidence rate ratios of PE per 100,000 
person-years in different time period of pregnancy and outside 
pregnancy 
Time period N Rate (95%CI) IRR (95%CI) 
Time outside pregnancy 789 10 (9-11) 1.00 
Antepartum overall 65 25 (19-32) 2.53 (1.96-3.27) 
Trimester 1 14 18 (10-30) 1.80 (1.06-3.07) 
Trimester 2 11 13 (7-23) 1.28 (0.70-2.33) 
Trimester 3 40 42 (30-57) 4.13 (3.00-5.69) 
Postpartum overall 104 123 (101-149) 12.0 (9.8-14.8) 
Early postpartum 93 217 (177-266) 21.4 (17.2-26.7) 
Week 1 14 194 (115-328) 19.2 (11.3-32.7) 
Week 2 16 223 (136-364) 22.0 (13.4-36.2) 
Week 3 19 265 (196-419) 26.8 (16.9-41.5) 
Week 4 21 295 (169-419) 29.2 (18.8-45.0) 
Week 5 13 183 (106-316) 18.0 (10.4-31.3) 
Week 6 10 141 (7-114) 13.9 (7.47-26.0) 
Late postpartum 11 26 (14-47) 2.59 (1.42-4.70) 
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2.4 Discussion 
2.4.1 Main findings 
Using data from a large population-based cohort, I found a relatively low rate 
of first VTE in pregnancy; however, this rate was still much higher than that 
seen in the time outside pregnancy, with a noticeably raised risk In the first 
five weeks postpartum. During the antepartum period, women In their third 
trimester were at a 5 fold Increased risk of first VTE compared to their time 
outside pregnancy whereas In the first and second trimester this rate was 
only marginally higher. It was also found women a g e d ~ 3 5 5 years were 41 % 
(absolute risk=O.l%) and 57% (absolute risk 0.5%) more likely to develop 
VTE compared to those aged 25-24 years during antepartum and postpartum 
periods respectively. These findings are generallsable to the majority of 
pregnant women who have not had a prior VTE providing valuable Information 
to accurately assess the risk of VTE and the potential need for prophylaxis. 
2.4.2 Strengths and limitations 
This study used Information from approximately 1.7 million women aged 
between 15 and 44 to accurately determine the absolute and relative risks of 
first VTE within specific antepartum and postpartum periods In a 
contemporary, population-based manner. It used an open cohort approach to 
the analysis that calculated the rate of VTE In pregnancy taking account of 
time varying risk periods using person-years as the denominator. This 
method adjusted for differences In the duration of antepartum and 
postpartum periods unlike traditional approaches (using number of 
pregnancies as the denominator) which assume that the time women spend 
In antepartum and postpartum periods Is Similar. Furthermore It also enabled 
me to capture the time period outside pregnancy and make appropriate 
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unbiased comparisons of these rates with those in the antepartum and 
postpartum periods. 
An important strength of this study is Its population-based nature with a large 
sample size in a nationally representative population which makes the 
estimates more generalisable and precise. A limitation to this generallsabllity 
Is the exclusion of pregnancies not resulting In live births or stillbirth from my 
subsequent trimester analysis due to lack of precise Information on length of 
gestation. However I believe that the effect of those exclusions on estimates 
is likely to be small as only 30 VTE events were associated with 
miscarriages/terminations. Our higher rate of VTE in the third trimester 
contradicts with the CMACE reports that have consistently highlighted higher 
proportions of deaths in the first trimester of the antepartum. However the 
case fatality associated with VTE is rare (case fatality of 0.2-3%). It Is also 
Important to consider that my study aim was to look at the incidence of VTE 
which Included both fatal and non fatal VTE events as opposed to CMACE 
reports which are only based on only few fatal VTE events (3 deaths between 
2006-2008) resulting in death (mortality rates). In my study population there 
were only 14 deaths which occurred during the antepartum period of which 4 
occurred during the first trimester. Even assuming that all those deaths 
during the first trimester were due to VTE, the Incidence of VTE Increased 
only slightly (57 versus 53 per 100,000 person-years). 
Another potential weakness of this study Is the use of anonymlsed patient 
records with no direct access to Individual patients. I was therefore dependent 
on the physicians for accurate recording of diagnoses. However, a large 
proportion of practices in THIN also contribute to a similar database, the 
Clinical Practice Research Datallnk, that has been extensively used for 
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research and the definition of VTE I used has been previously validated in this 
database.85 
My comparisons to time outside pregnancy need to be Interpreted with the 
understanding that some of the non-pregnant women will be taking the 
combined oral contraceptive which is known to increase VTE risk.88 However, 
trying to characterise periods of oral contraceptive use within t h ~ ~ non-
pregnant time was beyond the scope of the present work. Furthermore in the 
UK, women may get oral contraceptive from other sources other than GPs 
(e.g. family planning clinics), so exposure maybe mlsclasslfied In these data. 
Finally, the absolute rate of VTE was lower in the present study during the 
period outSide pregnancy than in those from Denmark and the U.S.A. 31, 37 
The definition of VTE used In the present study was found to have a positive 
predictive value of 84% when validated among women of childbearing ~ g e e In 
the CPRD. Such validation however does not give an Indication of the 
negative predictive value (or sensitivity), and I cannot Ignore the potential for 
my absolute rates of VTE to be underestimated If some anticoagulant 
prescriptions emanated from secondary rather than primary care. Regardless 
of the limitations highlighted above, Huerta et al. reported an age and sex 
standardised Incidence rate of VTE In the general population using the GPRD 
which was similar to that observed In other Western studies, when using an 
Identical VTE definition to that of the present analysis.4 Another potential 
limitation is the lack of cause of death Information In my data. Deaths 
occurring within one month of VTE were automatically assumed to be VTE 
related which may not be true. However, the Impact of this limitation Is small 
as only 1% of total VTE cases were confirmed based on death alone. It Is also 
worth stating that all VTE events occurring within one month of the start of 
study period were excluded. This was based on the high Incidence rate In the 
first month following registration with the practice. It may be argued whether 
104 
a 1 month cut off was sufficient to exclude prevalent cases as women are 
more likely to join a practice when they are pregnant or planning to be 
pregnant. However my sensitivity analysis demonstrated that even excluding 
6 and 12 month periods following registration did not alter the pattern of my 
derived estimates. 
The ability to identify the use of either heparin or warfarin In primary care 
allows a greater level of detail than previous studies. When a restricted case 
definition was applied by including only cases with evidence of therapeutic 
anticoagulant use (I.e. excluding any potential use of prophylactic heparin) It 
was found that the absolute rates of VTE were drastically reduced In the 1st 
and 2nd trimester but not so much In the 3rd trimester or In the postpartum 
period. Given that heparin Is the treatment of choice In pregnancy this Is not 
surprising but means that the estimated rates may actually be too low In the 
sensitivity analysis as I would have certainly removed VTE cases that were 
receiving heparin as treatment rather than prophylaxis. Nonetheless the 
overall interpretation of my results did not alter. 
The lack of detailed Information on the diagnosis of VTE In primary care data 
restricted my ability to assess severity of the disease. This could potentially 
lead to over diagnosis of VTE among pregnant women. Similarly the Increased 
risk In the third trimester could also be the result of frequent GP visits during 
that time. However my sensitivity analysis showed that despite this rates of 
VTE have Increased In pregnant and postpartum women over time yet the 
relative Increase compared to the time outside pregnancy has remained fairly 
constant. Furthermore, the relative Increase In risk during different time 
periods of antepartum and postpartum also remained unchanged when I 
restricted my analysis only to PE where over-diagnosis would seem less likely. 
It Is also Important to note that ascertainment bias Is not just about the 
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exposure to health professionals but also about their specific concerns 
regarding VTE which is not possible to measure in these data. Higher rates of 
VTE during the postpartum might be mediated by certain complications 
associated with pregnancy or other co-morbidities. However I did not look at 
risk factors for VTE as it was beyond the scope of the current study. 
Secondly, hospitalization increases the risk of VTE70 which I was not able to 
take into account in this study. 
2.4.3 Comparison to other studies 
My absolute rates are slightly higher than those reported previously using the 
same primarY care database up to 2004.36 This may be due to better case 
ascertainment over the years. However, the updated incidence rate ratios are 
broadly similar for both antepartum and postpartum periods to what they 
were In the earlier analysis. Apart from that, only three previous studies have 
compared rates of VTE in pregnancy with those outside of pregnancy.31, 37, 78 
Recently, Vlrkus et al.37 reported absolute and relative risks of VTE within 
Individual trimesters of antepartum and weeks of early postpartum among 
Danish women which were similar to those In the present study. However, 
their rates were higher In the late third trimester suggesting that the risk of 
VTE in that period Is similar to that Immediately following childbirth In 
contrast to our results. This contradictory finding could potentially be due to 
lack of precise dates of VTE diagnosis. The use of date of admission as the 
date of diagnosis by Vlrkus et al. might have shifted the distribution of VTE 
event to the left so that events which occurred In the 1-2 weeks following 
delivery were recorded as taking place just before delivery. This could 
account for why in the current study the Incidence of VTE in the weekly 
Intervals Immediately following delivery were noticeably higher than the 
weeks preceding delivery, unlike In the Danish study. My findings were also 
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broadly similar to those reported in a p o p u l a t i o n ~ b a s e d d cohort In Olmsted 
County in the United States.31 However, their considerably smaller sample 
size (50,080 live births and 105 VTE events occurring around pregnancy), 
meant that there was insufficient power to rigorously compare risks in each 
trimester or In individual weeks postpartum with time outside pregnancy or 
by age strata. S9 Finally Pomp et aJ.79 In their case-control study reported a 5 
and 60-fold increased risk of VTE during the antepartum and postpartum 
periods respectively compared to n o n ~ p r e g n a n t . . However the lower 
proportion of controls (1.2% compared with an expected 2.2%) in first three 
months postpartum in their study may have resulted in the overestimation of 
odds ratio during the postpartum period. Finally, convenience sampling was 
used to recruit controls which somewhat limits the generaJisability of their 
study findings. 
2.4.4 Conclusion and Implications for clinicians 
Whilst guidelines issued In 2004 on the prevention of VTE around pregnancy 
could possibly have contributed to a reduction in the number of maternal 
deaths from VTE recently reported in the United KingdomS, there is stili 
considerable morbidity associated with VTE, which further targeted 
prophylaxis could effectively reduce. In the current analysis I demonstrated 
high absolute risks of VTE In the third trimester and first 5 weeks postpartum, 
whereas during the first two trimesters and late postpartum periods the risks 
were only marginally higher compared to time outside pregnancy. 
Furthermore, when comparing women aged 3S and over to the majority of 
pregnant women I found only a small excess absolute risk of VTE during the 
antenatal and postnatal periods. 
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I believe my results have important implications for the way In which 
thromboprophylaxis is delivered In the health care settings of developed 
nations and would hope that they will aid the targeting of such prophylaxis in 
three ways. Firstly, my observation that the highest rates of VTE occur 
mainly within 5 weeks postpartum suggests that giving thromboprophylaxis In 
those considered at high risk for this length of time may be appropriate. 
Secondly, I have found that the risk in the first and second trimester is not 
greatly increased for those women without previous VTE compared with time 
outside pregnancy. Therefore, initiation of prophylaxis where It Is needed 
could potentially be delayed until the start of the third trimester thus, 
avoiding any adverse effects of low molecular weight heparin and prolonged 
antenatal use In some women. Finally, current clinical guidelines often Include 
age 21, I.e. being ~ 3 5 5 years old, as an Independent risk factor for VTE. My 
results Imply that the absolute excess risk In postpartum women 35 years or 
older compared to the majority of postpartum women Is of the order of 1.8 
per 1000 person years. If we assume that thromboprophylaxls Is 100% 
effective at preventing VTE then my results Imply that to prevent one excess 
VTE occurring In this age group we would need to give prophylaxis to 
approximately 556 women. Overall this study provides new evidence that will 
aid the ability of cliniCians to judge when women are at highest risk of VTE 
during and Immediately after pregnancy. Therefore these findings should 
Influence the development of updated thromboprophylaxls guidelines and 
Impact on the delivery of care to pregnant women across the developed 
world. 
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3 Risk factors for first venous thromboembolism around 
pregnancy: A population based cohort study from the 
United Kingdom 
This chapter sets out to determine how risks of antepartum and postpartum 
VTE are modified by established and newly identified risk factors. It uses the 
same computerized primary care data (THIN) and covers both risk factors 
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mentioned in the current RCOG guidelines for thromboprophylaxis during 
pregnancy along with some additional variables highlighted from previous 
studies. The following study has been published from this work.9o 
3.1 Introduction 
Overall, there is disagreement and Inconsistency regarding the characteristics 
that put women at higher risk of developing a first VTE during pregnancy or 
postpartum combined with a lack of data about the relative impact of those 
risk factors with respect to the absolute risk of VTE. For example, existing 
estimates of the Increase In risk of VTE among pregnant women with high 
BMI (ii!30 kg/m2) compared to those with normal BMI range from 1.S-fold to 
S.3-fold higher during antepartum and postpartum periods" 12, 41, ss. Similar 
Inconsistencies surround women's demographic risk factors (e.g. maternal 
age), comorbidltles (such as diabetes) and possible pregnancy complications 
(e.g. mode of delivery, obstetriC haemorrhage and other complications)" 10-12, 
43, 44, SO, 53, ss particularly since many studies have Inappropriately assumed 
that these risk factors Impact similarly on occurrence of VTE In antepartum 
and postpartum periods." 12, 50, 55 Of the studies that have separately 
assessed antepartum and postpartum VTE rlsks,10, 41, 43, 44, 53 most have used 
a case-control design or relied on cross-sectional analysis of hospital 
discharge records based on risk factor Information recorded around the time 
of delivery. Neither of these enables estimation of absolute risks of VTE based 
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on recognized risk factors over the entire period of gestation and Immediately 
following childbirth. 
3.1.1.1 Justification and aim 
The current Royal College of Obstetricians and Gynaecologists (RCOG)21 and 
American College of Chest Physicians (ACCP)64 guidelines on obstetric 
thromboprophylaxis are based on suboptimal Information to distinguish 
between women who are at low and high risk. Therefore the aim of this 
study was to determine population level absolute and relative risks of VTE 
according to women's pre-existing and pregnancy-related factors in both 
antepartum and postpartum periods, with the primary objective of allowing 
targeted provision of obstetric thromboprophylaxls. Secondly, I aimed to 
estimate specific absolute risks of VTE for women categorised as having low, 
Intermediate and high risk pregnancies according to the UK's RCOG guidelines 
on who should receive prophylaxis. 
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3.2 Method 
3.2.1 Study population 
The study population for this study was obtained from THIN. All Incident 
pregnancies ending in live birth or stillbirth for women aged 15-44 years who 
contributed data to THIN between January 1995 and July 2009 were 
identified. Pregnancies of women with previous VTE were excluded regardless 
of whether those events were diagnosed during or outside pregnancy. 
Therefore, where women developed a VTE In one pregnancy, person-time 
resulting from subsequent pregnancies was Ignored. The pregnancy-related 
person time for each woman during the study period was divided Into 
antepartum (from the date of conception to the pregnancy outcome) and 
postpartum (up to 12 weeks following the pregnancy outcome). The database 
Is described In more detail In section 2.2.7. 
3.2.2 Defining incident VTE 
All first VTE events Including deep vein thrombosis (OVT) and pulmonary 
embolism (PE) experienced by women (excluding superficial VTE) were 
Identified during the study period. VTE cases and person time occurring within 
one month of the study start date were excluded to ensure only Incident 
cases were retained. VTE cases were defined using methods similar to those 
previously described in chapter 2 (Section 2.2.8). 
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3.2.3 Defining risk factors 
3.2.3.J Basic characteristics 
Previous studies have found maternal age, smoking status and body mass 
index to be associated with an increased risk of VTE during pregnancy (Table 
1-4). Therefore information on those characteristics was extracted using Read 
codes. Maternal age was defined as a time varying covarlate and was 
assessed in three equal sized categories (15-24, 25-34 and 35-44 years). BMI 
and smoking status was defined as follows; 
3.2.3.1.1 Body mass index 
High BMI is associated with an Increased risk of VTE In pregnancy.10, 12,43 For 
this purpose, weight and height Information from the additional health 
Information file and medical codes relating to BMI (e.g. Body Mass Index >30 
- Obese) were extracted for all pregnant women with live births/stillbirths. 
BMI was categorized using the World Health Organization categorization: 
normal (18.5 - 24.9 kg/m2), underweight «18.5 Kg/m2), overweight (25.0 -
29.9 Kg/m2), and obese ( ~ 3 0 0 kg/m2). Women with no BMI data recorded at 
any time where they were contributing data were placed In a missing 
category so that they can be Included In the analysis. A BMI value was 
assigned to each pregnancy using the most recent record before conception. 
The Read codes used to extract BMI Information are presented as Appendix 8 
3.2.3.1.2 Smoking status 
There is also evidence suggesting that the risk of VTE Is affected by Cigarette 
smoklng44, 50 Smoking status for each pregnancy was extracted from 
additional health data relating to smoking and medical records. Women were 
categorized as "cigarette smoker" or "non-smoker" (Included current and ex-
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smokers) using the most recent smoking related code before the pregnancy 
outcome. Although this categorization of smoking might create some 
misclassification, current smoking recording In the general practice data Is 
reasonably well recorded.91 Codes used to extract Information on smoking are 
presented in Appendix 9. Women with no information on smoking before a 
respective pregnancy were categorized as a non-smoker. 
3.2.3.2 Pregnancy related characteristics and complications 
Pregnancy related factors considered were mode of delivery, birth outcome 
(live or stillborn child), length of gestation, multiple gestation and number of 
previous births. Pregnancy complications (including eclampsia/pre-eclampsia, 
haemorrhage, diabetes and hypertension) were extracted using Read medical 
codes if recorded during the pregnancy/postpartum period. The Read codes 
used to extract obstetric haemorrhage and ec/ampsla/preeclampsla are 
summarised In Appendix 10 and Appendix 11 
3.2.3.2.1 Gestational diabetes 
Women were defined as having gestational diabetes If they had a Read code 
specifying "gestational diabetes" during pregnancy. Women were also 
considered as having gestational diabetes If they had a first record of type 1, 
type 2 or non-specific diabetes recorded during pregnancy with no prior 
prescriptions for oral hypoglycaemlcs or Insulin. 
3.2.3.2.2 Gestational hypertension 
Women were defined as having gestational hypertension If they had a Read 
code specifying gestational hypertension during pregnancy. Women were also 
considered as having gestational hypertension If they had a first record of 
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hypertension recorded during pregnancy or had 3 or more readings of high 
blood pressure (systolic> 140 with/or dlastolic>90) with no prior prescriptions 
for oral antihypertensive medication documented before the Index pregnancy. 
3.2.3.2.3 Acute systemic infection 
I also separately investigated two common acute Infections: urinary tract 
infection and acute respiratory tract infection (Including pneumonia, acute 
bronchitis, chest infection and Influenza) during pregnancy because of their 
Increased risk associated with VTE.68• 92 The Read codes used to extract 
Information on acute respiratory tract infection and urinary tract infection are 
summarised in Appendix 12 and Appendix 13 respectively. 
3.2.3.2.4 Mode of del1very 
For each pregnancy resulting in live or stillbirth, mode of delivery was 
assigned. This was categorised as spontaneous vaginal delivery, assisted 
delivery or caesarean (elective or emergency). For women with no 
Information on mode of delivery were assumed to have undergone 
spontaneous vaginal delivery. 
3.2.3.3 Medica' co-morbid/ties 
Information on important co-morbidltles was extracted based on previous 
literature and the current RCOG guideline on thromboprophylaxls. 21 Women 
were defined as having a relevant medical co-morbidity If they had ever been 
diagnosed with cancer, systemic lupus erythematosus (SLE), nephrotic 
syndrome, varicose veins, inflammatory bowel disease (IBO) or cardiac 
disease (including congestive cardiac disease, coronary artery disease, 
congenital heart disease, cardiomyopathy, angina or myocardial Infarction) 
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during or prior to pregnancy. Finally pregnant women were defined as having 
pre-existing diabetes or pre-existing hypertension using combinations of Read 
and prescription codes (excluding Read codes for gestational hypertension 
and gestational diabetes) for such conditions if they were recorded before 
conception. The Read codes used to extract cancer Information were similar 
to those we have used previously for research Into VTE among cancer 
patients,93 which Included 2,548 codes for various cancer types (available on 
request). The Read codes used to obtain Information on IBD, nephrotic 
syndrome, varicose veins, SLE and cardiac disease are summarised In 
Appendix 14. 
3.2.4 Statistical analyses 
3.2.4.1 Risk factor ana/ysls 
Absolute rates (AR) of VTE per 100,000 person-years were obtained by 
dividing the total number of events by the person-years of follow-up. To 
assess how these risks varied according to the women's risk factors I 
calculated ARs per 100,000 person-years for each category of variables 
relating to maternal characteristics (e.g. maternal age category), pregnancy-
related characteristics and complications (e.g. each mode of delivery, 
obstetric haemorrhage etc.), and medical comorbldltles (e.g. varicose veins, 
cardiac disease etc). Values of each risk factor (other than age) were 
assumed to be fixed for the whole pregnancy regardless of whether It was 
recorded during or before pregnancy. For factors relating to labour or the 
puerperium (e.g. mode of delivery) ARs were estimated only for the 
postpartum period. Incident rate ratios (IRR) of VTE associated with each risk 
factor were calculated using Poisson regression models and were adjusted for 
maternal age, body mass Index, smoking status and number of previous 
births (Model 1), which were selected on the basis of previous literature. 
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Additionally risk factors that were associated with an Increased risk of VTE In 
the Initial antepartum and postpartum analyses were included in a separate 
model (Model 2). As pregnancies are not Independent events, a clustering 
term was fitted In all models to account for women experiencing more than 
one pregnancy during the study period. 
3.2.4.2 Integration of UKs of RCOG guidelines for 
thromboprophylaxls 
Current UK RCOG guidelines for thromboprophylaxls during pregnancy and 
postpartum use a set of recognised clinical factors to categorise pregnant 
women as low, Intermediate or high risk to guide which women are offered 
hydration/mobilization and which are offered low molecular weight heparin 
(LMWH) as thromboprophylaxls21 • The absolute rates of VTE were calculated 
using the number of pregnancies as the denominator In this Instance. This 
was done for each factor In Isolation where possible. For Instance, the value 
for a g e ~ 3 S S years In block 3 (In Figure 3-1), Is the rate per 100,000 
pregnancies for women with no other risk factors as these would receive 
mobilisation and hydration If this risk factor occurred In Isolation. Additionally 
I Incorporated factors from my Initial analysis that are not currently In the 
RCOG guideline but were highlighted In either the existing literature or this 
study (Including pre-exlstlng diabetes, stillbirth and preterm birth), which 
were placed In Intermediate or high risk groups based on their AR of VTE In 
this study. To ensure reasonable precIsion, I only calculated ARs for 
pregnancies where ~ S S VTE events occurred among women with the risk 
factor. For this reason the following medical co-morbldltles; SLE, cancer, 
nephrotiC syndrome, cardiac disease and IBD, were grouped together as 
current guidelines Indicate that women with anyone of these risk factors 
should be considered for prophylaxis. Pregnancies complicated by medical co-
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morbidities where there were no VTE events (e.g. nephrotic syndrome) during 
the antepartum and/or postpartum period, were still included In the analysis 
so as to contribute to the denominator for calculating the incidence rate for 
VTE, but these were not investigated individually. Also, high BMI ( ~ 3 0 k g / m 2 ) )
was separated into obese ( B M I ~ 3 0 0 Kg/m2 & BMI<40Kg/m2) and class 3 obese 
( B M I ~ 4 0 K g / m 2 ) ) whereas acute respiratory tract and urinary tract infections 
were collectively assessed as stated in the current thromboprophylaxls 
guideline21 • All analyses were carried out using Stata SEll. 
3.2.4.3 Power calculatIon 
The current study was sufficiently powered such that for a relatively rare risk 
factor which affects 1% of all pregnancies we had greater than 90% power to 
detect a 2-fold Increase (IRR=2) in risk of VTE In both antenatal and 
postpartum periods separately. 
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3.3 Results 
3.3.1 Basic characteristics of study population 
There were a total of 376,154 pregnancies resulting In live or stillbirths 
occurring among 280,451 women. Women's basic characteristics for each 
pregnancy are summarized in Table 3-1. The total person-years associated 
with the antepartum and postpartum periods were 255,947. and 84,370 
respectively. The overall incidence of VTE during antepartum and postpartum 
period was calculated to be 84 and 337 per 100,000 person-years 
respectively (as fully described in chapter 2 results). 
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Table 3-1: Basic characteristics of women for each pregnancy 
Variables Pregnancies 
(N=376,154 In 280,451 
women) 
Maternal characteristics 
Body mass index 
Normal (18.5-24.9) 164,883 
underwelght( <18.5) 12,309 
overwelght(25-29.9) 66,068 
o b e s e ( ~ 3 0 ) ) 38,101 
Missing 94,793 
Cigarette smoking 88,617 
Pregnancy related characteristics" complication 
Birth outcome 
Live birth 
Stillbirth 
Mode of delivery 
Spontaneous delivery 
Caesarean 
Assisted delivery 
Previous number of births 
None 
1 
2 
3 or more 
Multiple gestation 
Preterm delivery «37 weeks) 
Eclampsla/pre-eclampsla 
Obstetric haemorrhage 
Gestational hypertension 
Gestational diabetes 
Acute respiratory tract Infection In 
pregnancy 
Urinary tract Infection In pregnancy 
375,002 
1,152 
294,426 
58,109 
23,619 
213,697 
116,351 
33,819 
12,287 
6,251 
26,528 
1,897 
4,607 
6,294 
2,656 
12,980 
30,765 
Percentage 
43.8 
3.3 
17.5 
10.2 
25.2 
23.5 
99.7 
0.3 
78.3 
15.5 
6.3 
56.8 
30.9 
8.9 
3.4 
1.7 
7.1 
0.5 
1.2 
1.7 
0.7 
2.4 
8.1 
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Table 3-1: Basic characteristics of women for each pregnancy 
(continued •• ) 
Variables 
Pre-exlstlng diabetes 
Pre-exlstlng hypertension 
Varicose veins 
Nephrotic syndrome 
Systemic lupus erythematosus 
Cancer 
Inflammatory bowel disease 
Cardiac disease 
Pregnancies 
(N=37fi,154 In 280,451 
women) 
Medical co-morbldities 
4,022 
11,718 
8,373 
214 
188 
5,012 
1,472 
354 
Percent 
age 
1.0 
3.1 
2.2 
0.06 
0.05 
1.3 
0.3 
0.09 
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3.3.2 Risk factors for VTE during the antepartum period 
The relative risk of antepartum VTE was only marginally higher for women 
a g e d ~ 3 S S years, B M I ~ 3 0 K g / m 2 , , and cigarette smoker corresponding to a 
42%, 50% and 15% increased risk compared to their respective baselines 
(Table 3-2). Of pregnancy related characteristics and complications only 
urinary tract infection was found to be significantly associated with an 
increased risk of VTE (88% increase in risk) at the S% level. However, 
medical co-morbidities including pre-existing diabetes, recording of varicose 
veins and IBO (but not pre-existing hypertension or cancer) were all 
associated with significantly higher rates of VTE, with absolute rates ranging 
from 216 (varicose veins) to 288 (IBO) per 100,000 person-years. These 
remained largely unchanged when mutually adjusted for other risk factors 
associated with an increased risk of antepartum VTE (Model 2). 
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Table 3-2: Absolute and relative rates of VTE by risk factors in the antepartum period 
Variable 
Maternal age 
15 - 24 
25 - 34 
35 - 44 
Body mass index 
Underweight « 18.5 kg/m2) 
Normal (18.5-24.9) 
Overweight (25-29.9) 
Obese ( ,,=30) 
No BMl recorded before conception 
Cigarette smokers 
Events 
45 
120 
50 
3 
86 
49 
30 
47 
55 
Rate1 IRR2 
(Model 1) 
Maternal characteristics 
73 (54-98) 0 .87 (0 .61-1.24) 
79 (66-95) 1.00 
112 (85-148) 1.42 (1.01-1.93) 
34 (11-1074) 0.48 (0.15-1.54) 
73 (59-90) 1.00 
103 (75-136) 1.41 (0.99-2.00) 
109 (76-156) 1.50 (0.99-2.28) 
85 (63-113) 1.18 (0.82-1. 71) 
89 (68-116) 1.15 (0.83-1. 58) 
IRR3 
(Model 2) 
0 .89 (0.62-1.27) 
1.00 
1.40 (0. 99-1. 96) 
0.48 (0 .15-1.53) 
1.00 
1.40 (0.98-2.00) 
1.40 (0.90-2.16) 
1.16 (0.85-1.69) 
1.16 (0.84-1.60) 
I Absolute rate calculated as per 100,000 person-years. '(Model 1) Adjusted for age, parity, BMI and smoking status when not stratified by them. 3(Model 2) Adjusted for 
age, parity, BMI, pre-existing d iabetes, I BD, varicose veins, acute systemic infection and smoking status when not stratified by them . . ' Incidence rate ratio (IRR) compared 
to women without r isk factor under study. 
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Table 3-2: Absolute and relative rates ofVTE by risk factors in the antepartum period (continued .. ) 
Variable Events Rate1 - ---- IRR2 --XRR3 
(Model 1) (Model 2) 
Pregnancy associated characteristics and complication4 
Previous births 
None 127 90 (75-107) 1.00 1.00 
1 60 72 (56-93) 0 .76 (0 .56-1.03) 0 .72 (0.53-0.98) 
2 19 78 (50-123) 0 .79 (0.49- 1.28) 0.71 (0.43-1.16) 
3 or m ore 9 103 (53-198) 0.97 (0.48- 1.93) 0.89 (0.45- 1. 78) 
Multiple gestation 3 73 (23-227) 0 .83 (0 .26-2.61 ) 0.83 (0.26-2.60) 
Eclampsia/pre-eclampsia 0 
Gestational hypertension 4 9 5 (35-254) 1.0 1 (0.37-2.76 ) 0 .99 (0 .36-2.72) 
Gestational diabet es 3 165 (53-514) 1.7 1 (0 .54-5.41) * 
Acute respiratory tract infection 13 142 (82-245) 1.70 (0 .97-2 .99) 1.65 (0 .94-2.90) 
Urinary tract infection 31 145 (102-206) 1.88 (1. 28-2 .77) 1.80 (1. 22-2.67) 
1 Absolute rate calculated as per 100,000 person-years. 2(Model 1) Adjusted for age, parity, ElM! and s-moking status when not stratified by them. 3(Model 2) Adjusted for 
age, parity, BMI, pre-ex isting diabetes, IBD, var icose veins, acute systemic infection and smoking status when not stratified by them . . 'Incidence rate ratio (IRR) compared 
to women without risk factor under study. 
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Table 3-2: Absolute and relative rates of VTE by risk factors in the antepartum period (continued .. ) 
Variable Events 
Pre-existing diabetes 8 
Pre-existing hypertension 7 
Varicose veins 13 
Nephrotic syndrome 0 
Systemic lupus erythematosus 0 
Cancer 6 
Inflammatory bowel d isease 3 
Cardiac disease 0 
Rate 1 
Medical co-morbidities4 
282 (141-565) 
82 (39-173) 
216 (125-373) 
169 (76-373) 
288 (93-895) 
IRR2 
(Model 1) 
3.08 (1.42-6.39) 
0.90 (0.42-1.94) 
2.69 (1.53-4.70) 
1. 97 (0.87-4.44) 
3.46 (1.11-10.7) 
IRR3 
(Model 2) 
3.54 (1.13-11.0) 
0.74 (0.32-1.71) 
2.21 (1.55-4.76) 
1.95 (0 .86-4.41) 
3.50 (1.12-10.9) 
1 Absolute rate calculated as per 100,000 person-years. 2(Model 1) Adjusted for age, parity, BMI and smoking status when not stratified by them. J(Model 2) Adjusted for 
age, parity, BMI, pre-existing diabetes, !BD, varicose veins, acute systemic infection and smoking status when not stratified by them .. 4Incidence rate ratio (IRR) compared 
to women without r isk factor under study. 
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3.3.3 Risk factors for VTE during the postpartum period 
In the postpartum period, a 4-fold increased risk of VTE In women with 
BMI;::30Kg/m2 (Incidence rate ratio (IRR}=3.75 95% Cl 2.76-5.07) compared 
to those with normal BMI (Table 3-3) was observed. However, the rate of VTE 
was only moderately higher for other maternal characteristics, Including 
a g e ~ 3 5 5 years and current smoking, when compared with baseline. For 
pregnancy related characteristics and complications I found a 2-fold or 
greater increase in the rate of VTE compared to baseline for those with 
caesarean section delivery, 3 or more previous births, obstetric haemorrhage, 
and pre-term «37 weeks) delivery (ARs ranging between 637-963 per 
100,000 person-years). Pregnancy ending In stillbirth was associated with a 
6-fold Increase In the rate of VTE compared with a live birth outcome 
(AR=2444) with rates associated with medical co-morbldltles (Including 
varicose veins, IBD and cardiac disease) ranging from 113 to 2374 VTEs per 
100,000 person-years. When all risk factors aSSOCiated with an Increased risk 
of VTE were fitted together (Model 2) the calculated estimates remained 
broadly similar. 
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Table 3-3: Absolute and relative rates of VTE by risk factors in the postpartum period 
Variable 
Maternal age (years) 
15 - 24 
25 - 34 
35 - 44 
Body mass Index 
Underweight «18.5 kg/m2) 
Normal (18.5-24.9) 
Overweight (25-29.9) 
Obese ( ~ 3 3 ) )
No BMI recorded before conception 
Current smokers 
Events Rate1 
Maternal characteristics 
48 255 (192-339) 
156 316 (270-370) 
81 497 (399-618) 
4 145 (54-386) 
88 237 (192-292) 
48 324 (244-429» 
79 926 (742-1554) 
66 305 (239-390) 
80 403 (324-504) 
IRR2 IR-R? 
(Model 1) (Model 2) 
0 .80 (0.57-1.12) 0.86 (0.62-1.00) 
1.00 1.00 
1.51 (1.15-1. 98) 1.37 (1.23-3.01) 
0.63 (0.23-1.71) 0 .61 (0.22-1.67) 
1.00 1.00 
1.33 (0.93-1.89) 1.29 (0 .90-1.83) 
3 .75 (2.76-5 .08) 3.45 (2.54-4 .69) 
1.40 (1.01-1.92) 1.46 (1.06-2.01) 
1.31 (1.01-1.71) 1.30 (1.00-1.69) 
1 Rate calculated as per 100,000 person-years. 1 (Model 1) Adjusted for age, parity, BMI and smoking status when not stratified by them:-:- 3 (Model 2) Adjusted for age, parity, BMI, mode of 
delivery, pregnancy length, obstetric haemorrhage, varicose veins, IBD, cardiac disease and smoking status when not stratified by them. 'Incidence rate ratio (IRR) compared to women 
without risk factor under study. 
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Table 3-3: Absolute and relative rates of VTE by risk factors in the postpartum period (continued .. ) 
Variable 
Mode of delivery 
Spontaneous 
Assisted 
Caesarean 
No of previous live births 
None 
1 
2 
3 or more 
Stillbirth 
Multiple gestation 
Pre-term birth 
Pre-ecla mpsia/ecla mpsia 
Obstetric haemorrhage 
Gestationa l diabetes 
Gestational hypertension 
Acute respiratory tract infection 
Urinary tract infection 
Events Rate1 IRR2 
(Model 1) 
Pregnancy related characteristics and complication4 
186 
· 16 
83 
152 
75 
33 
25 
6 
7 
51 
3 
10 
6 
10 
18 
27 
281 (243-325) 
302 (185-494) 
637 (513-790) 
318 (271-373) 
285 (228-358) 
432 (307-608) 
904 (611-608) 
2444 (109- 5440) 
491 (234-1030) 
854 (649-1124) 
705 (227-2188) 
963 (518-1791) 
1013 (455-2255) 
705 (379-1311) 
617 (389-980) 
391 (268-571) 
1.00 
1.18 (0.70-1.99) 
1.99 (1.52-2.58) 
1.00 
0.81 (0.61-1.08) 
1.13 (0.77-1.66) 
2.07 (1.34-3.20) 
6.24 (2.77-14.1) 
1.39 (0.65-2.93) 
2.69 (1.99-3.65) 
1.84 (0.59-5.78) 
2.89 (1.53-5.43) 
1. 97 (0.87-4.45) 
1.63 (0.85-3.12) 
1.65 (1.02-2.66) 
1.15 (0.77-1.71) 
IRR3 
(Model 2) 
1.00 
1.22 (0.73-2.06) 
1.88 (1.44-2.45) 
1.00 
0.82 (0.62-1.09) 
1.08 (0.73-1.60) 
1.92 (1.22-2.99) 
4 .07 (1.73-9.56) 
0 .94 (0.43-2.07) 
2.28 (1.66-3.14) 
1.17 (0.36-3 .77) 
2.53 (1.34-4.79) 
1.68 (0.74-3.82) 
1.49 (0.78-2.84) 
1.56 (0.97-2.53) 
1.06 (0.71-1.58) 
I Rate calculated as per 100,000 person-years. « ModetljAdjlJsted for age, parity, BMI and smoking status when not stratified by them . . 3 (Model 2) Adjusted for age, parity, BM I, mode of 
delivery, pregnancy length, obstetric haemorrhage, varicose veins, IBD, cardiac disease and smoki ng status when not stratified by them. 'Incidence rate ratio (IRR) compared to women 
without risk factor under study. 
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Table 3-3: Absolute and relative rates of VTE by risk factors in the postpartum period (continued .. ) 
Variable 
Pre-existing diabetes 
Pre-existing hypertension 
Varicose veins 
Nephrotic syndrome 
Systemic lupus erythematosus 
Cancer 
Inflammatory bowel disease 
Card iac disease 
Events Rate1 
Medical co-morbidities4 
4 445 (167-1186) 
3 113 (36-353) 
25 1330 (899-1969) 
0 
1 2374 (344-16856) 
5 446 (185-1073) 
5 1514 (630-3638) 
2 2258 (646-10335) 
IRR2 IRR3 
(Model 1) (Model 2) 
0.88 (0.33-2.38) 0 .69 (0.25-1.85) 
0.25 (0.81-0.79) 0 .22 (0.71-0.68) 
3.83 (2.51-5 .82) 3.90 (2 .56-5.93) 
6 .69 (0 .95-47.0) 5.40 (0.76-38.3) 
1.21 (0.49-2.96) 1.14 (0.46-2.79) 
4.56 (1.88-11.0) 4.07 (1.73-9.57) 
6.58 (1.63-26.5) 5.30 (1.30-21.5) 
1 Rate calculated as per 100,000 person-years. 2 (Model 1) Adjusted for age, parity, BMI and smoking status when not stratified by them .. 3 (Model 2) Adjusted for age, parity, BM I, mode of 
delivery, pregnancy length, obstetric haemorrhage, varicose veins, IBD, cardiac disease and smoking status when not stratified by them. ' Incidence rate ratio (IRR) compared to women 
without risk factor under study. 
128 
3.3.4 Risk of VTE per 100,000 pregnancies according to the UK's 
RCOG guideline 
Figure 3-1 and Figure 3-2 contain the risk factors currently listed In the RCOG 
guideline21 for antepartum and postpartum thromboprophylaxis with the 
addition of pre-existing diabetes (antepartum), stillbirth and pre-term birth 
(both postpartum only). It was found that among women who were classed 
as being at intermediate risk for antepartum VTE on the basis of a single risk 
factor the highest risk of VTE was 180/100,000 pregnancies for women with 
pre-existing diabetes (Figure ,3-1). Postpartum, women with a B M I ~ 4 0 K g / m 2 2
had a higher risk of VTE (AR=221/100,OOO pregnancies) than those women 
with any other single intermediate risk factor (pre-term birth, prior medical 
co-morbidlties, caesarean section delivery and haemorrhage) (Figure 3-2). Of 
factors currently used to classify women as low risk for postpartum VTE If 
occurring in isolation (I.e. those who are offered non-pharmacological 
thromboprophylaxis including early mobilization and hydration), high risks of 
VTE were observed for women with a BMI between 30 and 40 Kg/m2 
(AR= 143/100,000 pregnancies) and varicose veins (188/100,000 
pregnancies) In the absence of other risk factors. The risk of VTE, however, In 
the postpartum following stillbirth was calculated to be 0.5% which was 
higher than any other risk factor. 
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Figure 3-1: Rate of VTE per 100,000 pregnancies during the 
antepartum according to the national guideline. 21 
Obstetric thromboprophylaxis risk assessment and management guidelines 
Block 1 (High risk factors) 
x -Single previous VTE+ 
Thrombophilia 
Unprovoked previous VTE 
x-previous recurrent VTE (>1) 
.. 
Block 2 .. 
Intermediate risk factors 
x -Single previous VTE with no 
family history or thrombophilia 
x -Thrombophilia + no VTE 
v'- Medical co-morbidities (SLE, 
Cancer, IBD, cardiac disease or 
nephrotic syndrome) 
x-Sickle cell 
X-Intravenous drug users 
x -Surgical procedure 
o -Pre-existing diabetes 
Block 3 
Low risk factors 
v'-Age ~ 3 5 5
v'-Obese B M M ~ 3 0 K g / / 2 2
v'-Previous b i r t h s ~ 3 3
v'-Cigarette smokers 
v'-Eclampsia/preeclampsia 
v'-Acute systemic infection 
v'-Varicose veins 
x -Any surgical procedure 
X-Prolong labour (>24 hours) 
x -Mid -cavity rotational operation 
x - Immobility 
x -Dehydration 
v'-Multiple pregnancy 
Key 
.. 
.. 
Antenatal thromboprophylaxis with LMWH 
No data from current study 
Any 1 Factor (may be accompanied by other 
risk factors in block 3 but not block 2 ~ ~
Antenatal thromboprophylaxis with LMWH 
Variable Events Rate 
(95% Cl) 
Medical co -morbidities 9 130 (72 -371) 
Pre-existing diabetes 7 180 (72 -371) 
Any 1 risk factor 18 165 (97-260) 
2:2 factors with no other risk factors In block 1 
and 2 
Antenatal thromboprophylaxls with LMWH 
Variable Events Rate 
{95%CI} 
Two or more risk factors 47 95 (69 - 125) 
1 factor with no other risk factors In block 2 
and 3 
Mobilisation and hydration 
Variable Events Rate 
.(95%CI) 
Age ~ 3 5 5 23 70 (44 - 104) 
B M M ~ 3 0 0 7 42 (16-85) 
Previous b l r t t s s 3 3 3 92 (18 -268) 
Cigarette smokers 24 44 (27-64) 
Varicose veins 5 149 (48 -346) 
Acute systemic Infection 13 65 (24- 11) 
Anyone risk factor 75 55 (43 -69) 
No risk factors 73 41 (32-51) 
v'Factor is included in the current thromboprophylaxls guideline and In current study analysis 
x Factor is included in the current thromboprophylaxis guideline but not Included in the current 
study analysis 
oFactor is included in the study analysis but Is not in the current thromboprophylaxis guidelines 
LMWH = Low molecular weight heparin 
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Figure 3-2: Rate of VTE per 100,000 pregnancies during the 
postpartum according to the national guideline21 
Obstetric thromboprophylaxis risk assessment and management guidelines 
Block 1 (High risk factors) ... 
o -Still births 
x -Previous VTE 
X-Antenatal VTE 
Block 2 
Intermediate risk factors 
v -Caesarean section delivery! 
v -Very o b b s e B M M ~ 4 0 K g / / 2 2
x-Thrombophilia 
O-Preterm birth 
v -Medical co-morbidities (SLE, 
Cancer, IBD, cardiac disease or 
nephrotic syndrome) 
v -Obstetric Haemorrhage 
x -Surgical procedures 
x -Intravenous drug users 
x -Sickle cell disease 
x -Prolonged hospital admiss ion 
... 
Block 3 ... 
Low risk factors 
v -Age ~ 3 5 5
v -Obese ( B M M ~ 3 0 K g / / 2 2 & 
BMI <40Kg/m2) 
v -Previous b i r t t s s 3 3
v -Cigarette smokers 
v -Eclampsia/preeclampsia ..... 
v -Acute systemic infection ....,. 
v -Varicose veins 
x-Any surgical procedure 
x-Prolong labour (>24 hou rs ) 
X-Mld-cavity rotational operation 
x -Immobility 
Key 
Factor may be accompanied by other risk factors 
in block 2 and 3 
6 weeks postnatal thromboprophylaxls 
Variable , Events , Rate (95%CI) 
Stillbirths , 6 I 523 (192-1135) 
Any 1 Factor (may be accompanied by other risk 
factors In block 3 but not block 1 or 2) 
7 days postnatal thromboprophylaxls with LMWH 
Variable Events Rate (95% Cl) 
Caesarean section 49 101 (7 5-134) 
BMI ~ ~ 40Kg/m2 6 221 (81-481) 
Medical co-morbidities 7 137 (55 -282) 
Premature birth 22 121 (76-184) 
Haemorrhage 5 154 (50-361) 
~ 2 2 factors with no other risk factors in block 1 
and 2 
7 days postnatal thromboprophylaxls with LMWH 
Variable , Events' Rate (95%CI) 
Two or more r isk facto rs I 41 , 111 (80-151) 
1 factor with no other risk factors In block 1, 2 
and 3 
Hydration and mobilisation 
Variable Events Rate (95%CI) 
Ag e ~ 3 5 5 14 44 (24-75) 
B M M ~ ~ 0 0 & <40Kg/m2 16 143 (82 -233) 
Previous b i r t t s ~ 3 3 2 78 (9-284) 
Cigarette smokers 17 38 (22-61) 
Varicose veins 5 188 (61-440) 
Acute systemic Infection 5 32 (10 -75) 
Anyone r isk factor 61 56 (43 -72) 
No r isk factors 51 36 (26-47) 
vFactor is included in the current thromboprophylaxls gu ideline and In current study analysis 
xFactor is included in the current thromboprophylaxis gu ideline but not included in the current 
study analysis 
<>Factor is included in the study analysis but is not in the current thromboprophylaxis guidelines 
!Includes elective and emergency caesarean section 
LMWH = Low molecular weight heparin 
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3.4 Discussion 
3.4.1 Main finding 
In this large nationally-representative cohort of almost 400,000 pregnancies, 
I have provided population based estimates of the absolute and relative risks 
of VTE in women during and immediately after pregnancy, combining their 
soclo-demographic, lifestyle and clinical risk factors to better Inform targeting 
of thromboprophylaxis. I have demonstrated that except for pre-existing 
diabetes, risk factors have a greater Impact In the postpartum period In terms 
of Influencing the absolute risk of VTE than the antepartum period. It was 
also found that women with stillbirths, obstetric haemorrhage, high BMI, 
preterm birth, prior co-morbidities (IBD and cardiac disease) and caesarean 
section delivery have higher risk of VTE postpartum, In contrast, cigarette 
smoking, maternal age ~ 3 S S years, acute infection and number of previous 
births were only moderately aSSOCiated with VTE In both antepartum and 
postpartum periods. 
3.4.2 Strength and limitations 
The use of nationally representative data not only makes my study findings 
generallsable to the majority of the pregnant women in the UK, I.e. those who 
have not had a prior VTE but also provides Information on risk factors for VTE 
In a contemporary and population based manner. Most previous studies have 
relied on cross-sectional analyses of hospital discharge records collected 
around the time of delivery/' 10, 12 were unable to separate first from 
subsequent VTE7, 10, 44 or relied on retrospective recall of risk factor 
Information 11, 53, 55, In contrast, my open cohort approach to analysis and 
prospective nature of data recording enabled me to look at the impact of 
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existing and pregnancy related risk factors on the Incidence and relative risk 
of VTE separately for antepartum and postpartum time periods. 
A potential limitation of this study Is the lack of validation studies of obstetric 
complications in the current dataset and the scarcity of national UK or 
international data estimating the true prevalence of obstetric complications In 
the general population. Whilst all major medical events in secondary care 
should be recorded in the general practice notes, minor complications that are 
we" managed In hospital may not be recorded in primary care data. For 
instance the estimated prevalence of obstetric haemorrhage ranges from 2% 
to 8% with the prevalence of severe haemorrhage estimated to be between 
0.01 and 1.86%.94-96 I found a prevalence of 1% in the present study which 
Indicates my cases are more likely to represent severe haemorrhage (same 
may be the case for gestational hypertension and pre-eclampsia). 
I also acknowledge that certain risk factors Including mild to moderate pre-
eclampsia might not always get reported in the hospital discharge summaries 
which are sent to generai practitioners thus underestimating their 
prevalence51, 61, 97, 98. In particular, residual confounding caused by the under 
ascertainment of pre-eclampsia could have accounted for some of the 
postpartum effect observed for stillbirths and pre-term births. However 
around 50% of stillbirths are unexplalned62 • Furthermore the prevalence of 
caesarean section In the current study (15%) was lower than expected (24%) 
which may have underestimated my estimates for that risk factor. I was also 
not able to assess certain parameters Including mother's ethnicity and fertility 
treatments which may often be associated with Increased risk of VTE. 
However, I believe that the following should be conSidered. Firstly, 91%99 of 
the UK population are white which I believe would have limited the Impact of 
confounding by race on our estimates. Additiona"y, a case-control study from 
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the UK showed no association between antenatal PE and ethnicity.ll 
Secondly, the overall reporting of fertility problems In the UK using primary 
care data100 is reported to be 0.5% per annum with an Infertility treatment 
rate of 0.1% per annum. Moreover, the actual number of women conceiving 
after treatment may be even lower, although I was not able to evaluate this 
in the current data. This depicts the limited scope of this variable to modify 
my conclusions from these data. My finding of low absolute and relative rate 
of VTE observed among cigarette smokers should be Interpreted with caution 
as we did not evaluate the amount of cigarette smoked. 
A few other aspects of our data are worthy of note. The current data relied on 
BMI measured prior to pregnancy in line with most existing research; 
however, one previous study found that weight gain during pregnancy was a 
more Important predictor of VTE rlsks3, something which I was unable to 
assess. My finding of a high risk of VTE in those with a prior diagnosis of 
varicose veins should also be Interpreted with caution as It may potentially be 
a consequence of a past unrecorded or concurrent deep vein thrombosis. 
Finally, I was not able to assess thrombophilia as a potential risk factor In our 
study. However a diagnosis of thrombophilia cannot be used to predict VTE as 
an outcome as routine thrombophilia screening Is not recommended for 
pregnant women. 
It may be argued that my estimates do not take Into account the number of 
pregnant women already on thromboprophylaxls prior to a VTE event. 
Although I excluded women with prior history of VTE from our study, It was 
found that 0.4% of pregnant women without VTE received heparin/LMWH 
prescribed by a general practitioner during antepartum/postpartum period 
(which were Included in the analysis) which may be due to certain clinical risk 
factors as suggested In the current RCOG guideline. This however Is certainly 
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an underestimate as I was unable to look at thromboprophylaxis prescriptions 
emanating from secondary care where prophylaxis around the time of 
delivery is most likely to occur. I believe though that the impact of this would 
be small as the first national RCOG guidelines for antenatal 
thromboprophylaxis were only published in 2004 with an updated version 
published in 2009. 
In the light of this fact I calculated the risk of VTE during pregnancy and 
postpartum pre- and post-2004 which showed no statistical difference in the 
postpartum and a 46% (statistically significant) increase in the risk of VTE 
post 2004 in the antepartum period suggesting minimal Impact of the national 
guidelines on the incidence of VTE. I should also emphasise that assessing the 
effectiveness of the current national guidelines for obstetric 
thromboprophylaxis is beyond the scope of this study. One way of assessing 
this could be calculating the number needed to treat (NNT) and number 
needed to harm (NNH) from the current data. For Instance, if we were to 
assume that prophylaxis reduces the risk of VTE by 50% as has been 
reported in trials outside of pregnancyl01, then based on my estimate of the 
absolute risk, 89 VTE events could be prevented per year in women whose 
pregnancies end in caesarean mode of delivery (NNT=1980). These values 
should be Interpreted with caution as they are based on speculative data 
regarding the reduction In risk resulting from LMWH from which there Is an 
absence of RCT data In pregnant women. Also, the absolute risk difference 
upon which the NNTs are estimated assumes causality which may not also be 
true. 
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3.4.3 Comparison to previous studies 
My observed relative increases in the risk (more than 2-fold) of VTE in those 
with preterm birth, obstetric haemorrhage, caesarean section, stillbirth and 
varicose veins compared to women without those respective risk factors are 
of roughly similar magnitude to those reported in other studies7, 10, 12,44, 53, 55, 
56. I believe that the strong association between VTE events and stillbirths is a 
finding of real importance which has received only limited attention to date.56 
My finding of low relative increases in the risk of VTE among women over age 
35 years, current smokers and those with high BMI during the antepartum 
period are also in concordance with previous studies. 10, 12, 44 
3.4.4 Conclusion and clinical implications 
My overall results may have important implications for the way obstetric 
thromboprophylaxis is delivered in the health care settings of developed 
countries and I hope that they will aid the targeting of such prophylaxis in 
three ways. Firstly, I found an Increased risk of VTE among pregnancies of 
women with preterm birth or stillbirth, factors which have received limited 
consideration to date and are not currently incorporated Into the guidelines 
for risk assessment of VTE. If they did then thrombotic events associated with 
those risk factors could potentially be prevented. Secondly, the current data 
support many of the existing national RCOG guideline recommendations (In 
terms of high absolute rates), especially that postpartum thromboprophylaxls 
may be Indicated in women with very high BMI ( ~ 4 0 0 kg/m 2), those who have 
prior co-morbidities, obstetric haemorrhage or who have a caesarean section 
delivery. Thirdly, my results showed a high risk of VTE In women with BMI 
between 30 and 40 kg/m 2 or varicose veins even If these risk factors occur 
In Isolation which may require careful consideration. The recommendation on 
whether thromboprophylaxis with lMWH may be effective in pregnant and 
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postpartum women with specific risk factors will of course be highly 
dependent on the risk reduction from prophylaxis, for which there is a 
noticeable void of data from pregnant women. Another Important 
consideration is the costs involved In prophylaxis both financial and also the 
tolerability surrounding a daily heparin prescription not to mention the well-
recognised side effects of allergy and bleeding. For instance, the benefits 
would need to be weighed against a risk of major haemorrhage which. is 
believed to occur in 1% of pregnant women64 and for which we showed a 2.5-
fold associated risk with VTE. Such a risk-benefit analysis clearly goes beyond 
the scope of the present work; however, I believe my presentation of 
population-based risks of VTE based on a number of established risk factors 
goes some way to help clinicians involved In making decisions in this area. In 
summary, my analysis provides new and interesting observations on absolute 
rates of VTE across a range of risk factor categories. It provides valuable 
Information to clinicians for better decision making in terms of Identifying high 
risk pregnant and postpartum women who may require some form of 
thromboprophylaxis. 
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4 Defining the incidence of venous thromboembolism in and 
around pregnancy using linked primary and secondary care 
data: A population based cohort study and comparative 
meta-analysis 
Using data from primary care (chapter 2 and chapter 3) I was able to look at 
the incidence of VTE during the antepartum and postpartum and compare It 
to the time outside pregnancy. I found that the risk of VTE is particularly high 
during the third trimester of antepartum and early postpartum corresponding 
to a S-fold and 21-fold increased risk respectively compared to time outside 
pregnancy. Furthermore, I also found that the high risk of VTE extends 
beyond the first week of postpartum. THIN also gave me the opportunity to 
look at some of the risk factors for VTE both during pregnancy and following 
childbirth. It was observed that postpartum, the strongest association with 
VTE was with stillbirth followed by medical co-morbldities (including women 
with varicose veins, Inflammatory bowel disease (ISO) or cardiac disease), 
B M I ~ 3 0 k g / m 2 , , obstetric haemorrhage, preterm delivery, and caesarean 
section (ARs=637/100,OOO person-years or higher). Antepartum, only 
varicose veins, IBD, acute systemic Infection and pre-exlstlng diabetes were 
associated with a higher risk of VTE. Despite the fact that THIN gave me the 
opportunity to answer Important clinical questions and for the first time 
provide population level estimates of absolute and relative risk, there are 
some fundamental Issues with only using primary care data which are worth 
stating. Firstly, the under-ascertainment of some of the risk factors In THIN 
may have Inevitably biased estimates (I.e. differential or non-differential bias 
resulting from miss-classification of the risk factors). Moreover the strong 
association observed for stillbirth and preterm birth with postpartum VTE may 
have been confounded by pre-eclampsia/eclampsia to a certain extent due to 
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the underestimated prevalence of pre-eclampsia/eclampsia. For instance if we 
consider HES maternity statistics as the gold standard information on 
pregnancy in the UK, then the prevalence of pregnancy associated 
characteristics and complications previously reported In THIN was much lower 
(Table 4-1). Secondly the Incidence of VTE in individual weeks of the 
postpartum (Figure 2-4) gives the impression that the rate of VTE peaks in 
the third week and that the high risk of VTE extends well beyond the first four 
weeks, thus lengthening the duration of time for prophylaxis that may needed 
to be offered following delivery. However in reality it might be that the 
recording of VTE from secondary care is delayed and thus this pattern may be 
incorrect. This also restricted my ability to look at the impact of certain risk 
factors on the incidence of VTE during the specific postpartum periods. 
Moreover, this deiay in recording from secondary to primary care may also 
cause mlsclassificatlon between antepartum and postpartum VTE around the 
time of delivery leading to low and high a b s o l u t ~ ~ rate of VTE for antepartum 
and postpartum respectively. Lastly, some of the VTE events from the 
secondary care might not always get recorded in primary care thus leading to 
underestimation of Incidence In all or certain exposure periods. Therefore In 
the following chapters I report results from a series of studies utilising linked 
primary and secondary care data to help circumvent some of these 
limitations. This study has not been accepted for publication and Is currently 
in press. 
139 
Table 4-1: Prevalence of risk factors in THIN versus the expected 
prevalence 
Variables THIN HES maternity61 
Mode of delivery 
Spontaneous delivery 78 .3 
Caesarean overall 15.5 
Elective caesarean Not well recorded 
Emergency caesarean Not well recorded 
Assisted delivery 6.3 
Haemorrhage 
Antepartum haemorrhage 0.6 
Postpartum haemorrhage 0.6 
Stillbirth 0.3 
Multiple gestation 1.7 
Preterm delivery « 37 weeks) 7.1 
Eclampsia/pre-eclampsia 0.5 
Gestational hypertension* 1.7 
Gestational diabetes* 0.7 
Hospitalisation -
Duration of hospitalisation -
vInformatlon on risk factor present, - Information not present 
* Also depends on the definition selected 
64 .9 
23. 5 
v 
v 
11.5 
7.6 
8.8 
0.5 
1.4 
7.7 
2.4 
5.0 
1.1 
v 
v 
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4.1 Background 
Venous thromboembolism (VTE) is a serious complication of pregnancy, 
however due to the low incidence of pregnancy related VTEs and uncertainties 
over risk factors, prospective studies are unlikely to be done because of 
prohibitive costs. Therefore, to study its occurrence and risk factors, studies 
using routine data have been used as they provide sufficient power and 
population coverage to give robust and generalisable estimates. 33. 37 The 
recent linkage of electronic primary data in the Clinical Practice Research 
Datalink (CPRD) with the secondary care English Hospital Episode Statistics 
database (HES) may be useful in providing valuable information on maternal 
risk factors for VTE including hospitalisation, life style related factors and co-
morbidities. However, there have been no studies done using these linked 
data to quantify the incidence of VTE in and around pregnancy. Furthermore 
no studies have assessed the disparities between the results from secondary 
and primary care data in a standalone fashion versus when used together. 
Additionally, defining VTE may be a concern as currently there have been no 
studies done to validate VTE in linked primary and secondary data. Whilst VTE 
has been previously validated in primary care data in non-pregnant women 
with a positive predictive value (PPV) of 84%,85 it is important to assess 
whether secondary care data add any further information on VTE events 
around pregnancy especially In the United Kingdom where almost all women 
deliver in hospital. For Instance, the previous validation study does not give 
an Indication of the negative predictive value and we cannot Ignore the 
potential for the incidence of VTE recorded In primary care to be 
underestimated If certain VTE cases are solely recorded in secondary care. 
Further validation is also required to assess potential false positive diagnoses 
In the peripartum period. 
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4.2 Study justification and aim 
One way of assessing clinical information captured on VTE during antepartum 
and postpartum periods is to compare estimates of VTE incidence with 
previous studies. However to-date, there has not been any formal data 
synthesis of these previous studies nor an attempt at providing pooled 
estimates of the incidence of VTE during the antepartum and postpartum 
periods. The aim of this study was therefore, twofold: to use linked primary 
and secondary care data to determine an optimum definition for estimating 
the incidence of first VTE in and around pregnancy; and secondly to conduct a 
systematic literature review of studies on perinatal VTE Incidence with the 
purpose of comparison with my estimates. 
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4.3 Method 
4.3.1 Data source used 
For the purpose of current study and those presented in chapters 5 and 6, 
following datasets was used; 
4.3.1.1 Clinical practice research datallnk 
The Clinical Practice Research Datalink (CPRD)102 formerly known as The 
GPRD is a computerized primary health care database containing 
demographic, medical, prescription and lifestyle related Information from 
anonymised patients across the United Kingdom. This database Is similar to 
the previously used THIN database in terms of data recording and validation 
and uses the same Vision software. It contains data from 613 practices with a 
total of 12.4 million patients. Overall the database Is split Into ten files each 
of which can be merged using a unique patient Identifier. 
4.3.1.1.1 Data guality l03 
CPRD has historically undertaken a set of Internal data quality measurements 
In an effort to ensure high quality data within a subset of UK practices. These 
are done on both a practice and patient level. The practice level quality check 
Is recognised by the "up to standard" (UTS) date and the patient quality level 
by the patient acceptability flag. Patients In the CPRD are categorised as 
"acceptablen for research by a process that allows the excfusion of patients 
with questionable validity. The UTS date ensures that the data provided by a 
particular practice is of research quality. It is based on two central concepts. 
Firstly, the practice mortality rate must be within an acceptable range. This 
ensures that data provided for patients who have died; death Is being 
recorded and is a marker for Irregularities In practice. Secondly, It ensures 
that there is continuity in the data recording within a practice. CPRD Is used 
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extensively for research and has been validated for several health 
outcomes. 104• 105 For example a systematic review by Herrett et al. found the 
overall median accuracy of the diagnosis In CPRD for a wide range of disease 
group (including circulatory and respiratory diseases) to be 89%.104 
4.3.1.1.2 Date information in CPRD 
A patient file is also accompanied by first registration date, current 
registration date and transfer out date. The first registration date is the date 
when a patient is first registered with the practice. If patient only has 
'temporary' records then this is the date of their first encounter with the 
practice. If the patient has 'permanent' records it is the date of the first 
'permanent' record (excludes preceding temporary records). The current 
registration date is the date the patient's current period of registration with 
the practice began. If there are no 'transferred out periods', then this is the 
same as the first registration date. If there are 'transferred out periods' then 
it is the date of the first 'permanent' record after the latest transferred out 
period. Finally the transfer out date is the date when a patient is transferred 
out of a practice, if relevant. It is empty for patients who have not transferred 
out. The work presented in this thesis is restricted to women with permanent 
records. 
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4.3.1.2 Hospital episode statistics 
The Hospital episode statistics (HES)106 database contains details of all 
admissions to NHS hospitals In England. These also Include private patients 
and those resident outside England who were treated at an NHS hospital as 
well as care delivered by treatment centres funded by the NHS. It contains 
demographic data along with the Information on discharge diagnoses and 
procedures which are coded using ICD-IO and OPCS-4 respectively. All 
diagnoses within hospitalisation periods are presented In the form of episodes 
which are categorised as primary; the main condition treated or Investigated, 
or secondary; not the main condition Investigated or treated. Each episode 
may have multiple diagnoses whereas each hospitalisation period may have 
multiple episodes. The version of HES used for this study contained admitted 
patient care data on approximately 2.3 million patients. Broadly the data 
structure of HES can be categorized as patient, hospitalization, diagnosis, 
critical care, source and maternity. The key Information contained within each 
file Is summarized as Table 4-2. All flies can be linked together by a unique 
patient identifier. 
Table 4-2: Overview of data structure of HES 
File name 
Source 
Patient 
Hospitalization 
Diagnosis 
Critical care 
Maternity 
Information contained 
Acceptable patients In CPRD which are eligible for HES linkages 
Demographic, registration with HES Information 
Hospitalization dates, duration and method of admission 
Medical history and diagnoses by hospitalization and eplsode1 
Days In critical care and life support 
Birth outcome, mode of delivery, length of gestation and multiple 
birth 
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4.3.1.3 HES maternity 
HES maternity contains data on all births which take place In England and 
aims to include those taking place at home and In non-NHS hospitals as well 
as the majority of births that take place in NHS hospitals. The vital 
information contained in HES maternity includes, antenatal and postnatal 
hospital stay, mode of delivery, place of delivery length of gestation and birth 
outcome (live or still). Most patients admitted to hospital are categorized as 
general inpatient; even women admitted to hospitals with the clear intention 
of birth will be classified as a general admission. However, as soon a women 
has given birth it becomes a maternity record and is updated in HES 
maternity. There are two types of maternity records in HES; the delivery 
record and birth record. The delivery record is the HES record for the mother. 
It contains the same data as a general record but has a baby tail for 
information about the baby. The birth record is the HES record for the baby 
and again has the same format as general record, but it also has a baby tall 
containing same information recorded in the corresponding tail of the delivery 
record. Delivery and birth episodes in HES can either be consultant episodes 
or midwife episodes, depending on who has responsibility for the patient. For 
the purposes of this study I only looked at the delivery record. As HES 
maternity data (a subset of HES) is the primary source of maternity statistiCS 
in England, more than 90% of its delivery records and 80% of its baby 
records could be linked to birth registration and NHS Number for Babies 
(NN4B) dataset. 107 Furthermore, information found in HES maternity data 
such as birth outcome, baby weight and baby gender is also in good 
concordance with those data. 
4.3.1.4 Linkage 
The anonymised patient identifiers from CPRD were linked to HES from 1997 
onwards. This was done by a trusted third party using NHS number, date of 
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birth and gender. As only English hospitals are covered in HES, practices from 
Northern Island, Wales and Scotland are excluded. At the time of the study 
51.3% of the CPRD practices were linked to HES all of which are in England. 
The CPRD does not use a set sampling approach to for its linkage with 
secondary care HES data. It is based on practices that have consented to be 
linked to HES in CPRD. However all patients within a consented practice are 
included. Additionally, the comparison of CPRD-HES linked data to Office for 
National Statistics (ONS) data showing the age distribution of the UK 
population has demonstrated marked similarities between the two data 
sources. lOB 
4.3.2 Study population 
The study time period was defined between 1997 and 2010 during which 
potentially fertile women between the ages of 15 and 44 year registered 
within the CPRD-HES linked practices were Identified. The study start date 
was defined as the latest date of patient's registration with practice, the first 
day of April 1997, the date on which the practice became up to standard and 
the date of woman's 15 th birthday. The end date of the study was defined as 
the earliest date of transfer out date, date of death, first day of October 2010 
and the date of the woman's 45th birthday. 
4.3.3 Defining pregnancy and birth outcome 
In order to Identify birth episodes and birth outcomes, HES maternity data 
were used. Information on birth outcome (Including live birth and stillbirth) 
was Identified using the mother's delivery record. For Instances where birth 
outcome was not specified In the HES maternity data, It was Identified using 
ICD-l0 codes for live and still births (Appendix 15) from the hospital 
diagnosis file in HES. HES also has Information on pregnancy terminations 
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and miscarriages for which women had an inpatient hospital stay, however 
these are not classified in HES maternity data. Since many of these outcomes 
will not result in hospital stay, miscarriages and terminations are less well 
captured at population level and were thus not assessed in my study here. 
4.3.4 Multiple births 
All live or still births were categorized as Singleton, twins or triplets or more. 
However the baby tail coverage is not complete as the rest of HES and there 
are a number of quality issues, for instance trusts submitting Information on a 
higher number of delivery episodes (mother record) with no Information on 
birth episodes (baby record), can cause concerns when identifying multiple 
births. In order to minimize the impact of this issue information on multiple 
births was also extracted from the ICD-10 codes (Appendix 15). A woman 
was said to have multiple births If there was ICD-10 code Indicating multiple 
births. However if a woman had no ICD-10 code for multiple birth but had 
valid Information on more than one infant In the birth tall (valid birth outcome 
or valid birth weight), she was still considered to have multiple births. Initially 
birth outcome for all multiple gestations was defined as live (if all infants were 
born alive), still birth (if all infants were still born) or live with still birth. 
However due to a low number of multiple gestatlons resulting in both live and 
stillbirth (0.03%), this category was ignored. Therefore in this study I only 
included pregnancies with multiple births only if all pregnancy outcomes were 
live births or stillbirths. 
4.3.5 Generating the date of delivery 
Primarily the date of delivery was extracted from the mother's HES maternity 
record. Date of delivery was also extracted from the OPCS-4 codes which 
suggested a valid delivery method (eg. emergency caesarean section), or 
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method used to facilitate delivery (eg. episiotomy). These are presented In 
Appendix 16. For women with no date of delivery, the start date of the 
delivery episode was considered as the date of delivery. 
4.3.6 Date of conception 
The date of conception was defined by subtracting the length of gestation 
from the date of delivery. For pregnancies with no information on the length 
of gestation specified in HES maternity, leD-l0 codes. for length of gestation 
were extracted. Those with an leD-l0 code for "pre-term birth" (leD-l0 
code=060) during the delivery related hospitalisation were assigned gestation 
length of 36 weeks whereas those with "prolonged pregnancy" codes (leD-l0 
code=048) were labelled as having a gestational length of 43 weeks. All 
remaining pregnancies resulting in live or stillbirth with no Information on 
length of gestation in HES maternity or leD-l0 codes for pregnancy length 
(33% of pregnancies) were assigned an estimated length of gestation of 40 
weeks. This corresponds to that for the median gestation length of pregnant 
women in the NHS's maternity statistics for England.10g 
4.3.7 Defining Venous thromboembolism 
VTE diagnosis codes (Including pulmonary embolism and deep vein 
thrombosis) were extracted from women's primary care data using medical 
Read codes. From HES, all women with an leD-l0 code of venous 
thromboembolism Including pulmonary embolism (126.0, 126.9), deep vein 
thrombosis (180.1-180.9) and portal vein thrombosis (182.0-182.9) were 
extracted. leD-l0 codes for VTE specifically related to pregnancy or 
postpartum (022.2, 022.3, 087.1, 087.0, 008.2 and 088.2) were also 
extracted. Information from either or both primary and secondary care data 
sources was used to define a VTE event and the first VTE diagnosis recorded 
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in either data source was considered as the incident date. I assessed only the 
first recorded VTE during the study period and all subsequent VTEs were 
excluded. I then developed the following three VTE definitions; 
Definition A: My most stringent definition included only VTE diagnoses 
supported by prescription or evidence of anticoagulant therapy (with either 
warfarin, unfractionated heparin or low molecular weight heparin) within 90 
days of the event or death within 30 days of the event. Given the restricted 
use of oral anticoagulants (e.g. warfarin) during the antepartum period due to 
its teratogenicity, the majority of cases during the antepartum period were 
confirmed based on heparin prescriptions. 
Definition B: This consisted of cases where signs or symptoms of DVT (e.g. 
leg pain, calf pain), PE (e.g. chest pain, shortness of breath) or diagnostic 
tests for VTE (e.g. D-dimer, Ventilation-Perfuslon (VQ) scan, Computed 
Tomography (CT)-scan, venography) had been recorded between 15 days 
before and 15 days after a first recorded diagnosis of VTE, but there was no 
evidence of anticoagulant therapy. Cases were also Included If they had VTE 
diagnoses In both primary and secondary care up to 60 days apart, a cut-off 
based on the initial examination of the recording of VTE In both data sets and 
prior work others have published on Identifying acute medical events In linked 
data.llO. 111 
Definition C: This Included all other diagnoses of VTE that did not fit the 
criteria for VTE definitions A or B. Specifically, all VTE diagnoses with no 
accompanying anticoagulant prescription, medical code Indicating 
anticoagulant therapy, death, signs or symptoms of VTE, diagnostic tests for 
VTE. These cases were only recorded In one data source (HES or CPRD). 
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4.3.8 Defining exposure period 
Women's follow-up time between ages 15-44 years was divided Into time 
associated with pregnancy (defined from the date of any conceptions she had 
during follow-up until 12 weeks postpartum) and time outside pregnancy (all 
other available follow-up time, which included all time for women who were 
never pregnant during the study period; as previously described In Chapter 
2).36 For the purpose of this study I excluded time period associated with 
miscarriages and termination (from 10 weeks prior to 6 weeks following 
miscarriage/termination). I ~ ~ the VTE event was recorded during the same 
hospital admission as the women's delivery (which accounted for 11% of all 
VTE events), there was thus potential for misclassifylng the timing In relation 
to delivery. As 91% of deliveries occurred on the day women were admitted 
to hospital for delivery or on the day after and the median duration of hospital 
stay for delivery was only 2 days, the time associated with pregnancy was 
divided into the antepartum period (trimesters from the date of conception 
until 2 days before the date of delivery), time around delivery (1 day before 
until 2 days after delivery) and the postpartum period (3 days after delivery 
until 12 weeks postpartum). The postpartum period was subdivided Into 
Individual weeks and also into early (first six weeks) and late (second six 
weeks) postpartum. 
4.3.9 Statistical analysis 
4.3.9.1 Cohort analysis 
The absolute rates (AR) of VTE per 100,000 person-years and 95% 
confidence Interval (Cl) were calculated for the antepartum, time around 
dei/very, postpartum and time outside pregnancy separately using VTE 
definitions A, Band C. This was done by dividing the total number of VTE 
events by person-years of follow-up. I then restricted the analysis to first 
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VTEs identified only in primary care data and then VTEs only In secondary 
care data to compare these with the overall estimates using both sources. 
4.3.9.2 Systematic review and meta-analysis of existing VTE 
incidence studies 
For the purpose of comparing my calculated rates to the existing literature, I 
systematically reviewed previous studies that have estimated VTE Incidence 
among pregnant or postpartum women. I searched MEDLINE and Embase for 
studles- published between January 1960 and January 2013, combining a 
similar search strategy to that used in a previously published VTE systematic 
review29 with an adapted version of the Cochrane Pregnancy Group search 
strategy to obtain pregnancy studles. 3o The strategy used for MEDLINE and 
Embase Is summarised in Appendix 1 and Appendix 2 respectively. I Included 
studies only if they had estimated the rate of VTE In pregnant and postpartum 
women In a manner that allowed me to extract the data for the purposes of 
meta-analysls. Studies' abstracts were Independently reviewed for selection 
by two Investigators (AAS and lW) with differences resolved by consensus. 
For each study included In my meta-analysls, the natural logarithm of the 
Incidence rate of VTE per 100,000 person-years was obtained along with the 
standard errors (l/v'VTE events). For studies reporting rates of vrE per 
100,000 pregnancies I converted this Into person-years of antepartum time 
by multiplying the number of pregnancies by 0.75. For the meta-analysls, I 
only assessed the first six weeks after childbirth during the postpartum 
(although this was only the early postpartum period In my cohort study) as 
this was the definition of postpartum used In the majority of the included 
publications. These were then pooled separately for antepartum and 
postpartum periods assuming random effects using the generic Inverse 
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variance method. This method considers the Inverse variance of the effect 
estimates i.e. l/(standard error)2 as the weight given to each study, so a 
study with more VTE events was given greater weight than studies with fewer 
VTE events. A pooled estimate was also calculated for the third trimester of 
pregnancy. 
Given that diagnosis modalities have Improved over the years allowing for 
better ascertainment of VTE diagnosis in addition to the increasing prevalence 
of maternal risk factors for VTE (for example obesity), I performed a 
subgroup analysis by stratifying studies based on calendar year (before and 
after 2005). This cut-off was based on the Initial examination of the forest 
plot for the incidence of VTE during pregnancy which showed a marked 
difference in the rates of VTE before and after 2005. I also stratified my 
analyses based on whether or not VTE cases were subjected to a degree of 
validation/confirmation, which varied from study to study, however, 1 
accepted methods similar to my own criteria. The methods used to 
validate/confirm VTE ranged from using a validated algorithm to confirm VTE 
diagnosis or a registry where VTE cases were previously validated with 
reasonable accuracy to only Include cases where VTE had been objectively 
confirmed by diagnostic tests. A diagnosis of pulmonary embolism may have 
been confirmed by pulmonary angiography, eT, Magnetic Resonance Imaglng, 
VQ scan, or pathological confirmation of thrombus. A diagnosis of DVT may 
have been confirmed by Doppler ultrasound, duplex ultrasonography, 
venography, or pathological confirmation of thrombus. The heterogeneity was 
assessed in terms of 1. 2 All data management and statistical analysis was 
done using STATA MPll 
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4.3.10 Ethical statement 
This study along with the subsequent studies in chapters 5 and 6 was 
approved by the Independent Scientific Advisory Committee (ISAC) reference 
number=10_193R. 
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4.4 Results 
4.4.1 Cohort analysis 
Overall there were 1,117,691 women with follow-up data between the ages of 
15 and 44 years experiencing 248,953 pregnancies resulting In live or 
stillbirth (Table 4-3). The median follow-up for each women was 3.2 years 
(IQR= 1.23-6.50). 
Defining first VIE using linked primary and secondary care data 
There were 3,507 cases of first VIE using both data sources. Around 51% of 
the VIE cases were categorised under VIE definition A of which 51% of 
diagnoses were recorded both in primary and secondary care data (Table 
4-4). Twenty percent of all VIE cases were categorised under VIE definition B 
as they had supporting evidence including signs or symptoms or a diagnostic 
test documented 15 days before or after the date of VTE diagnosis but did not 
meet my criteria for VIE definition A. A total of 29% of all the VTEs were 
categorized as VTE definition e, I.e. diagnoses with no supporting evidence, 
the majority of which were In primary care data. When only using the 
primary care data to identify first VIE cases, a total of 2,923 cases were 
Identified of which 58%, 19% and 23% where categorised under VIE 
definition A, Band C respectively (data not shown). Similarly 1,946 potential 
VIE cases were identified when only using secondary care data to Identify 
first VIE of which 64%, 18% and 18% were categorized as VTE definition A, 
Band e respectively (data not Shown). 
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Table 4-3: Basic characteristics of study population 
Variables 
Total women in study 
Women experiencing at least one pregnancy resulting In live or 
stillbirth 
Median follow-up (IQR) in years 
Pregnancy outcome (total pregnancies N=248,953) 
Live births 
Stillbirths 
Study follow-up time In person-years (total study 
period =4,821,334 ) 
Time outside pregnancy 
Antepartum 
Time around delivery 
Postpartum 
N (Ofo) 
1,117,691 
204,929 
3.2 (1.23-6.50) 
247,436 (99.3) 
1,517 (0.61) 
4,613,196 
156,541 
2,381 
49,216 
Table 4-4: Percentages of VTE cases categorised under VTE definition 
A, Band C. 
cases of first VTE 
VIE definition Ai Total 
Diagnosis of VTE In HES and CPRD 
Diagnosis in HES only 
Diagnosis In CPRD only 
VIE definition aJ Total 
Diagnosis of VTE In HES and CPRD 
Diagnosis of VTE In HES only with supporting evidence 
Diagnosis of VTE In CPRD only with supporting evidence 
VIE definition C'Total 
Only HES with no supporting eVidence 
Only CPRD with no supporting evidence 
N=3,507 
n (Ofo) 
1,805 (51.0) 
925 (51.2)' 
168 (9.4)" 
712 (39.4)" 
728 (20.6) 
161 (22.1)" 
162 (22.2)' 
405 (55.6)" 
974 (27.6) 
316 (32.4)" 
658 (67.5)" 
lRecorded VTE with supporting anticoagulant prescription, or medical code Indicating 
anticoagulant therapy within 90 days of the event or death within 30 days of the event. 
2Recorded VTE codes with supporting sign or symptom of VTE within 15 days before or after the 
. date of event 
lRecorded VTE with no evidence of signs and symptoms or anticoagulant therapy. 
·Percentages based on different denominators (in bold) 
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4.4.2 Timing of VTE diagnosis (for cases diagnosed both In primary 
and secondary care 
Of the total 1,086 VTE cases documented In both primary and secondary 
care, 35% (n=377) had the same date of diagnosis for VTE In both datasets. 
Of the total cases with a different date of diagnosis, 82% (n=581) were first 
diagnosed in HES with a median delay of 7 days (IQR=3-13) until it was 
recorded in patients' primary care records. For VTE cases first diagnosed In 
primary care (number of cases=128) there was a median of 4 days difference 
(IQR=1-18) in the recording between primary and secondary care date of 
VTE. This was broadly the same in the antepartum and postpartum period 
and time outside pregnancy. 
4.4.3 Incidence of VTE in and around pregnancy 
The rate of any VTE (VTE definition A, B or C) during the time outside 
pregnancy using both primary and secondary care data was 61 per 100,000 
person-years (Table 4-5). This rate decreased by half when restricting to VTE 
definition A (32 per 100,000 person-years). When relying solely on primary 
care recording of first VTE, the rate using VTE definition A during the 
antepartum period, around delivery and postpartum period was calculated to 
be 80, 461 and 324 per 100,000 person-years respectively (Table 4-6). 
Relying solely on secondary care data for the recording of first VTE, the 
calculated VTE rate during the time around delivery and postpartum period 
was calculated to be 1799 and 180 per 100,000 person-years respectively. 
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Table 4-5: Incidence rat e of VTE per 100,000 person-years using different definitions of VTEs in and around pregnancy (for 
pregnancies resulting in live or stillb irths) and outside pregnancy using both primary and secondary care data to identify 
first VTE events 
Time period VTE defin it ion Ai, 8 2 or VTE definit ion Ai or 8 2 VTE d-efiriition Ai 
Cl 
n Rate* (95% CI) n Rate* (95% CI) n Rate* (95%CI) 
Time outside 2,817 61 (58-63) 2040 44 (42-46) 1480 32 (30-33) 
pregnancy 
Antepartum 377 240 (217-266) 268 171 (151-192) 156 99 (85-116) 
Trimester 1 47 95 (71-127) 41 83 (61-113) 23 46 (31-70) 
Trimester 2 76 148 (118-186) 49 95 (74-126) 30 58 (41-83) 
Trimester 3 254 450 (398-509) 178 315 (272-365) 103 182 (150-221 ) 
Around del ivery 76 3192 (423-546) 38 1596 (1161-2193) 34 1428 (1020 -1998) 
Postpartum 237 481 (423-546) 187 379 (3 29-438) 135 274 (231-324) 
Early postpartum 200 801 (695-920 ) 157 629 (537-735) 117 468 (391 -561) 
Late postpartum 37 151 (109-208) 30 122 (95-175) 18 73 (46-116) 
* Rate per 100,000 person-years 
**With women recorded as having a VTE event if they had a diagnosis in either database. 
lRecorded VTE with supporting anticoagu lant prescription, or med ica l code ind icating anticoagulant therapy within 90 days of the event or death within 
30 days of the event. 
2Recorded VTE codes with supporting sign or symptom of VTE withi n 15 days before or after the date of event 
3Recorded VTE with no evidence of signs and symptoms or anticoagu lant therapy 
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Table 4-6: Incidence rate of VTE per 100,000 person-years In and 
around pregnancy (for pregnancies resulting in live or stillbirths) by 
data source 
Time period VTE definition A i 
n Rate* (95% Cl) 
Using only primary care data to Identify first VTE 
events 
Time outside pregnancy 1387 30 (28-31) 
Antepartum 126 80 (67-95) 
Trimester 1 22 44 (29-68) 
Trimester 2 31 60 (42-86) 
Trimester 3 73 129 (102-162) 
Around delivery 11 461 (255-833) 
Postpartum 160 324 (278-379) 
Early postpartum 138 552 (467-652) 
Late postpartum 22 89 (591-136) 
Using only secondary care data to Identify first VTE 
events 
Time outside pregnancy 985 21 (19-22) 
Antepartum 123 78 (65-93) 
Trimester 1 18 36 (23-58) 
Trimester 2 25 48 (32-72) 
Trimester 3 80 141 (113-176) 
Around delivery 43 1799 (1334-2426) 
Postpartum 89 180 (146-221) 
Early postpartum 76 303 (242-279) 
Late postpartum 13 52 (30-91) 
*Rate per 100,000 person-years 
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During the early postpartum, the observed rate of VTE using both primary 
and secondary care data, peaked around the time of delivery and first week 
of postpartum (AR=991 per 100,000 person years) after which the rates 
showed a graded decline throughout the remaining postpartum period (Figure 
4-1). Compared to rates from the combined data sources, secondary care 
data showed a similar rate around delivery but much lower rates postpartum 
that decreased more rapidly following delivery, whereas primary care data 
showed lower rates around delivery but higher postpartum rates that 
remained consistently high until 4 weeks postpartum. 
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Figure 4-1: Rate of VTE in and around pregnancy and outside pregnancy using data using only established VTEs for 
pregnancies resulting in live or stillbirths 
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4.4.4 Systematic review and meta-analysis of perinatal VTE incidence 
studies 
I Identified 1,831 articles of which 34 had their full-texts reviewed and 21 
were eventually included (Figure 4-2). The characteristics of the Included 
studies are presented in Appendix 17. The overall pooled Incidence rates In 
the antepartum and postpartum periods are shown In' Figure 4-3 and Figure 
4-4. Antepartum, the Incidence rate of VTE during from previous studies 
ranged from 37 per 100,000 person-years In the UK to 144 per 100,000 
person-years in the U.5.A. The pooled incidence rate of VTE was 76 per 
100,000 person-years (95% Cl 65-90; heterogeneity /2=97.6%). The 
Incidence rate during the first six weeks postpartum ranged from 126 to 2815 
per 100,000 person-years. The pooled Incidence rate was 410 per 100,000 
person-years (95% Cl 302-555) with /2=99.2%. 
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Figure 4-2: PRISMA flow diagram for identification of VTE incidence 
studies during pregnancy and/or postpartum 
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Figure 4-3: Rate of VTE per 100,000 person years during the 
antepartum period 
Year of 
last data Incidence 
Author collection rate (95% Cl) 
Lindqvist 1993 86 (77, 96) 
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Figure 4-4: Rate of VTE per 100,000 person years during the 
postpartum period. 
Year of 
last data Incidence 
Author collection rate (95% Cl) 
----_ .. __ . __ . __ ._--_._._ .. 
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165 
When restricting only to studies where VTE cases were validated/confirmed 
(14 studies), I found higher incidence of VTE after 2005 (AR=118 per 
100,000 person-years /2=40%) compared to the rate before 2005 (AR=64 
per 100,000; /2=0.0%) for the antepartum. (Figure 4-5). The pooled absolute 
rate of VTE during the third trimester of pregnancy post 2005 (based on 389 
VTE cases; Figure 4-7) was calculated to be 142 per 100,000 person-years 
(95% Cl 93-158; /2=70%) when a similar restriction was applied. Similarly 
the pooled absolute rate of VTE during the first six week postpartum (post 
2005) was calculated to be 424 per 100,000 person-years (95%CI 238-755; 
/2=96%; Figure 4-6). 
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Figure 4-5: Rate of VTE per 100,000 person years during the 
antepartum period only including studies where some degree of case 
validation/confirmation was used. The data were stratified by year. 
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Figure 4-6: Rate of VTE per 100,000 person years during the 
postpartum (first six week after childbirth) period only including 
studies where some degree of case validation/confirmation was used. 
The data were stratified by year. 
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Author collection 
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Figure 4-7: Rate of VTE per 100,000 person years during the third 
trimester of antepartum period only including studies where some 
degree of case validation/confirmation was used. The data were 
stratified by year. 
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4.4.5 Comparison of meta-analysis estimates to the cohort analysis 
The estimates from the meta-analysis post-200S were lower those generated 
using inclusive VTE definition (VTE definition A, B or C and VTE definition A or 
B). However using only cases categorised under VTE definition A (those 
confirmed based on prescriptions or death), the incidence rate of 99, 182 and 
468 during the antepartum, third trimester of antepartum and early 
postpartum (first six week after birth) from my cohort analysis are in 
concordance with the pooled estimates from recent studies (118, 142 and 
424 respectively). 
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4.5 Discussion 
4.5.1 Main findings 
In this study, I have shown that a highly specific definition of VTE (VTE 
definition A) using data from both primary and secondary care health care 
settings is required to accurately estimate the incidence of VTE In and around 
pregnancy. The estimates I have derived are comparable with the pooled 
incidence rates for the antepartum and early postpartum periods from the 
existing literature. With the use of linked primary and secondary care data I 
was able to get a far more accurate date of diagnosis for VTE which resulted 
in more precise estimates of rates close to delivery. Whilst the VTE rate can 
be accurately estimated in the separate data sources in some circumstance 
(e.g. trimesters of antepartum), when relying solely on primary care data I 
found that the rate of VTE was much lower during the time around delivery 
but higher during the postpartum period compared to solely using secondary 
care data. This difference is likely because of a delay In hospitalised events 
being recorded In primary care. However when solely relying on secondary 
care data the rate of VTE was much lower during the postpartum period and 
the time outside pregnancy. The best method for defining and quantifying 
the Incidence of VTE in and around pregnancy is therefore to use both 
primary and secondary care data and applying my VTE definition A to Identify 
cases, as It has previously been validated In non-pregnant populatlon85 and Is 
externally comparable to other pregnancy studies. 
4.5.2 Ascertainment of VTE events 
In this study, I was able to analyse 1,117,689 women of childbearing age and 
over 248,000 pregnancies to determine how the incidence of VTE In and 
around pregnancy varies based on the VTE definition and the dataset used; 
such analysis had not been done before. My VTE definition A mimics a 
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previously validated VTE definition in primary care CPR085 data in a non-
pregnant population with a reported positive predictive value of 84%. To this 
algorithm I added secondary care diagnosis data which has an overall 
accuracy of 91 %112. One current drawback of UK secondary care data is the 
lack of information on hospital prescribed heparin and warfarin which may 
have lead to under ascertainment of cases using VTE definition A. However, I 
believe that the impact of this limitation should be minimal as pregnant 
women with a VTE diagnosis are expected to be on anticoagulation therapy 
throughout their pregnancies and this therapy period extends up to three 
months for postpartum women. 16 Therefore these prescriptions are likely to 
be captured in the primary care data. 
I must acknowledge that 33% of pregnancies had no information on the 
length on gestation. When I conducted a sensitivity analysis, however, and 
calculated the rate of VTE stratified by those with and without information on 
gestational age this showed no difference in my estimates of VTE within each 
trimester of pregnancy. It is also worth stating that I excluded pregnancies 
resulting In miscarriages and terminations from my analysis as I did not 
extract this information from women's primary care data which was beyond 
the scope of the present work. 
4.5.3 Date of VTE diagnosis 
Another strength of linked data is the improvement in estimation of the date 
of diagnosis of VTE. The majority (84%) of the VTEs diagnosed In both 
primary and secondary care using the linked data had the diagnosis made In 
secondary care data first. Therefore if I was completely reliant on primary 
care data alone there would be a concern with the delay In recording of VTE 
from secondary to primary care. My study demonstrated a median lag of 7 
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days in the recording of VTE events from secondary to primary care. This 
delay can restrict the ability to give precise Incidence estimates In narrow 
windows of time such as around delivery and probably explains my low 
incidence rate during the time around delivery and prolonged high risk during 
the early weeks of postpartum when only relying on primary care data for 
VTE diagnosis. One potential limitation of the secondary care data Is the 
reliance on episode start date as the date of VTE event. This creates problems 
in separating out antepartum versus postpartum VTE events occurring around 
the time of delivery. An example of this problem Is that reported In a cohort 
study of women delivering in hospital by Virkus et.al37 who considered the 
date of admission to hospital as the date of diagnosis for VTE. They reported 
a high rate of VTE during the third trimester of the antepartum compared to 
previous studies in the meta-analysls after 2005. This may be explained by 
some postpartum VTE events occurring during the maternal admission having 
been classified as antepartum. A similar, yet not acknowledged, problem may 
be the case for other studies utilizing hospital discharge data. 7, 10 In the 
present study HES provides a better option In terms of date of episodes for 
each diagnosis within each hospital period. I think this rather than the date of 
hospital admisSion or discharge will more accurately estimate the true VTE 
diagnosis date (although not necessarily the actual biological onset of the 
VTE). Furthermore the division of pregnancy periods as antepartum, around 
delivery, and postpartum adequately addresses the concern of mlss-
classification of VTE events around childbirth. 
4.5.4 Meta-analysls 
My meta-analyses showed high levels of heterogeneity occurring among the 
Individual studies both in the antepartum and postpartum analyses. In 
descriptive epidemiological studies where a statistic Is estimated among a 
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single group (such as pregnant women in this review), the potential for 
heterogeneity is far greater than for analytic or comparative studies (I.e., 
when two groups are compared to calculate a measure of effect such as an 
odds or risk ratio). This is because incidence rates are very sensitive to the 
choice of study population, outcome definition and dataset used meaning at 
least some heterogeneity will be inevitable; other published meta-analyses of 
this type also report very high levels of heterogenelty.29. 113. 114 The 
heterogeneity in my data during the antepartum period was partially 
explained by calendar year and whether VTE cases were subjected to a 
certain degree of validation/confirmation or not. For Instance, when I 
restricted my analysis only to studies where VTE cases were 
validated/confirmed and stratified them by calendar year, my 12 value was 
less than 50%. For the postpartum period, Incidence rates during the first six 
weeks post-delivery were largely Inconsistent even after restricting to studies 
with validated/confirmed VTE and stratifying the estimates by calendar year. 
This wide variation In the reported rates can probably be explained by the 
various countries' health care systems and their thromboprophylaxls practices 
after childbirth. The UK Royal College of Obstetricians and Gynaecologists 
recommendation on VTE risk assessment and thromboprophylaxls post-
caesarean section dates back to 1993, which may have been adapted by 
different countries at different pOints in time. For Instance a study from 
China43 reported the rate of VTE to be 1228 per 100,000 person-years where 
there was no concept of thromboprophylaxls prior to the year 2000 versus 
studies from Norway32 and UK36 with lower reported rates CAR around 400 per 
100,000 person-years). This is something I was not able to take account of In 
my meta-analysis for postpartum VTE. Most of the previous literature on this 
subject has relied on secondary care data which will Inevitably miss many 
non-fatal VTE events diagnosed and managed exclusively in primary care, 
particularly during the postpartum period. 33• 34. 37.40 
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Although I did no external validation of my VTE definitions among women 
Included in my cohort study, based on my most Inclusive definition (I.e. 
including events categorised under VTE definition A, B or C) my calculated 
rates of VTE during the antepartum and postpartum periods were 
considerably higher than the pooled Incidence rate of previous studies. This 
suggests the inclusion of many false positive events, limiting the validity of 
such an inclusive VTE definition. The same occurred, although to a lesser 
extent, when Including VTE events classified under VTE definition A or B 
where I Included cases with clinical signs and symptoms of VTE or evidence of 
diagnostic tests in addition to anticoagulant therapy. This may be due to the 
fact that leg swelling and calf pain are common In the third trimester of 
pregnancy In women without DVT which can lead to p o t e n t i ~ 1 1
mlsclassification. Additionally, D-dlmer levels Increase17 In pregnancy with 
gestational hypertension, and in preterm labour leading to false positive 
events which may add to that misclasslficatlon. In contrast the absolute rates 
of VTE using VTE definition A for antepartum and postpartum periods of 99 
and 468 per 100,000 person-years respectively are broadly In concordance 
with pooled estimates from previous studies using Similar methodology where 
VTE cases were validated/confirmed. 
4.5.5 Conclusion and Implications 
My results have important Implications for the way In which VTE Is studied In 
pregnancy using routinely available electronic health care records, data which 
are crucial for assessing outcomes that are severe and rare and thus rely on 
evidence from large population-based sources. F I ~ t l y , , I have quantified the 
incidence of VTE in and around pregnancy using a variety of VTE definitions. 
This demonstrated that the absolute rate of VTE greatly varies based on the 
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VTE definition used, with my VTE definition A providing the most comparable 
estimates of the absolute rates to previous work. I also demonstrated that 
there are some important limitations in using solely primary care or 
secondary care data in terms of the date and ascertainment of VTE diagnosis 
which needs to be considered when interpreting studies that do this. I have 
shown In my study that using both primary and secondary care data not only 
provide better estimation of the date of VTE diagnosis but also enable 
researchers to comprehensively identify VTE cases diagnosed and recorded 
both in primary or secondary care. Furthermore, the use of both primary and 
secondary care data combined may provide better ascertainment of maternal 
risk factors for VTE, information on hospitalization, primary care prescriptions, 
information on life style related factors and co-morbldltles. This vital 
Information could be used to better understand the occurrence of and risk 
factors for VTE in and around pregnancy for future research 
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5 Risk of first Venous thromboembolism In hospitalised 
pregnant women: A population based cohort study from 
England 
This chapter describes a cohort study conducted to assess the impact of 
hospitalisation and post-hospitalisation on the incidence of VTE during the 
antepartum period using the linked primary and secondary care data 
described in detail In the previous chapter. 
5.1 Background 
Of all potential risk factors for VTE, hospitalisation must be considered as 
potentially the most important given that in non-pregnant populations, the 
risk of VTE during episodes of hospitalisation has been found to be more than 
100-fold7o higher than time outside hospital. In the UK alone hospitalisation Is 
responsible for an estimated 25,000 deaths from VTE annually3. However, It 
Is not clear if the same magnitude of risk exists for pregnant women. Also, 
the risk of VTE post-hospital discharge needs to be determined to assess the 
need for thromboprophylaxls post hospitalisation. 
5.1.1 lustification and aim 
The current Royal College of Obstetricians and Gynaecologist (RCOG) 
guidelines21 recommends antenatal pharmacological thromboprophylaxls for 
prolonged hospitalisation (three or more days) If accompanied by two or 
more VTE risk factors (e.g. B M I ~ 3 0 K g / m 2 , , medical co-morbldltles etc). 
However, estimates of the absolute risks of VTE during and following 
antepartum hospitalisation, including those in women with no other medical 
co-morbldities or risk factors are not available. Utilising linked primary and 
secondary care data sources I have conducted the first study to determine 
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the risk of first VTE in hospitalised pregnant women while accounting for 
other maternal and pregnancy associated risk factors and medical co-
morbidities. 
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5.2 Method 
5.2.1 Study population 
The population for this study came from the Clinical Practice Research 
Datalink (CPRD) and Hospital Episode Statistics (HES) details of which are 
summarised in Chapter 4. The study time period was defined between 1997 
and 2010 during which women between the ages of 15 and 44 years 
registered within CPRD-HES linked practices with no prior confirmed VTE 
experiencing at least one delivery resulting In live birth or stillbirth were 
identified. Pregnancies occurring among women with previous confirmed VTE 
were excluded regardless of whether those events were diagnosed within or 
outside pregnancy. Therefore, where women developed a VTE In one 
pregnancy, person-time resulting from subsequent pregnancies was Ignored. 
5.2.2 Defining pregnancy and associated time period 
Person-time for each woman with at-least one pregnancy was divided Into 
antepartum (from conception up to two days before childbirth) and "outside 
pregnancy" (excluding 1 day before childbirth up to 12 weeks afterwards 
which was time associated with the peripartum and postpartum). Methods 
used to define pregnancy and exposure periods are presented In Sections 
4.3.3 and Section 4.3.8. 
5.2.3 Hospitalisation 
For each woman, information on all hospltalisatlons (non-delivery related) 
where VTE was not the primary recorded reason for admission lasting ~ 1 1 day 
was obtained (I.e. where there was at least one overnight stay). For all 
hospital admissions which Involved a VTE event, 30 days of electronic primary 
and secondary data before and after the VTE event were Independently 
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reviewed by two Investigators (AAS and JW) to determine whether the VTE 
event was the cause or consequence of the admission. There was good 
concordance between the investigators (Kappa =0.81) with all differences 
resolved by consensus. I considered hospitalisation as a time varying 
covariate with 3 levels: "hospitalised" (defined as the time between the date 
of admission and date of discharge); "post-discharge" (defined as the earliest 
of the date of delivery minus 2 days and the discharge date plus 28 days), 
which was further divided Into weeks; and "time outside hospital" (time not 
associated with hospitalisation) (Figure 5-1). My choice of 28 days for the 
post-discharge period for the majority of my analyses was arbitrary but 
mainly based on recommendations of thromboprophylaxls among patients 
undergoing knee surgery. us As such I also ascertained the risk In the period 
from 28 days to ten weeks after discharge to assess to what extent the risk of 
VTE persists longer term. The choice of ten weeks was based on the median 
follow-up duration from hospital discharge until the date of delivery 
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Figure 5-1: Division of antepartum person-time into "hospitalised 
time" and "time outside hospital". 
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5.2.4 Information on other risk factors 
I extracted information on women's demographic factors such as body mass 
index (most recent recording before conception), smoking status (latest 
recording before the date of delivery) and age (as described previously) from 
their medical records using primary care CPRO data using methods similar to 
that described In section 3.2.3.1. For each woman, I also extracted 
information on pregnancy associated characteristics (multiple gestatlons) and 
pregnancy associated complications (hyperemesis, antepartum haemorrhage, 
gestational diabetes and hypertension and gestational systemic Infection) 
using data from both primary and secondary care If they were recorded 
during pregnancy. The Read codes used to extract Information on 
hyperemesis are listed in Appendix 18 whereas ICO-10 codes used extract 
secondary care information on antepartum haemorrhage, gestational acute 
systemic infection and hyperemesis are listed In Appendix 19. Information on 
gestational diabetes, gestational hypertension, and medical co-morbldltles 
Including varicose veins, 180, nephrotiC syndrome, cardiac disease, pre-
existing hypertension and pre-existing diabetes was extracted using similar 
methods to those described In section 3.2.3.2.1 and section 3.2.3.2.2 with 
the addition of relevant ICO-10 codes to Identify events recorded In hospital 
records (Appendix 20). 
5.2.5 Venous thromboembolism 
VTE was defined as the recording of a medical code relating to the diagnosis 
of pulmonary embolism or deep vein thrombosis In HES or CPRO where there 
was evidence of anticoagulation within 90 days of diagnosis or If death 
occurred within 30 days of diagnosis (VTE definition A as previously 
highlighted in chapter 4). 
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5.2.6 Statistical analysis 
Absolute rates (AR) of VTE per 100,000 person-years and 95% CIs were 
calculated by dividing the total number of VTE events by the person-years of 
follow-up. In order to determine which factors were associated with an 
increased risk of VTE, incidence rate ratios (IRRs) were calculated for each 
category of the risk factor for antepartum compared with baseline using a 
Poisson regression model. Similar methods were used to compare rates of 
VTE during hospitalisation and the 28 days post-discharge with time outside 
hospital for antepartum (for comparative purposes this analysis was repeated 
for "time outside pregnancy"). Initially, I estimated the IRR comparing the 
rate of VTE during hospitalisation and post-discharge period to time outside 
hospital adjusted for age and calendar year. The calculated IRRs were also 
adjusted for additional risk factors found to be associated with increased risk 
of VTE. Women with missing Information on BMI were initially placed In a 
separate category for purposes of presenting rates of VTE according to body 
mass Index. For the adjusted analyses of VTE rate by hospitalisation, missing 
values for BMI were replaced using multlvarlate normal imputation. This 
Involved regressing existing BMI values on age and performing analyses on 
10 imputed datasets before results were combined. Imputations were carried 
out using actual BMI values, after which this variable was categorised (using 
existing BMI categories) prior to analysis. A sensitivity analysis was also 
conducted where I categorised missing BMI as a separate category and 
included it in our regression analysis. I also fitted a clustering term to take 
account of multiple pregnancies experienced by a woman. The current RCOG 
guideline suggests pharmacological thromboprophylaxis for pregnant women 
hospitalised for 3 or more days with the presence of two or more risk factors 
Including obesity (BMI>30kg/m2) and any significant co-morbidity. Therefore 
I also calculated the absolute and relative rate for hospitalisation and post 
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discharge period restricting only to pregnancies In women without those 
factors. 
Subsequent sub-group analyses for antepartum combined the hospitalisation 
and post-discharge periods due to the relatively small number of VTE events 
which occurred in either of these periods. These analyses Included 
stratification of results according to maternal age, BM I, trimester of 
pregnancy, duration of hospital stay and calendar year (before and after 2004 
based on the publication of first national guideline for thromboprophylaxls 
during pregnancy). I also formally tested for interaction between maternal 
age and hospitalisation by fitting an Interaction term between them and 
conducting a likelihood ratio test at the 5% level of significance. Similarly, I 
tested for an interaction between hospitalisation and BMI category using the 
same methods. All statistical analysis was conducted using Stata version 
11.2. 
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5.3 Results 
5.3.1 Basic Characteristics 
A total of 206,785 women had 245,661 pregnancies resulting in live or 
stillbirth during the study period. The median follow-up for women in the 
study was calculated to be 6.1 years (Inter quartile range=2.0-10.2 years). 
The basic characteristics of women with those pregnancies are summarised in 
Table 5-1. During the antepartum period, the total person-years associated 
with hospitalisation and post-discharge was 342 and 2,956 respectively. 
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Table 5-1: Characteristics of pregnancies occurring among women In 
linked CPRD-HES data* 
Variable Number of pregnancies 
" 245,661 
Hospitalisation •• 
Not hospitalized 203,405 82.80 
Hospitalized once 30,784 12.53 
Hospitalized twice 7,470 3.04 
Hospitalized thrice or more 4,002 1.63 
Demographic characteristics 
Body mass Index 
Normal(18.5-24.9) 107,275 43.67 
Underweight( <18.5) 7,733 3.15 
Overweight(25-29.9) 45,132 18.37 
Obese(>=30) 28,701 11.68 
Missing 56,820 23.13 
Smoking status 
Non smoker 186,926 76.09 
Current smoker 58,735 23.91 
Pregnancy associated characteristics and complication 
Diabetes 
Gestational diabetes 3,807 1.57 
Pre-existing diabetes 2,739 1.13 
Hypertension 
Gestational hypertension 13,039 5.65 
Pre-existing hypertension 14,962 6.43 
Gestational acute systemic infection 32,668 13.30 
Hyperemesis 8,502 3.46 
Antepartum haemorrhage 11,614 4.73 
Multiple gestation 3,564 1.45 . 
Varicose veins 6,244 2.54 
Cardiac disease 2,471 1.01 
IBO 1,213 0.49 
Nephrotic syndrome 181 0.07 
* Pregnancies occurred in 206,785 Individual women. Where women had more than one 
pregnancy, the status of all the above risk factors could pote.ntlally differ between pregnancies. 
** Hospitalisation during antepartum period 
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5.3.2 Hospitalisation 
Around 17% of women's pregnancies (42,256 pregnancies), had at least one 
hospitalisation spell with 4.7% hospitalised more than once during an 
individual pregnancy (Table 5-2). This amounted to a total of 59,537 non-
delivery hospitalisation spells that occurred during the antepartum period of 
which 57%, 22% and 22% concluded within one day, two days and three or 
more days respectively. The overall rate of antepartum hospitalisation was 
calculated to be 242/1000 pregnancies. This was much higher In the third 
trimester (176/1000 pregnancies) compared to first and second trimester (29 
and 37/1000 pregnancies respectively). In total 16,137 (27%) antepartum 
hospitalisation spells occurred among women with pre-exlsting medical risk 
factors (including cardiac disease, varicose veins, pre-exlstlng diabetes, 
hypertension, ISO and nephrotiC syndrome during pregnancy or women with 
a SMI2:30kg/m2). 
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Table 5-2: Basic Characteristics of hospitalisation during the 
antepartum period 
Variable Number Percentage 
59,772 
hospita lisation 
among 245,661 
pregnancies 
Overall antepartum 
Total hospitalisation 59,573 
Hospital duration 
1 day 33,560 56.3 
2 days 12,883 21.6 
3 or more days 13,094 21.9 
First trimester 
Total hospitalisation 7,256 
Hospital duration 
1. day 3,341 46.0 
2 days 1,767 24.6 
3 or more days 2,148 29.6 
Second trimester 
Total hospitalisation 9,100 
Hospital duration 
1 day 4,747 52.1 
2 days 2,013 22.1 
3 or more days 2,340 25.7 
Third Trimester 
Total hospitalisation 43,181 
Hospital duration 
1 day 25,472 58.9 
2 days 9,103 21.0 
3 or more days 8,606 19.9 
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5.3.3 Venous thromboembolism events 
Initially, I identified 100 women who developed venous thromboembolism 
during or within four weeks after admission (of whom 35 women were 
pregnant at the time of diagnosis). After the independent reviews, I classed 
72 venous thromboembolism events as being a consequence of the 
admission, of which 46 and 26 occurred during the time outside pregnancy 
and antepartu m period, respectively. There were 176 venous 
thromboembolism events diagnosed during the antepartum period, of which 
15% (n=26) occurred when the woman was an inpatient (occurring during or 
up to four weeks after admission and when venous thromboembolism was not 
the reason of admission). 
5.3.4 Rate of VTE by materna. risk factors 
Overall the rate of VTE during the antepartum period and time "outside 
pregnancy" was calculated to be 112 and 32/100,000 person-years 
respectively. I found high rates of antepartum VTE (>2-fold compared with 
their respective baseline) in women who had gestational diabetes, gestational 
acute systemic infection, hyperemesis, varicose veins or cardiac disease 
(Table 5-3). These absolute rates were broadly similar to those presented In 
chapter 3. 
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Table 5-3: Absolute rate of VTE per 100,000 person-years and 
incidence rate ratios during the antepartum period by potential risk 
factors 
Variable VTE Rate1(95% Cl) 
N 
Demographic characteristics 
Maternal age 
15 -24 years 38 101 (74-139) 
25 - 34 years 103 114 (94-138) 
35- 44 years 35 118 (85-164) 
Body mass Index 
Normal(18.5-24.9) 61 85 (66-110) 
Underweight«18.5) 3 59 (19-185) 
Overweight(25-29.9) 37 120 (87-166) 
O b e s e ( ~ 3 0 ) ) 35 178 (128-248) 
Missing 40 130 (95-177) 
Smoking status 
Non smoker 128 107 (90-127) 
Current smoker 48 127 (96-169) 
Antepartum compllcatlons2 
Hyper emesis 
Antepartum haemorrhage 
Multiple gestation 
Gestational diabetes 
Gestational systemic infection 
Gestational hypertension 
Varicose veins 
Cardiac disease 
Pre-existing hypertension 
11 222 (123-402) 
4 181 (67-482) 
5 223 (93-537) 
9 361 (187-694) 
30 269 (188-358) 
14 170 (100-287) 
Medical co-morbldltles2 
11 253 (140-458) 
5 303 (126-728) 
18 174 (110-277) 
iRate calculated as per 100,000 person-years 
2IRR compared to pregnancies without condition under study 
IRR (95% Cl) 
(Unadjustedl 
0.89 (0.61-1.29) 
1.00 
1.03 (0.70-1.52) 
1.00 
0.85 (0.64-2.09)* 
1.29 (0.85-1.96)· 
1.76 ( 1 . 1 6 ~ 2 . 6 7 ) · ·
•• 
1.00 
1.18 (0.85-1.65) 
2.05 (1.16-3.78) 
1.63 (0.60-4.39) 
2.02 (0.83-4.92) 
3.30 (1.69-6.46) 
2.69 (1.81-3.98) 
1.63 (0.94-2.83) 
2.35 (1.27-4.32) 
2.75 (1.13-6.70) 
1.64 (1.03-2.74) 
Note: No VTE events were observed In pregnancies complicated by 180, nephrotiC syndrome or 
pre-exlstlng diabetes during the antepartum period 
**Mlsslng data were Imputed 
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5.3.5 Rate of VTE by hospitalisation and post-hospitalisation 
The risk of antepartum VTE markedly increased during hospitalisation and 
post-discharge with absolute rates (AR) of 1752 and 676/100,000 person-
years respectively (Table 5-4). After adjusting for potential confounding 
factors (including maternal age and calendar year), there was an 17.5-fold 
(95%CI=7.69-40.0) and a 6-fold (95%CI=3.74-10.5) Increase In risk of VTE 
during hospitalisation and post-discharge period respectively compared to 
outside hospital in the antepartum period. When I only considered 
hospitaJisations which occurred among women with no associated pre-exlstlng 
medical co-morbidity or BMI>30Kg/m2, the magnitude of the Increase In 
relative risk aSSOCiated with hospitalisation remained similar. When I assessed 
risk of VTE aSSOCiated with hospitalisation for time outside pregnancy, I found 
that hospitalisation and post-discharge corresponded to a 66-fold and a 33-
fold Increases in risk (after adjusting for age and calendar year) respectively 
compared to time outside hospitalisation (Table 3). For antepartum, I found 
the rate of VTE to be altered by the duration of hospital stay. Those with a 
hospital stay of <3 days had 4-fold higher risk whereas those with ~ 3 3 days of 
hospital stay had a 12.2-fold Increased risk of VTE during 
hospitalisation/post-discharge period compared to time outSide hospital In the 
antepartum period. 
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Table 5-4: Rate of VTE during antepartum by hospitalisation and post-
hospitalisation 
Variable 
Time outside hospital 
Hospitalisation 
Post-discharge 
VTE Rate1 (95%CI) 
N 
Antepartum overall 
150 97 (83-114) 
6 1752 (787-3900) 
20 676 (436-1048) 
IRRz (95% Cl) IRR' (95% Cl) 
1.00 1.00 
18.2 (8.04-41.3) 17.5 (7.69-40.0) 
7.08 (4.41-11.3) 6.27 (3.74-10.5) 
Pregnancies not complicated by BMI>30 or major medical co-morbldltl 
Time outside hospital 109 84 (69-101) 1.00 
Hospitalisation 5 1821 (757-4375) 22.0 (8.97-54.3) 
Post-discharge 15 623 (375-1034) 7.56 (4.36-13.1) 
Variation by duration of hospital stay (comblnln, hospltallsatlon/post-dlscharae) 
Antepartum overall 
Time outside hospital 
Less than 3 days 
3 or more days 
Time outside hospital 
Hospita lisation 
Post-discharge 
150 97 (83-114) 
13 558 (331-943) 
13 1511 (858-2661) 
Time outside pregnancy 
326 28 (25-31) 
11 1890 (1046-3412) 
35 911 (654-1269) 
1.00 1.00 
5.85 (3.37-10.1) 4.05 (2.23-7.38) 
15.7 (8.71-28.5) 12.2 (6.65-22.7) 
1.00 
66.2 (36.3-120) 
32.3 (22.8-45.8) 
IRate calculated per 100,000 person-years 2Adjusted for maternal age and calendar year when not 
stratlfled by them lAdjusted for maternal age, calendaryear, BMI, gestational Infection, cardiac disease, 
varicose vein, gestational diabetes & hyperemesis 
"IncludIng varicose veIn and cardiac disease 
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5.3.6 Variation of the risk by age, trimester, BMI and calendar year 
I also found the collective rate of VTE during hospitalisation and post-
discharge to be higher In the third trimester of pregnancy (AR=961/100,OOO 
person-years; Table 5-5). The rate VTE Increased with age with highest risk 
among those a g e ~ 3 5 5 years (AR=1756/100,OOO per-years). Furthermore, I 
observed a statistically significant Interaction between age and hospitalisation 
(p value=O.Ol). My results highlighted that the Increased risk associated with 
hospitalisation and post-discharge· period remains broadly unaltered by 
women's BMI as supported by a non-significant test for Interaction between 
BMI category and hospitalisation (p value=0.36). I also observed higher 
absolute and relative rates of VTE post 2004 during both hospitalisation and 
the post-discharge period. All my calculated IRRs remained broadly similar 
when additionally adjusted for other risk factors significantly aSSOCiated with 
Increased risk of VTE (model 2). 
5.3.7 Rate of VTE In the weeks following hospital admission 
The rate of post-hospitalisation VTE was highest during the first two weeks 
post discharge (763/100,000 person-years; IRR-7.98 95%CI 4.50-14.1) 
(Figure 5-2). The risk decreased after 4 weeks with an absolute rate of 
387/100,000 person-years (IRR=4.19 95%CI 4.57-11.6) between 5 and 10 
weeks post-discharge. 
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Table 5-5: Rate of antepartum VTE during hospitallsation/post-
discharge stratified by trimester, calendar year, age and BMI 
Variable VTE Rate! (9S%CI) IRRz (95% Cl) IRR' (95%CI) 
N 
Variation by Antepartum trimester 
Trimester 1 and 2 
Time outside hospital 60 60 (46-77) 1.00 1.00 
Hospitalisation/post-discharge 5 449 (186-1078) 7.61 (3.03-19.0) 8.43 (3.27-21.7) 
Trimester 3 
Time outside hospital 90 162 (134-203) 1.00 1.00 
Hospitalisation/post-discharge 21 961 (426-1473) 5.93 (3.64-9.65) 5.57 (3.32-9.34) 
Variation by calendar year In hospltallsatlon/post-dlschal1e 
1997-2003 
Time outside hospital 62 96 (74-123) 1.00 1.00 
Hospitalisation/post-discharge 8 550 (275-1100) 5.82 (2.76-12.2) 4.59 (2.08-10.1) 
2004-2010 
Time outside hospital 88 . 98 (79-121) 1.00 1.00 
Hospitalisation/post-discharge 18 975 (614-1548) 10.1 (6.03-16.9) 8.51 (4.94-14.6) 
Variation by maternal ale 
15-24 years 
Time outside hospital 34 93 (66-131) 1.00 1.00 
Hospitalisation/post-discharge 4 363 (136-967) 3.88 (1.37-10.9) 3.80 (1.25-11.5) 
25 -34 years 
Time outside hospital 90 101 (82-124) 1.00 1.00 
Hospitalisation/post-discharge 13 771 (447-1328) 7.61 (4.24-13.6) 6.15 (3.24-11.7) 
35-44years 
TIme outside hospital 26 89 (60-131) 1.00 1.00 
Hospitalisation/post-discharge 9 1756 (913-3376) 19.6 (9.20-42.0) 21.7 (9.62-49.0) 
Variation by BMI 
Normal BMI (18.5-24.9 Kr/mz) 
Time outside hospital 51 72 (55-95) 1.00 1.00 
Hospitalisation/post-discharge 10 766 (412-1423) 6.24 (2.41-16.1) 4.72 (1.71-13.0) 
Overweight (25-29.9 Kr/mz) 
Time outside hospital 34 113 (81-158) 1.00 1.00 
Hospitalisation/post-discharge 3 474 (153-1472) 10.3 (5.15-20.8) 9.42 (4.38-20.5) 
Obese ( ~ 3 0 0 Kum2) 
Time outside hospital 30 157 (109-224) 1.00 1.00 
Hospitalisation/post-discharge 5 974 (405-2341) 4.30 (1.30-14.1) 4.50 (1.23-16.4) 
-'iRate calculated per 100,000 person-years lAdjusted for maternal age and calendar year 
when not stratified by them 3Adjusted for maternal age, calendaryear, BM I, gestational 
Infection, cardiac disease, varicose vein, gestational diabetes &. hyperemesis 
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Figure 5-2: Rate of VTE per 100,000 person years by weeks of post 
discharge during antepartum period 
1400 ____ . _ - _ - - . : . . . - : . . = ~ - - - - - - - - - - = _ - = _ = = = _ = = =_ _:_=_=_==-_=-
-----------------------,----------
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5-10 w ek post 
discharge 
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5.4 Discussion 
5.4.1 Main finding 
Using nationally linked primary and secondary care data, I was able to 
provide population-level absolute and relative rates of antepartum VTE by 
hospitalisation (including post-discharge) while taking into account other risk 
factors for VTE in particular pre-existing medical co-morbldities which would 
pre-dispose women to both an increased risk of both a hospital admission 
during pregnancy and of developing a VTE. I found that 17% of pregnant 
women were admitted to hospital at least once during pregnancy (prior to the 
delivery admission). Most admissions were of short duration and occurred 
during the third trimester. Whilst 85% of antepartum VTE events occurred In 
out of hospital, the risk of VTE per unit of time was 17-fold higher during 
hospitalisation compared with time "outside hospital". I also found a higher 
rate of VTE during the first 28 days post-discharge corresponding to 6-fold 
Increased risk compared to baseline. While the rate of VTE whilst hospitalised 
and following discharge was particularly high for women with 3 or more days 
of hospital stay, a 4-fold increase In the risk of VTE still existed for those 
admitted to hospital for less than three days. The rate for 
hospitalisation/post-discharge period was also high In all three trimesters of 
antepartum and those a g e d ~ 3 5 5 years. The strong association between 
hospitalisation and VTE remained when I restricted our analysis to women 
without medical co-morbiditles Including obesity, cardiac disease and varicose 
veins. 
5.4.2 Strength and limitations 
This study used an open cohort approach, with prospectively collected data 
and utilised information from linked primary and secondary care data sources. 
This not only enabled me to obtain comprehensive Information on risk factors 
196 
documented in either level of care but gave me the opportunity to follow 
pregnant women in and outside hospital with accurate dates of admission and 
discharge. This also permitted me to calculate the absolute and relative rates 
of antepartum VTE with respect to hospitalisation while taking Into account 
other potential risk factors which has not been assessed previously In the 
literature. It also makes my study findings nationally generalisable. The 
completeness of HES data and recording of diagnosis In different centres Is 
always a concern. However, the Department of Health has undertaken studies 
to assess the completeness of HES coverage which Is reported to be hlgh. 116 
Moreover a systematic review of discharge coding In HES had found that the 
accuracy for diagnostic codes Is 91%.112 Utilising data from both primary and 
secondary care, the prevalence of risk factors In the current study such as 
diabetes In pregnancy, gestational hypertension and antepartum 
haemorrhage Is similar to the expected prevalence In the UK. 117-1l9 
A limitation of this study is the relatively small number of VTE events 
occurring either within or Immediately following hospitalisation. This not only 
gave estimates with wide confidence Intervals but restricted my ability to 
stratify analYSis by reason for admission. I also acknowledge that the 
Increased risk of VTE during hospitalisation may be due to other well 
understood risk factors for VTE (eg. unmeasured co-morbldltles) leading to an 
overestimate In the Independent effect of hospitalisation/post-hospitalisation 
on VTE. However my calculated estimates for hospitalisation and post-
discharge periods remained unchanged when excluding pregnant women with 
other known risk factors for VTE. I also found that the Increased rate of VTE 
decreases In the weeks following hospital discharge which should not have 
been the case if the effect was solely due to other risk factors. Despite the 
fact that the risk of VTE was high In the late post-discharge period, the 
decrease In the risk of VTE from 1800 (during hospitalisation) to 408 per 
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100,000 person-years (during late post-discharge: 5-10 weeks) demonstrates 
some longer term effect of hospitalisation on the Incidence of VTE. While the 
cause of the association between hospitalisation and VTE Is not clear, 
immobility is often considered the main culprit. 53 Regardless of the reasons 
for hospitalisation, pregnant women admitted to hospital for reasons other 
than delivery represent a group at high risk as evident by a 5-fold Increased 
risk of VTE in those with hospital duration of less than 3 days. 
It may be argued that my conclusions, in part, depend upon two authors 
agreeing on whether VTE was a cause or consequence of the hospital 
admission. To address this, 30 days of electronic primary and secondary data 
before and after all VTE events occurring during the antepartum period were 
carefully and independently reviewed by two of the Investigators. Overall, 
agreement between Investigators was very high. When I repeated analyses 
accepting only cases where antepartum VTE was judged to be the 
consequence of the hospitalisation by Investigators 1 (n=24 VTE events) and 
2 (n=27 VTE events) separately, the Impact on our effect estimates was only 
modest and my conclusions were unaltered. Subsequently I also Involved, a 
third Investigator who independently agreed with the consensus assessment 
of Investigators 1 and 2 for all cases. 
My estimates for hospitalisation and post-discharge VTE risk do not take Into 
account that some pregnant women may already be receiving 
thromboprophylaxis during those periods. However, I believe that Since the 
first RCOG guidelines for antenatal thromboprophylaxls were only published In 
2004 (updated 2009), the use of antenatal thromboprophylaxls with LMWH 
was rare before 2004 except for those women with previous VTE. I found that 
both absolute and relative rates of VTE have Increased since 2004 which 
should not be the case if those women were given adequate pharmacological 
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thromboprophylaxis. This however does not take Into account Increasing 
ascertainment of less severe VTEs which would account for an Increase In risk 
of diagnosed VTEs in recent years. Additionally, 67% of all pregnant women 
diagnosed with antepartum pulmonary embolism (In 2005 and 2006) In the 
UK did not receive pharmacological thromboprophylaxls according to national 
guidelines even though they qualified for thromboprophylaxls. ll This suggests 
that even with the existence of the RCOG guidelines, widespread prophylaxis 
of at risk women is not sufficiently taking place. 
5.4.3 Comparison to previous studies 
To my knowledge this is the first study to assess the Impact of antepartum 
hospitalisation on the Incidence of VTE during pregnancy. Therefore I cannot 
directly compare my finding to any prior research. However a previous study 
carried out In Rochester, Minnesota has shown an age adjusted 135-fold7o 
increased risk of VTE among hospitalised patients compared to non-
hospitalized patients In the non-pregnant population (Including men), 
somewhat similar to 67-fold Increase observed outside pregnancy In the 
present study. Whilst my confidence Interval surrounding this estimate (95% 
Cl 36 to 120) does not Include the effect size observed In the Rochester 
study, this may not be surprising given that this study was carried out In a 
much older population (mean age=65 years) who would therefore be more 
likely to have longer Inpatient spells complicated by co-morbidity. 
5.4.4 Conclusion and clinical Implication 
I believe that this study has Important Implications In the way 
pharmacological thromboprophylaxls Is delivered to pregnant women and 
hope that It will help targeting prophylaxis In three ways. Firstly I found 6-fold 
Increased risk of VTE In the 28 days following hospital discharge. This 
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suggests prudent consideration of all pregnant women during that period In 
terms of VTE risk assessment. Secondly, at present RCOG guidelines advise 
that prophylaxis should be considered for women at the time of hospital 
admission provided that she has two or more risk factors including obesity 
(BMI>30Kg/m2), significant medical co-morbidity and is expected to be 
immobile for 3 or more days. This study demonstrated that the risk of VTE 
during hospitalisation and post-discharge period remained around 21-fold and 
8-fold respectively, even in women without such risk factors. Therefore 
thromboprophylaxis with LMWH may be appropriate during hospitalisation 
and for the 28 days post-discharge particularly in women with longer hospital 
duration or a g e d ~ 3 5 5 years regardless of other risk factors. Finally, the risk of 
VTE remained increased by 4-fold (during hospitalisation and 28 days post-
discharge period) even in women in hospital for iess than 3 days (rate 
equivalent to 0.4% per year). Whether prophylaxis would also be advised for 
hospital spells antiCipated to be of shorter duration would of course depend 
on the threshold for intervention which would depend both on the costs and 
tolerability surrounding a daily heparin injectlon22 which was beyond the 
scope of this work. In conclusion I found that hospitalisation exerts a 
noticeably Increased risk of VTE in pregnant women as has been found in 
other populations. ConSideration of which women should receive prophylaxis 
during an antepartum hospitalisatIon and for how long Is therefore needed. 
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6 Risk factors for VTE during the postpartum period using 
linked primary and secondary care data: A population based 
cohort study from England 
This chapter identifies the risk factors for VTE during the postpartum period 
utilising linked primary and secondary care data. It also evaluates the Impact 
of those risk factors on the timing of VTE around delivery and specific periods 
of postpartum. 
6.1 Introduction 
Whilst previous studies have shown the rate of VTE to be highest during the 
postpartum period,31, 33, 36 there Is limited evidence on specific risk factors for 
VTE resulting In difficulty when targeting thromboprophylaxls for VTE 
prevention. The few studies that have specifically assessed risk factors for 
postpartum VTE Indicate that obesity, postpartum haemorrhage, caesarean 
section delivery, pre-eclampsia, stillbirth and pre-term birth Increase a 
woman's risk. 1o, 39, 41, 44, 53 Most of the risk factor estimates are Inconsistent 
across studies with a lack of studies providing Information on absolute rates. 
For Instance, Increased risks of VTE after caesarean section delivery range 
from 2.6- fold to 7-fold,10, 39, 41, 44 with only few studies assessing whether the 
I mpact of elective differs from emergency caesarean delivery. 32. 43 In 
particular, there Is a lack of studies which comprehensively assess the relative 
Importance of risk factors occurring before, during and after childbirth while 
taking Into account both their Interrelations and also confounding by women's 
background risk factors such as obesity or pre-exlstlng diabetes. 
Furthermore, there also Is lack of evidence quantifying whether the Impact of 
risk factors on the Incidence of VTE differs from early to later postpartum 
periods, which is important for planning thromboprophylaxls reglmens. 120 
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6.1.1 Justification 
The current Royal College of Obstetricians and Gynaecologist (RCOG)21 and 
American College of Chest Physician (ACCP)64 thromboprophylaxis guidelines 
are based on limited evidence that does not allow adequate separation of 
antepartum from postpartum risk factors for VTE. Moreover, the RCOG21 and 
ACCP64 recommendation of seven days and in-hospital (the duration of 
delivery admission) pharmacological postpartum thromboprophylaxls 
respectively for women with intermediate risk factors and no previous VTE are 
based on expert clinical consensus rather than on robust evidence. Using 
prospectively recorded primary care and secondary care data the current 
study provides precise estimates of the risks of postpartum VTE associated 
with pregnancy complications, delivery events and women's co-existing 
morbldities, and examines the timing of VTE In speclflc postpartum periods. 
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6.2 Methods 
6.2.1 Study population 
I used longitudinal primary care data from the Clinical Practice Research 
Datalink (CPRD)102 linked to Hospital Episode Statistics (HES)106 data 
containing information on all hospitalisations In England Including discharge 
diagnoses and procedures (details of which are summarised in Chapter 4). 
Pregnancies ending In live birth or stillbirth between 1997 and 2010 for 
women age 15-44 years, registered with CPRD-HES linked practices and with 
no VTE before or during pregnancy were Identified from the study population. 
6.2.2 Defining venous thromboembolism in postpartum time periods 
Information on first VTE events was extracted using Read codes In CPRD and 
ICD-10 codes in HES. For the purpose of this study VTE was defined as a 
medical code relating to the diagnosis of pulmonary embolism or deep vein 
thrombosis In HES or CPRD or both (taking the first date as the date of 
diagnosis) which was confirmed using the algorithm presented In section 
4.3.7 (VTE definition A). For VTE events first recorded In HES, the date of VTE 
was taken as the date of hospital admission. As 90% of deliveries occurred on 
the day women were admitted to hospital for delivery or on the day after, the 
postpartum period was defined from one day before up to 12 weeks post 
delivery. This was to ensure complete capture of all postpartum VTE events 
diagnosed during hospital admissions. 
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6.2.3 Defining potential risk factors 
6.2.3.1. Demographics, lifestyle characteristics and pre-exlstlng co-
morbidities 
For all pregnancies I extracted information on women's demographic and 
lifestyle characteristics as well as important co-morbldltles from both primary 
and secondary care data. Information on body mass Index (BMI) (Kg/m2), 
cigarette smoking and age at delivery was obtained from CPRD data, whilst 
cardiac disease, varicose veins, Inflammatory bowel disease (IBO), pre-
existing diabetes and hypertension were ascertained using both CPRD and 
HES using methods similar to previously descrlbed.9o Similarly I also defined 
women as having pre-existing renal disease if they had a diagnosis of acute 
or chronic kidney disease, glomerular or renal tubule-Interstitial disease 
before conception In HES or CPRO. 
6.2.3.2 Pregnancy characteristics and complications 
Information on pre-eclampsla/eclampsla, hyperemeSiS, multiple birth, 
gestational diabetes or hypertension (as previously defined90) was extracted 
using both CPRO and HES. I also Investigated two common acute systemic 
Infections during pregnancy (urinary and respiratory tract (pneumonia, acute 
bronchitis, chest Infection and Influenza» as these have been associated with 
VTE In non-pregnant populatlons.68• 92 
6.2.3.3 Delivery characteristics and complications 
From HES I extracted risk factors occurring around delivery: length of 
gestation, mode of delivery (spontaneous, aSSisted (forceps, breech or 
vacuum), emergency or elective caesarean), stillbirth, and postpartum 
haemorrhage (including Intra-partum haemorrhage). We also Investigated 
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acute systemic infections during the postpartum period, termed puerperal 
infection. The ICD-lO codes used to extract Information on postpartum 
haemorrhage pre-eclampsia/eclampsla from HES are presented In Appendix 
21. 
6.2.4 Statistical analysis 
I calculated incidence rates of VTE per 100,000 person-years and 95% 
confidence intervals by dividing the number of VTEs by the postpartum 
follow-up time, stratified by each demographic and lifestyle characteristic, 
pre-exlsting co-morbidity, pregnancy and delivery characteristic and 
complication. Using Poisson regression I calculated unadjusted Incidence rate 
ratios (IRR) to examine the associations between each risk factor and VTE. 
Risk factors where the likelihood ratio (LRT) test p-value was <0.1, were 
Included In multivarlate models that were constructed using a pre-developed 
conceptual hierarchical framework (Figure 6-1) that considers the complex 
causal pathways between variables. m For Instance, some of the Impact of 
delivery complications (e.g. mode of delivery, postpartum haemorrhage) on 
postpartum VTE may be confounded by pregnancy characteristics (e.g. pre-
eclampsia), pre-exlsting medical co-morbldities (e.g. cardiac disease) or 
demographic factors (e.g. maternal age). However each of these factors may 
also have direct effects on postpartum VTE that are not mediated through 
delivery complications. 
In my hierarchical framework I grouped factors that were considered to have 
more proximate associations with postpartum VTE (e.g. caesarean section) 
separately from more distant factors (e.g. pre-pregnancy BMI) that may have 
direct effects on VTE but may also have Indirect effects mediated through 
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proximate risk factors (e.g. pre-pregnancy BMI is related to one's likelihood of 
developing pre-eclampsia).58 Based on this I created three modelling 
frameworks (MF) to present rate ratio estimates adjusted for different groups 
of risk factors. In modelling framework 1 I created separate models for each 
pre-existing co-morbidity, pregnancy and delivery characteristic/complication 
to estimate their overall effects on postpartum VTE, adjusting only for 
demographic and lifestyle characteristics (e.g. maternal age, BMI). In MF 2, 
models from MF 1 were additionally adjusted for any pre-exlstlng medical co-
morbidities (e.g. cardiac disease). In MF 3, models were adjusted for 
demographic and life style related factors, pre-exlstlng medical co-morbldltles 
and pregnancy related characteristics and complications, to estimate each of 
their effects un mediated by their more proximate risk factors, and also the 
fully adjusted effects of each delivery characteristic/complication. At that 
point I re-added statistically non-significant variables previously excluded to 
assess If they became significant. Because the direction of causal pathways 
between assisted and caesarean delivery and other delivery complications 
(e.g. stillbirth) can vary, I carried out a subgroup analysis restricting to 
women who only underwent spontaneous vaginal or assisted delivery. 
For pregnancy and delivery complications showing Increased postpartum VTE 
risks with more than 10 associated VTE events (to ensure reasonable 
precision), I assessed whether the absolute and relative risks (AR and RR) of 
VTE differed during the early postpartum (weeks 1-3 and weeks 4-6 post 
delivery) and late postpartum (weeks 7-12 post delivery). As a sensitivity 
analysis, I re-ran all models, excluding a small proportion (7%) of VTE events 
first recorded In HES because they occurred during the same hospital 
admission as the delivery or another risk factor event (e.g. postpartum 
haemorrhage) and therefore precise temporality could not be established (I.e. 
I was not able to determine whether VTE was the cause or consequence of a 
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caesarean section or postpartum haemorrhage, particularly for those 
occurring on the same day). 
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Figure 6-1: Conceptual hierarchical framework for multivariate 
modelling of risk factors for VTE during the postpartum period 
Demographic Imd life styl e characteristics 
Maternal age, body mass index (Kg/m 2) , cigarette 
smoker 
! 
Pre-existing co-morbidities 
Var icose veins, cardiac disease, Inflammatory 
bowe I disease, pre-ex isting diabetes and 
hypertension 
1 
Pregnancy characteri s ti cs and compl i cation 
Gestational diabetes and gestational 
hypertension, Pre-eclampsla/eclampsla, multiple 
birth, acute systemic Infection, antepatum 
haemorrhage and hyperemesis 
~ ~ , 
Del ivery characteristi cs and compl i cad on 
Mode of delivery, stillbirth, postpartum 
haemorrhage and length of gestation, puerper 81 ~ ~Infection 
.-.. VTE 
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6.3 Results 
6.3.1 Basic characteristics 
Among 168,077 women there were 222,334 pregnancies ending in live birth 
or stillbirth. Fifty seven percent of women delivered between the ages of 25 
and 34 years, 29% had a pre-pregnancy BMI greater than 25kg/m2 and 23% 
were cigarette smokers. Table 6-1 shows absolute rates of postpartum VTE 
and aSSOCiations with each of the 21 risk factors assessed, 14 of which were 
significantly associated with postpartum VTE in bivariate models (LRT 
p<O.Ol). The highest absolute rates were related to stillbirth, ISO, varicose 
veins, pre-eclampsia/eclampsla, cardiac disease, preterm gestation and 
obesity. 
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Table 6-1: Prevalence, absolute rates of VTE per 100,000 person-
years and IRR of potential risk factors in the postpartum period 
Variable Pregnancies 
N (Ofo) 
VTE N Rate(95%CI)* 
Demographic and lifestyle characteristics 
Maternal age at delivery 
15 - 19 years 12,927 (5 .8) 5 170 (70 -408) 
20 - 24 years 36,960 (16 .6) 28 330 (228-478) 
25 - 29 years 58,207 (26 .1) 53 390 (298-551) 
30 - 34 years 68,753 (30.9) 37 228 (165-315) 
35 - 39 years 37,968 (17 .0) 44 491 (366-661) 
40 - 44 years 7,519 (3 .3) 11 625 (346-1130) 
BodV mass index (Kg/m2) 
Normal(18.5-24 .9) 98,730 (44.4) 60 259 (201 -334) 
Underweight( <18 .5) 7,339 (3 .30) 3 179 (56-545) 
Overweight(25-29 .9) 39,652 (17 .8) 33 353 (252-499 ) 
Obese(> =30) 24,141 (10 .8) 40 707 (519-964) 
Cigarette smoker 51,731 (23 .27) 51 428 (322-558) 
Pre-exlstlng co-morbldltles 
Varicose veins 5,895 (2.65) 
Cardiac disease 2,264 (1.0) 
Inflammatory bowel 1,105 (0 .5) 
disease 
Pre-exls ting 13,814 (6 .5) 
hypertension 
Pre-existing diabetes 2,501 (Ll) 
Pre-exlsting renal 1,493 (0 .7) 
disease 
* Rate calculated per 100,000 person-years . 
IRR: Incidence rate ratio 
Cl: confidence interval 
16 1154 (707-1884 ) 
5 945 (393-227 1) 
4 154 5 (580-411 7) 
17 524 (326-844 ) 
4 685 (257-1826) 
2 575 (143-2300) 
IRR (95%CI) 
Unadjusted 
0.43 (0 .17 -1.08) 
0 .84 (0.53-1.33) 
1.00 
0 .58 (0 .38-8 .9) 
1. 25 (0 .84-1.87) 
1.60 (0 .8 3-3.06) 
1.00 
0 .67 (0 .21-2 .16) 
1.36 (0 .89-2.09) 
2.72 (1.82-4 .06) 
1.33 (0 .96-1.84 ) 
3.59 (2. 15-6 .0 1) 
2. 80 (1.1 5-6. 83» 
4 .58 (1.69-12.3) 
1.68 (1.01 -2. 78 ) 
2.03 (0 .75-5.46) 
1.68 (0 .41 -6 .78) 
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Table 6-1: Prevalence, absolute rates of VTE per 100,000 person-
years and IRR of potential risk factors in the postpartum period 
(continued .. ) 
Variable Pregnancies VTE N Rate(95%CI) * IRR (95%CI) 
N (Ofo) Unadjusted 
Pregnancy characteristics and complications 
Antepartum 10,329 (4.6) 10 416 (224 -774) 1.22 (0 .64 -2.31 ) 
haemorrhage 
Acute systemic 26,572 (11.9) 20 323 (208-550) 0 .93 (0 .58-1.48) 
infection 
Pre- 5,237 (2.3) 14 1148 (679 -1938) 3.54 (2 .0 5-6.11) 
eclampsia/eclampsia 
Multiple birth 3,282 (1.4) 3 390 (125-1211) 1.14 (0 .36-3.57) 
Gestational 11,796 (5 .6) 18 655 (413 -1041) 2.1 0 (1.28-3.43) 
hypertension 
Gestational diabetes 3,518 (1.6) 4 486 (182-1294) 1.44 (0.53 -3.88) 
Hyperemesis 7,838 (3.53) 9 494 (257-950) 1.46 (0 .74 -2.86) 
Delivery characteristics and complications 
Length of gestation 
Normal gestation 184,744 (83 .0) 15 313 (264-370) 1.00 
Pre-term gestation 17,112 (7 .7) 29 727 (505-1047) 2.31 (1.55 -3.46) 
Prolonged gestation 20,478 (9.2) 14 293 (173-494) 0.93 (0 .53-1.62) 
Mode of delivery 
Spontaneous 141,1207 (63.5) 76 230 (184 -288 ) 1.00 
Assisted 26,943 (1 2. 1) 19 304 (1 94-476) 1.31 (0 .79-2. 18) 
Elective caesarean 22,341 (10 .0) 33 630 (448 -886) 2.73 (1.81 -4.11) 
Emergency 31,843 (14.3) SO 674 (511 -890) 2.92 (2.04 -4 .18) 
caesarean 
Sti llbirth 1,356 (0.61) 8 2595 (1 297-5189 ) 7 .86 (3.87-15.9) 
Postpartum 20,762 (9.34) 30 629 (440-900) 2. 00 (1.3 5-2.96 ) 
haemorrhage 
Puerperal infection 7,740 (3.4) 18 1291 (81 3-2049) 4.07 (2.50-6.63) 
* Rate calculated per 100,000 person-years. 
IRR : Incidence rate ratio 
Cl: confidence interval 
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6.3.2 Multivariate analvses of postpartum VTE risks 
When I assessed the direct and mediated effects of each factor using different 
modelling frameworks (Figure 6-1 and Table 6-2), I found that the risk of VTE 
Increased by only 2% for each year of maternal age and this was not 
statistically significant. Obesity (BMI 2:30 kg/m2) was associated with high 
postpartum VTE risk across all three models Indicating that little of the 
Increased risk associated with obesity was mediated through other factors, 
either pre-existing or pregnancy related. Similarly there were almost 4-fold 
and 3-fold increased risks for women previously diagnosed with varicose veins 
and cardiac disease respectively, which did not appear to be strongly 
mediated by other risk factors. 
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Table 6-2: Multivariate analysis for VTE risk factors during the postpartum period 
Variable 
Maternal age at delivery 
Age (years) 
Body mass index (Kg/ml) 
Normal (18 .5-24.9) 
Underweight( < 18.5) 
Overweight(25-29.9 ) 
Obese(> =30) 
Cigarette smoker 
Varicose veins 
Card iac d isease 
Inflammatory bowel d isease 
Pre-existing hypertension 
Pre-edampsia,ledampsia 
Gestational hypertension 
Incidence rate ratios (9S0f0CI) 
Modelling 
framework 1 
Modelling Modelling Modelling framework 3 restricted to 
framework 2 framework 3 
Demographic and lifestyle characteristics 
1.03 (1.00-1.06) 
1.00 
0.70 (0.21 -2 .27) 
1.35 (0.88-2 .07) 
2 .71 (1.81-4.04) 
1.43 (1.03-1.99) 
3.44 (2.05-5 .78) 
2.69 (1.10-6 .57) 
4.57 (1.69-12.3) 
1.49 (0.89-2.47) 
1.02 (0.99 -1.05 ) 
1.00 
0.69 (0 .21-2.23 ) 
0 .69 (0.21 -2 .23 ) 
1.36 (0 .89-2.09 ) 
1.44 (1.04-2 .01) 
1.02 (0 .99-1.05) 
1.00 
0.74 (0 .23-2.39) 
1. 21 (0.77-1.90) 
2.40 (1.55-3 .72) 
1.39 (0 .98-1.97) 
Pre-existing co-morbidities 
3.44 (2.05-5.78) 
2.60 (1.06-6.37 ) 
4.58 (1.69-12.4) 
3.97 (2.36-6.68) 
2.78 (1.02-7.53) 
2.62 (0.64-10.6) 
Pregnancy characteristics and complications 
3.22 ( 1.84-5 .62) 
1.89 ( 1.14-3.12) 
3.28 (1.88-5 .72) 
1.91 (1.15-3.15) 
4.41 (1.29 -15 .0) 
0.78 (0.26-2.33) 
Spontaneous vaginal/ Assisted 
deliveries 
1.02 (0 .98-1.07) 
1.00 
0.84 (0.19 -3.56) 
0.67 (0.30-1.46) 
3.41 (1.9 5-5.98) 
1.16 (0.71 -1.89) 
4 .88 (2.61-9.11 ) 
2.69 (0 .66-10.9) 
** 
3.02 (1.20-7.61») 
0.14 (0.05-4.15) 
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Table 6-2: Multivariate analysis for VTE risk factors during the postpartum period (continued ••. ) 
Incidence rate ratios (9S%CI) 
Variable 
Pregnancy length 
Normal gestation (37-42 weeks) 
Pre-te rm gestation «37 weeks) 
Pro-longed gestation ( >42 
weeks ) 
Mode of delivery 
S pontaneous 
Assisted del ivery 
Elective caesarean delivery 
Emergency caesarean delivery 
Stillbirth outcome 
Postpartum haemorrhage 
Puerperal infection 
Modelling 
framework 1 
Modelling 
framework 2 
Modelling 
framework 3 
Delivery characteristics and complications 
1.00 
2 .26 (1.51-3.39) 
0.91 (0.52-1.57) 
1.00 
1.37 (0.83-2.27) 
2.43 (1.58-3.74) 
2.75 (1.91 -3.95) 
7.52 (3.70-15.3) 
1.94 (1.31-2.88) 
3.98 (2.44-6,48) 
1.00 
2.28 (1.52-3.41) 
0.91 (0.52-1.57) 
1.00 
1.41 (0.85-2.33 ) 
2.44 (1.59-3.75) 
2.81 ( 1.95-4.05) 
7.63 (3.75-15.5) 
1.93 (1.03 -2.87) 
3.90 (2.39-6.37) 
1.00 
2.90 (1.39 -3.13)1 
0 .89 (0.49-1.61)1 
1.00 
1.28 (0 .75-2.19)2 
2.52 (1.63-3 .93)2 
2.25 (1.51-3.36)2 
7.34 (3.42-15.7) 
1.78 (1.17-2.74) 
3.55 (2.07-6.06) 
Modelling framework 3 restricted to 
Spontaneous vaginall Assisted 
deliveries 
1.00 
1.87 (1.03-3.39) 
1.02 (0.49-2.13 ) 
12.3 (5.67-26 .8) 
2.34 (1.32-4.14) 
3.15 (1.44-6.88) 
Modelling framework (MF) 1: Modeh are built for each risk factor separately, adjusting for demographic and lifestyle characteristics only 
Modelling framework 2: As MF 1 and additionally adjusted for pre-existing co-morbidities 
Modelling framework 3: As MF 2 and additionally adjusted for pregnancy characteristics and complications 
,oNo VfE events to perform analysis 
I Additionally adjusted for stillbirths 
2 Additionally adjusted for stillbirths, puerperal infection and postpartum haemorrhage 
J Gestational hypertension dropped from the model because of its co-Jinearity with pre-edampsialeclampsia 
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The 3-fold increased risk associated with pre-eclampsla/eclampsla was 
Independent of women's other pregnancy characteristics, pre-exlstlng medical 
co-morbidities, demographic and lifestyle factors, whereas the risk associated 
with gestational hypertension was modest. For delivery characteristics and 
complications I found a 7.3-fold (95%CI 3.42-15.7) Increased risk of VTE for 
those with stillbirth even after adjusting for Important background factors. 
Elective caesarean and emergency caesarean, puerperal Infection and pre-
term birth were associated with at least 2-fold Increased risks compared to 
spontaneous vaginal deliveries, those with no puerperal Infection and normal 
gestational length respectively. Furthermore, pregnant women with 
postpartum haemorrhage were 79% (95%CI 1.17-2.74) more likely to 
develop postpartum VTE. These factors were stili Important even after 
adjusting for women's pre-existing co-morblditles and factors occurring prior 
delivery. 
Even among women with spontaneous vaginal deliveries, stillbirth, 
postpartum haemorrhage, puerperal Infection, pre-term birth, pre-
eclampsia/eclampsia, varicose veins and BMI ~ ~ 30Kg/m2 were all stili 
associated with Increased risks. No associations changed when I excluded the 
7% of VTE events occurring during the same hospital admission as the 
delivery or risk factor event where I could not establish their relative order. 
The Increased risk of VTE observed with BMI ~ 3 0 0 Kg/m2 and caesarean 
section remained consistent when I restricted my analysis to women without 
any other risk factor (Table 6-3). 
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Table 6-3: Rate of VTE per 100,000 person-years and incidence rate 
ratio 
Variable N Rate (95%CI) IRR (95%CI) 
BMI ( ~ 3 O K g / / 2 ) 1 1
No 14 106 (63-179) 1.00 
Yes 13 528 (306-909) 5.29 (3.28 -8.65 ) 
Caesarean section2 
No 14 100 (59-169) 1.00 
Yes 16 464 (284-758) 4.32 (2 .80-6.45 ) 
1 Women without caesarean section and delivering at term or post term and without 
puerperal infection, stillbirth, postpartum haemorrhage, gestational hypertension, IBD, 
varicose veins and cardiac disease 
2 Women who are not obese and delivering at term or post term and without puerpera l 
infection, stillbirth, postpartum haemorrhage, gestational hypertension, I BD, varicose 
veins and cardiac disease 
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6.3.3 Variation in VTE incidence and incidence rate ratios during 
postpartum periods 
When I ascertained absolute risks of VTE within specific postpartum Intervals 
(Table 6-4), I found that the risk of VTE remained consistently high up to six 
weeks postpartum (AR > 700/100,000 person-years) for pregnancies among 
women with obesity or caesarean delivery. The relative risk of VTE was only 
elevated for three weeks postpartum (>850/100,000 person-years) In those 
with pre-term birth or postpartum haemorrhage. My absolute rates of VTE for 
the above stated risk factors were broadly similar when restricted to the first 
week compared to those over weeks 1-3 postpartum (Table 6-5). 
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Table 6-4: Incidence rate of VTE per 100,000 person-years and incidence rate ratios during different periods of postpartum 
and around delivery 
Variables 1-3 weeks postpartum 4-6 weeks postpartum 7-12 weeks postpartum 
n Rate (9S0f0CI)2 IRR (95%CI)1 n Rate(950f0CI)2 IRR (950f0CI)1 n Rate(95%CI)2 IRR (950f0CI)1 
B M I ~ 3 0 K g / m 2 2
No 40 598 (438-815) 1.00 9 161 (84-311) 1.00 11 101 (56-182) 1.00 
Yes 27 1650 (1131-2406 ) 2.74 (1.66-4 .52) 10 735 (395-1366) 4.18 (1.65-10 .5) 3 112 (36-350) 0.97 (0.4-3.88) 
Preeclampsia/eclampsia 
No 119 814 (680-974) 1.00 27 221 (151-322) 1.00 18 75 (47-119) 1.00 
Yes 8 2263 (1131-4525) 2.54 (1.23-5.26) 4 1360 (510-3623) 5.41 (1.84-15.8) 2 329 (8 7-1397) 4.76 (1.05-21.6) 
Length of gestation 
Normal (36-42 weeks) 98 788 (646-960) 1.00 22 211 (139-321) 1.00 15 73 (44-122) 1.00 
Pre-term «37 weeks) 20 1736 (1120-2691) 2.04 (1.26-3 .28) 5 519 (216-1247) 1.92 (0.77-4.78) 4 213 (80 -569) 2.81 (0.86-9 .16) 
Caesarean section 
No 75 662 (528-831) 1.00 9 95 (49-182) 1.00 11 59 (33-107) 1.00 
Yes 52 1425 (1086-1870) 1.89 (1.30-2.74) 22 722 (475-1096) 6.99 (3.07-15.9) 9 151 (78-290) 2.22 (0.85-5.79) 
Postpartum 
haemorrhage 
No 103 756 (623-917 ) 1.00 27 237 (163-346) 1.00 18 81 (51 -129) 1.00 
Yes 24 1778 (1192-2653) 2.22 (1.42-3.47) 4 347 (130-353) 1.38 (0.47-4.04) 2 88 (22-353) 1.00 (0.22-4.46) 
Puerperal infection 
No 114 775 (645-932) 1.00 28 230 (1 58-333) 1.00 18 76 (48-121) 1.00 
Yes 13 4813 (279-828) 5.99 (3.36-10.6) 3 899 (289-2787) 3 .56 (1.08-11.7) 2 253 (63-1011) 3.27 (0.73-14.6) 
lAdjusted for demographic characteristics, pre-existing medical co-momidit ies and pregnancy related compl ication and characteristics when not stratified 
by them 2Rate per 100,000 person-years 
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Table 6-5: Rate per 100,000 person-years of VTE In the first week of 
postpartum 
Variable 
BMI ( ~ 3 0 K g / m 2 ) )
No 
Yes 
Caesarean section2 
No 
Yes 
Postpartum haemorrhage 
No 
Yes 
Pre-eclampsla/eclampsia 
No 
Yes 
Length of gestation 
Normal (36-42 weeks) 
Pre-term (<37 weeks) 
Age>35 years 
No 
Yes 
Puerperal Infection 
No 
Yes 
N 
20 
13 
42 
26 
56 
12 
64 
4 
54 
9 
43 
25 
60 
8 
Rate (95%CI) 
678 (437-1051) 
1800 (1045-3100) 
843 (623-1141) 
1620 (1103-2379) 
933 (718-1212) 
2053 (1165-3615) 
995 (779-1271) 
2567 (963-6840) 
987 (756-1289» 
1776 (924-3414) 
821 (609-1108) 
1849 (1249-2736) 
944 (733-1215) 
3489 (1745-6977) 
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6.4 Discussion 
6.4.1 Summary of main findings 
This study provides precise absolute and relative risks of postpartum VTE for 
maternal risk factors occurring before, during and after childbirth and 
quantifies which have the greatest impact on VTE during specific postpartum 
Intervals. The highest risk occurred In women whose pregnancies ended In 
stillbirth, which was 7-fold higher than women whose pregnancies ended In 
live birth. Caesarean delivery (elective or emergency), pre-term birth, 
postpartum haemorrhage, puerperal Infection and B M I ~ 3 0 K g / m 2 2 were also 
associated with approximately 2-fold increased risks of postpartum VTE 
compared to their respective baselines. These augmented risks were not 
explained by other pregnancy characteristics and complications, pre-exlstlng 
co-morbidities, and demographic or lifestyle factors. My results remained 
consistent when I restricted my analyses to women who underwent 
spontaneous vaginal/assisted delivery. For women with obesity or those 
having caesarean deliveries, the rate of VTE remained elevated for 6 weeks 
postpartum whereas for women with postpartum haemorrhage or pre-term 
birth the relative rate of VTE was only Increased for the first 3 weeks 
postpartum. 
6.5 Strengths and limitations 
My study used Information on more than 222,000 pregnancies with 
postpartum follow-up from a nationally representative cohort of pregnant 
women which makes my study findings generallsable to the majority of 
pregnant women In England with no prior diagnosis of VTE. By using linked 
primary and secondary care data I had comprehensive medical Information on 
women's baseline health risks recorded before pregnancy as well as their 
pregnancy and delivery health records, all of which were prospectively 
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recorded. This enabled me not only to assess the Impact of specific risk 
factors on postpartum VTE while adequately controlling for confounding 
factors but also to assess the impact of risk factors on the incidence of VTE 
during specific postpartum periods. 
Another particular strength of this study was the use of a conceptual 
hierarchical framework to adjust my estimates for potential confounding 
factors. Most previous studies have used stepwise regression models for their 
risk factor analysis. This is solely reliant on statistical association rather than 
any conceptual basis for the interrelationship between factors where all 
explanatory variables are treated at the same hierarchical level, an 
assumption which may not be appropriate in all cases. In contrast my 
categorisation of risk factors and adjusting them in hierarchical order enabled 
me to evaluate whether the effect of a particular risk factor was direct (e.g. 
BMI, age) or mediated by other distant risk factors (Preeclampsia/eclampsia). 
A limitation of this analysis is my inability to establish temporality between 
VTE and risk factors that were recorded during the same hospital admission 
as the VTE event (e.g. postpartum haemorrhage). However this only affected 
7% of my cases and my sensitivity analysis demonstrated that removing 
those women from our analysis did not affect my estimates. I also 
acknowledge that I was not able to consider certain risk factors such as family 
history of VTE and thrombophilia. However I believe that the following 
arguments should be considered. Firstly, whilst family history may be 
Important, it has rarely been looked at in previous population-based studies, 
possibly for the reason that accurate recall of a family history Is problematic. 
Secondly thrombophilia screening Is not routinely recommended for pregnant 
women therefore pragmatically It cannot be used as a predictor for VTE 
outcome. 
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6.5.1 Comparison with previous studies 
My relative increased risk observed for those with BMI ~ ~ 30Kg/m2, cardiac 
disease, varicose veins, pre-eclampsia/eclampsia and puerperal infection are 
In concordance with most previous studies.7• 10. 41. 44. 53. 56 Additionally my 
study findings support increased risks of more than 2-fold and 6-fold in 
women experiencing pre-term delivery and stillbirth respectively, both of 
which have been previously reported 10• 56. 90 but are not Incorporated In the 
current thromboprophylaxis guidelines. I also found a 2-fold relative Increase 
in the risk of VTE for both elective and emergency caesarean delivery 
compared to spontaneous vaginal delivery. My finding of an increased risk of 
, 
VTE associated with elective caesarean section contradicts that of Jacobsen et 
al53 who only found an increased VTE risk associated with emergency 
caesarean section. Jacobsen et a1 53, however, obtained VTE cases using a 
patient registry for the whole population of Norway and controls from a single 
hospital where they had many more eiectlve caesarean sections (9.2%) 
compared to the general population (4.8%), which may have biased their 
estimates towards nUll. However, I was not able to look at the reasons for 
caesarean section In more detail, for example the urgency grade of the 
caesarean section 122 which may have caused mlsclasslficatlon between 
emergency and elective caesarean section. Conversely, Chan et.al4J found a 
more than ll-fold Increase risk of VTE for both elective and emergency 
caesarean delivery which may be due to difference in the study design, 
population and thromboprophylaxis practices post caesarean section. For 
Instance this study from Chlna43 reported the overall rate of VTE to be 
1228/100,000 person-years during the first six weeks postpartum where 
there was no concept of thromboprophylaxls up to the year 2000 as opposed 
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to studies from Norway32 and UK36 with lower reported rates (AR 
approximately 400 /100,000 person-years). 
There Is a lack of studies evaluating the impact of multiple risk factors on the 
absolute and relative rates of VTE during specific postpartum periods. Morris 
et als6 in a population-based study from Australia showed that a high absolute 
rate of pulmonary embolism (PE) perSists for up to 4 weeks after caesarean 
delivery. This may have been underestimated as only secondary care data 
were used to identify only PE cases and hospital admission date was 
considered as the date of diagnosis. Finally, the higher relative risk of VTE 
associated with obesity and caesarean delivery In weeks 4-6 following 
delivery than In the first three weeks may be explained by the fact that those 
women would have received some form of thromboprophylaxls during the 
Initial postpartum week, as suggested by the current thromboprophylaxls 
guidelines, which I was not able to quantify. 
6.5.2 Clinical Implications 
I believe that this study will have Important Implications In deciding how and 
when thromboprophylaxls is delivered In the obstetriC health care setting and 
hope that it will help targeting of thromboprophylaxls In the following ways; 
Firstly, women whose pregnancies are complicated by stillbirth, pre-term 
birth, caesarean section, puerperal infection or postpartum haemorrhage 
should be considered at high risk of VTE postnatally. These risk factors are 
not particularly mediated or confounded by factors occurring before delivery. 
Therefore pregnancies complicated by anyone of those factors may require 
careful conSideration in terms of VTE risk assessment during the postpartum. 
Secondly, the absolute and relative rates of VTE are similar for both elective 
and emergency caesarean .section. Therefore all women undergoing 
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caesarean section should be considered at high risk regardless of the type of 
caesarean section. Thirdly, there is a high risk of VTE among those with 
B M I ~ 3 0 K g / m 2 2 or in those who underwent caesarean mode of delivery for 6 
weeks postpartum whereas for postpartum haemorrhage or pre-term birth, 
the risk of VTE is increased only for up to three weeks postpartum. This 
suggests that the higher risk of VTE extends beyond the currently suggested 
7 days for certain risk factors. However recommendations on whether 
thromboprophylaxis with LMWH may be effective In pregnant and postpartum 
women with the above highlighted risk factors will of course be highly 
dependent on the risk reduction from prophylaxis and any adverse events 
from its use. Nevertheless throughout the developed world risk stratification 
models for the purposes of Intervening In this regard exist for cancer, 
hospitalised medical patients and pregnant women. This study provides the 
most robust, comprehensive, up-to-date, clinically relevant Information on 
risk factors for postpartum VTE that can be of direct use In formulating such 
guidelines. 
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7 Conclusion and implications of the work In this thesis 
7.1 Summary of the main findings 
7.1.1 Incidence of VTE in and around pregnancy utilising general 
practice primary care data 
Using data from a large primary care database (THIN), I reported a low rate 
of first VTE in pregnancy; however, this rate was still much higher than that 
seen in the time outside pregnancy when women are 15-44 years of age, with 
a noticeably raised risk in the postpartum which persisted for five weeks 
following delivery. During antepartum, women In their third trimester were at 
a 5-fold Increased risk of first VTE compared to their time outside pregnancy 
whereas in the first and second trimesters this rate was only marginally 
higher. 
7.1.2 Risk factors for VTE In and around pregnancy dUring the 
postpartum period using general practice primary care data 
Using the same primary care database, I investigated which factors Influence 
the risk of VTE during pregnancy and the postpartum. In this study I provided 
population based estimates of the absolute and relative risks of VTE In women 
during and immediately after pregnancy, taking account of their soclo-
demographiC, lifestyle and clinical risk factors. Overall, except for pre-exlstlng 
diabetes, I found that these risk factors had a greater Impact In the 
postpartum period In terms of Influencing the absolute risk of VTE than In the 
antepartum period. Specifically, I found that women with stillbirth, obstetriC 
haemorrhage, high BM I, preterm birth, prior co-morbldltles (specifically IBD 
and cardiac disease) and caesarean section delivery have a substantially 
higher risk of VTE postpartum. In contrast, Cigarette smoking, maternal age 
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~ 3 5 5 years, acute infection and number of previous births were only 
moderately associated with VTE In both antepartum and postpartum periods. 
7.1.3 Defining the incidence of venous thromboembolism In and 
around pregnancy using linked primary and secondary care 
data: A population based cohort study and comparative meta-
analysis 
This was my first study utilising the linked primary and secondary care data. 
In this study I demonstrated that a highly specific definition of VTE using data 
from both primary and secondary is required to accurately estimate the 
incidence of VTE in and around pregnancy and during the time outside 
pregnancy. These estimates are comparable with respect to the pooled 
incidence rates for the antepartum and postpartum VTE obtained from 
existing literature. With the use of linked primary and secondary care data I' 
was able to get a far more accurate date of diagnosis for VTE which resulted 
in more preCise estimates of rates close to and around delivery. Relying 
solely on primary care data I found that the rate of VTE was much lower 
during the time around delivery and higher during the postpartum period 
compared to solely using secondary care data due to a delay In events being 
recorded in primary care. However when solely relying on secondary care 
data the rate of VTE was much lower during postpartum period and the time 
outside pregnancy. Despite this, the relative incidence of VTE In the 
antepartum and postpartum compared to outside pregnancy were similar 
across all VTE definitions which supports my finding In section 7.1.1 and 
7.1.2. 
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7.1.4 Impact of hospitalisation on antepartum VTE 
Using the linked primary and secondary care data, I was able to conduct the 
first population-based study to estimate the absolute and relative rates of 
antepartum VTE by hospitalisation (including the period post-discharge) while 
taking into account risk factors for VTE which may pre-dispose women to 
being hospitalised. Whilst 85% of antepartum VTE events occurred In out-
patients, the risk of VTE was 17-fold higher during hospitalisation compared 
with time outside hospital when women were stili pregnant. I also found a 
high rate of VTE during the first 28 days post-discharge corresponding to 6-
fold increased risk compared to baseline. While the rate of VTE during 
hospitalised and post-discharge periods (combined) was particularly high for 
women with 3 or more days of hospital stay, a S-fold Increase In the risk of 
VTE still existed for those admitted to hospital for less than three days. The 
hospitalisation/post-discharge VTE rate compared with baseline was similar 
for the three trimesters but noticeably raised In women a g e d ~ 3 S S years. 
7.1.5 Risk factors for VTE in and around pregnancy during the 
postpartum period using linked primary and secondary care 
data 
Given some limitations with the primary care data highlighted In chapter 3, It 
was Important to repeat the analyses which ascertained risk factors for 
postpartum VTE utilising the linked primary and secondary care data. 
Furthermore, absolute and relative rates of VTE for recognised risk factors 
were presented separately for speCific periods of postpartum. Overall the 
magnitude of effect size for Individual risk factors was similar between CPRO 
and THIN VTE risk was highest for pregnancies ending In stillbirth compared 
with live birth pregnancies. Women of older age, having a caesarean delivery, 
pre-term birth, postpartum haemorrhage or with a B M I ~ 3 0 K g / m 2 2 also had 
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high VTE risks that were not mediated by other co-existing risk factors. Risk 
of VTE remained consistently high for six weeks postpartum In women with 
B M I ~ 3 0 K g / m 2 2 or caesarean delivery, whereas risk was high only up to three 
weeks postpartum in those with pre-term birth and who experienced acute 
gestational infection or postpartum haemorrhage. 
228 
7.2 Comparing data bases findings (THIN versus CPRD-HES linked) 
The THIN database gave me the opportunity to answer important clinical 
question and for the first time provide population level estimates of the 
absolute rate of VTE by risk factors, however there are some fundamental 
issues when only using primary care data which were addressed using the 
linked primary and secondary care data. These are presented below: 
7.2.1 Ascertainment of VTE 
When using the THIN database (chapter 2 and 3) I used a reasonably 
restrictive method for defining VTE In primary care data36 which has a positive 
predictive value of 84%85, however, this validation study excluded pregnant 
women from their analysis. As in the United Kingdom (UK) and other 
countries with similar health care provision almost all women will be In 
hospital over the time of delivery, there was a possibility of excluding VTE 
cases recorded solely in secondary care. With the addition of VTE cases 
Identified from HES to the validated algorithm using CPRD-HES linked data I 
was able to get estimates of .the Incidence that were more comparable to the 
pooled estimates of the previous studies done on the subject where VTE 
outcome was validated. Overall the rate of VTE In and around pregnancy was 
higher particularly in the third trimester and postpartum periods using CPRD-
HES linked data compared to previously published THIN data utilising data up 
to 2004 (Figure 7-1).This could be due to the better ascertainment of VTE In 
recent years. 
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Figure 7-1: Absolute rate of VTE in and around pregnancy in THIN versus CPRD 
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7.2.2 Ascertainment of risk factors 
My calculated rates of VTE in the weeks ~ f f postpartum were markedly 
different between the two data sources. As previously highlighted in chapter 
4, the CPRD-HES linked data provide a better estimation of the date of VTE 
events as majority the VTEs diagnosed in both primary and secondary care 
using the linked data had the diagnosis made in secondary care data first. 
The delay in the recording of VTE events from secondary to primary care may 
partly explain the consistently high rates up till the forth week postpartum 
using the THIN database as oppose to CPRD-HES linked data where the rate 
started to decrease immediately after childbirth (Figure 7-1). The uncertainty 
around the dates of VTE diagnosis during the postpartum using THIN data 
restricted my ability to look at the impact of risk factors on the incidence of 
VTE during specific postpartum periods as I was able to using CPRD-HES. 
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7.2.3 Ascertainment of risk factors 
The prevalence of ec/ampsia/pre-eclampsia in THIN was calculated to be 
0.05% compared to the CPRD-HES linked data (2.5%). This would Inevitably 
lead to the failure to detect any important effects this variable would have on 
the rate of VTE due to both insufficient statistical power and also Introduction 
of non-differential misclassification. 
It may also be argued that the residual confounding caused by the under 
ascertainment of pre-eclampsia!eclampsia could have accounted for some of 
the postpartum effect I observed for stillbirths and pre-term births using the 
primary care THIN data. Similarly, the under ascertainment of postpartum 
haemorrhage in primary care data may have accounted for some of the 
postpartum effect I observed for caesarean section. However these limitations 
were addressed to certain extent by using the HES-CPRD linked data. Overall 
my absolute rates remained fairly consistent across both data sources (Figure 
7-2 and Figure 7-3) with the exception of a few risk factors for which hospital 
data were more useful (acute systemic Infection, gestation diabetes and 
Preeclampsla!eclampsia). 
Whilst the use of CPRD-HES linked data supported my findings from the 
primary care only THIN data, In some Instances It provided more detailed 
Information on risk factors (e.g. emergency versus elective delivery, pre-
eclampsia, hyperemesis) which was lacking In the previous data source. The 
hospitalisation Information from the CPRD-HES linked data enabled me 
conduct the first study to look at the risk of first VTE In hospitalised pregnant 
women for which there was void of data from the existing literature. Better 
estimation of dates of VTE also enabled me to evaluate the Impact of those 
risk factors on the timing of VTE around delivery and during specific 
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postpartum periods which is of crucial clinical Importance when planning the 
duration of thromboprophylaxis. 
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Figure 7-2: Absolute risk of VTE during the antepartum by risk factors 
in THIN versus CPRD 
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Figure 7-3: Absolute risk of VTE during the postpartum by risk factors 
in THIN versus CPRD 
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7.3 Clinical implications 
The work done in this thesis has important Implications for the way 
thromboprophylaxis is delivered in the health care setting of countries where 
advanced health and antenatal care resources are available for almost all 
women and I hope it will aid in better targeting of such prophylaxis. Based on 
my thesis findings I have come up with the following recommendations which 
may be incorporated in the RCOG guideline which are due to be updated 
soon. 
7.3.1 Clinical implication for the antepartum period 
• I have found that the overall absolute and relative rate of VTE during 
the first and second trimester Is not greatly Increased for women 
without prior VTE. Therefore thromboprophylaxls among women 
considered at intermediate risk during the antepartum could 
potentially be delayed until the start of third trimester. 
• The absolute rate of VTE varies modestly by most recognised risk 
factors during the antepartum period particularly among women with 
agei!!35, parltyi!!3, Cigarette smoking, acute systemic Infection, 
medical co-morbldltles or multiple gestatlons. Therefore the need to 
offer pharmacological thromboprophylaxls to those women has to be 
carefully re-evaluated based on their absolute risk. The communication 
of low absolute risk associated with those factors to physicians and 
pregnant women will be helpful In placing their risk In perspective. 
• I have demonstrated that hospitalisation Is the single most Important 
Identifiable antepartum risk factor, Indudlng a 6-fold Increased risk of 
VTE in the 28 days following hospital discharge. This suggests prudent 
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consideration of all pregnant women during that period In terms of VTE 
risk assessment. 
• At present RCOG guidelines advise that prophylaxis should be 
considered for women at the time of hospital admission provided that 
they have two or more risk factors Including obesity (BMI>30Kg/m2), 
specific medical co-morbidities and are expected to be Immobile for 3 
or more days. However based on my results, thromboprophylaxls with 
LMWH may be appropriate during hospitalisation and 28 days post-
discharge period particularly in women with longer hospital duration or 
a g e ~ 3 5 5 years regardless of other risk factors. Whether prophylaxis 
would also be advised for hospitalization antldpated to be of shorter 
duration would of course depend on the threshold for Intervention 
. which would depend both on the costs and tolerability surrounding a 
daily heparin injectlon.22 
7.3.2 Clinical Implication for the postpartum period 
• My results have demonstrated that the overall rate of VTE Is relatively 
high during the time around delivery and In the first 4 weeks 
postpartum compared to time outside pregnancy. Therefore the need 
for thromboprophylaxls to those considered Intermediate risk of VTE 
during the postpartum may extends beyond the 7 days currently 
recommended by the RCOG guidelines. 
• The Increased risk of VTE among pregnancies of women with preterm 
birth or stillbirth factors has received limited consideration to date and 
Is not currently Incorporated Into the guidelines for risk assessment of 
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VTE. If they were then this would go some way to ensuring that LMWH 
was administered to the most at risk women. 
• My thesis findings support many of the existing national RCOG 
guideline recommendations (in terms of high absolute rates), 
especially that postpartum thromboprophylaxls may be Indicated In 
women with very high BMI ( ~ 4 0 0 kg/m 2), those who have prior co-
morbidities, obstetric haemorrhage, eclampsia/pre-eclampsla or who 
have a caesarean section delivery. I have also demonstrated that 
women with BMI between 30 and 40 kg/m2 or varicose veins even If 
these risk factors occur In Isolation which may require careful 
consideration. Additionally, the absolute and relative rate of VTE Is 
similar for both elective and emergency caesarean section. Therefore 
all women undergoing caesarean section should be considered high 
risk of VTE regardless of the type caesarean section. 
• I also found a high risk of VTE In those with BMI>30Kg/m2 or who 
underwent caesarean mode of delivery which persisted for 6 weeks 
postpartum. Similarly, for pregnancies resulting In postpartum 
haemorrhage or pre-terms birth, the risk of VTE Is high for three 
weeks postpartum. Therefore consideration should be given to 
extending the duration of pharmacological thromboprophylaxls up to 
three and six weeks postpartum In certain groups of women. 
• The recommendation on whether thromboprophylaxls with LMWH may 
be effective in pregnant and postpartum women with specific risk 
factors will of course be highly dependent on the risk reduction from 
prophylaxis, for which there Is a noticeable void of data from pregnant 
women. Another Important consideration Is the costs Involved In 
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prophylaxis both financial and also the tolerability surrounding a dally 
heparin prescription not to mention the well-recognised side effects of 
allergy and bleeding. For instance, the benefits would need to be 
weighed against a risk of major haemorrhage which Is believed to 
occur in 1% of pregnant women64 and for which we showed a 2.S-fold 
associated risk with VTE. Such a risk-benefit analysis clearly goes 
beyond the scope of the present work. 
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7.4 Suggestions for future research 
This thesis using routinely collected primary and secondary care data has 
answered many research questions regarding the occurrence and risk factors 
of VTE in and around pregnancy. This hopefully demonstrates the usefulness 
and potential of the data bases for future epidemiological research in maternal 
medicine. The future direction of research mainly involves the use of the 
linked primary and secondary care data some of which are presented below; 
7.4.1 Validation of VTE algorithm during pregnancy 
In this thesis I used a reasonably restrictive method for defining VTE In 
primary care data36• To this algorithm I added cases Identified in secondary 
care. Although, this algorithm has been validated by Lawrenson et al.85 In 
primary care data with a positive predicted value of 84%, It excluded 
pregnant women from their analysis. Additionally It Is not known to what 
extent the addition of a secondary care VTE diagnosis Impacts the positive 
predicted value of our VTE definition. Therefore one Important area of 
research would be to externally validate the modified VTE definition currently 
used. This would require replicating the study conducted by Lawreson et al. 
which Involved validating VTE cases by requesting additional Information from 
general practitioners (e.g. hospital Investigation or death certificate) using the 
modified VTE validation algorithm (addition of VTE cases from secondary 
care) and Including pregnant women In the analysis. 
7.4.2 Risk prediction model for VTE during the antepartum and 
postpartum periods 
Another important area of the research would be to create a VTE risk 
prediction score for women during antepartum and postpartum periods. Risk 
prediction models apply an algorithm to a combination of risk factors to 
240 
estimate the probability that an individual develops a health outcome during a 
specific period. This could then be used as a risk assessment tool to Identify 
women for whom thromboprophylaxis would be advised and could be 
incorporated into future updates of the RCOG guidelines. As the strongest 
approach to validate a risk prediction model Is to use an entirely Independent 
cohort, the risk prediction model developed in one dataset should then be 
tested using another independent data set. 
7.4.3 Risk of recurrent VTEs in and around pregnancy 
Limited and inconsistent data exist on the pregnancy associated VTE risk 
among women with a history of VTE. For Instance the rate of recurrence Is 
reported between 2.4% and 10.9%71-75 whereas rate of recurrent VTE In 
women who receive anticoagulation is reported to range between 0 and 
2.4%. Currently the RCOG guideline on thromboprophylaxls categorises 
pregnant women with prior VTE as Intermediate or high risk and these women 
are offered pharmacological thromboprophylaxls throughout the antepartum 
and up to 7 days postpartum. However there Is lack of data to show how 
pregnancy influences the risk of recurrent VTE during antepartum and 
postpartum period compared to the non-pregnant population. Additionally 
only few previous studies have looked at the incidence of recurrent VTE 
specifically during antepartum and postpartum. Therefore another Important 
area of research would be to look at the recurrence rate of VTE In and around 
pregnancy. 
7.4.4 Effectiveness of pharmacological thromboprophylaxls for 
preventing VTE 
Currently there is void of randomlsed controlled trails evaluating the 
effectiveness of pharmacological thromboprophylaxls for preventing VTE 
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among pregnant/postpartum women. Based on the Increased risk of VTE 
during the initial weeks of postpartum especially among women with certain 
risk factors (e.g. Caesarean section, preterm birth), another important area of 
research would be to conduct a clinical trial. This would involve randomlslng 
postpartum women with certain risk factors (e.g. caesarean section) to either 
Intervention (pharmacological thromboprophylaxls) or no-intervention 
(placebo) and prospectively following them up to look at the Incidence of VTE 
during the initial weeks of the postpartum period. 
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9 Appendices 
Appendix 1: Search strategy used for Medline database 
No. Terms 
1 epidemiologic studles.mp. [mp=tltle, abstract, original title, 
name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept, rare disease 
supplementary concept, uniQue Identifier] 
2 exp cohort studies/ 
3 (cohort adj (study or studles».tw. 
4 Epidemiologic Studles/ 
5 Cohort Studies/ 
6 (follow up adj (study or studles)).tw. 
7 (observational adi (study or studles)).tw. 
8 logitudinal.tw. 
9 retrospective. tw. 
10 Incidence/ 
11 exp Case-control studles/ 
12 case control. tw. 
13 or/1-12 
14 exp Venous thromboembolism! 
15 exp Venous Thrombosis! 
16 exp Thrombosls/ 
17 exp Pulmonary Embollsm/ 
18 exp deep vein thrombosls/ 
19 (dvt$ or (deep adj8 (vein$ or ven$) adj8 thromb$) or 
embol$).mp. [mp=tltle, abstract, original title, name of 
substance word, subject heading word, keyword heading 
word, protocol supplementary concept, rare disease 
supplementary concept, uniQue Identifier] 
20 14 or 15 or 16 or 17 or 18 or 19 
21 exp pregnancy/ 
22 exp antepartum/ 
23 exp postpartum/ 
24 21 or 22 or 23 
25 13 and 20 and 24 
26 limit 25 to yr="1960 -Current" 
27 limit 26 to engllsh language 
28 limit 27 to humans 
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Appendix 2: Search strategy used for Emb.se database 
No. Terms 
1 clinical study/ 
2 case control study 
3 family study/ 
4 longitudinal study! 
5 retrospective study / 
6 Prospective study/ 
7 Randomized controlled trials/ 
8 6 not 7 
9 Cohort analysisl 
10 (Cohort adj (study or studies».mp. 
11 (Case control adj {study or studles».tw. 
12 (follow up adj (study or studles».tw. 
13 (observational adj (study or studles».tw. 
14 (epidemiologic$ adj {study or studles».tw. 
15 (cross sectional adj (study or studles».tw. 
16 or/1-5,8-15 
17 exp pregnancy! 
18 antepartum. mp. 
19 antenatal.mp. 
20 postpartum.mp. 
21 postnatal.mp. 
22 17 or 18 or 19 or 20 or 21 
(dvt$ or (deep adJ8 (veln$ or ven$) adJ8 thromb$) Or embol$).mp. 
23 [mp=tltle, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
24 
exp embolism! or exp thromboembollsml or exp thrombosis/ or exp 
venous thromboembolism/ or exp vein thromboslS/ or exp lung 
embolism! 
25 exp pulmonary embolism/ 
26 exp deep vein thrombosis/ 
27 23 or 24 or 25 or 26 
28 16 and 22 and 27 
29 limit 28 to english language 
30 limit 29 to human 
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Appendix 3: Incidence rate VTE per 100,000 person-months in the months following registration 
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Appendix 4: VTE Read code list 
Readcodes 
BHTm.OO 
F0532DO 
F423Bll 
G401.DO 
G401.12 
G401000 
G401100 
G676000 
GB01.00 
G801.11 
G801.12 
G801.13 
G801600 
G801700 
GBOIAOO 
G801BOO 
G801COO 
GBOIDOO 
G801EOO 
G801FOO 
GBOlzOO 
G802000 
Gal .• 00 
GB2 •• 00 
Ga20.00 
Ga20. 
G822.00 
GaD . 
Description 
Referral to deep vein thrombosis cl inic 
Thrombophlebitis lateral venous sinus 
Retinal vein thrombosis 
PULMONARY EMBOLISM 
Pulmonary embolus 
Post operative pulmonary embolus 
Recurrent pulmonary embolism 
Cereb infarct due cerebral venous thrombosis, nonpyogenic 
Deep vein phlebit is and thrombophleb it is of the leg 
Deep ve in thrombosis 
Deep vein th rombosis, leg 
DVT - Deep vein thrombosis 
Thrombophlebitis of the femoral vein 
Thrombophlebitis of the popliteal vein 
Thrombophlebitis of the posterior tibial vein 
Deep vein thrombophlebitis of the leg unspecified 
Deep vein thrombosis of leg related to air travel 
Deep vein thrombosis of lower limb 
Deep vein thrombosis of leg related to intravenous drug use 
Deep vein thrombosis of peroneal vein 
Deep vein phlebitis and thrombophlebitis of the leg NOS 
Thrombosis of vein of leg 
Portal vein thrombosis 
Other venous embolism and thrombosis 
- Clliari syndrome (hepatic vein thrombosis) 
bosis 
,bosas 
lbosas 
G82z100 
GBy210D 
GBy2200 
L0964DO 
L413.DO 
L413.11 
L413000 
L4131DD 
L413200 
L413zDD 
L414.DO 
L414.11 
L41400D 
L4141DD 
L414200 
L414z00 
L417.DO 
L417000 
L417100 
L43 .. DD 
L43 .. 11 
L430.00 
L430000 
L430100 
L430300 
L430400 
L430z00 
L431.00 
L431000 
L431l00 
L431300 
Thrombosis of vein NOS 
Inferior vena cava syndrome 
Superior vena cava syndrome 
PULMONARY EMBOLISM FOLLOWING ABORTIVE PREGNANCY 
Antenatal deep vein thrombosis 
DVT - deep venous thrombosis, antenatal 
Antenatal deep vein thrombosis unspecified 
Antenatal deep vein thrombosis - delivered 
Antenatal deep vein thrombosis with antenatal compl ication 
Antenatal deep vein thrombosis NOS 
Postnatal deep vein thrombosis 
DVT - deep venous thrombosis, postnatal 
Postnatal deep vein thrombosis unspecified 
Postnatal deep vein thrombosis - delivered with pin comp 
Postnatal deep vein thrombosis with postnatal complication 
Postnatal deep vein thrombosis NOS 
Obstetric cerebral venous thrombosis 
Cerebral venous t hrombosis in pregnancy 
Cerebral venous t hrombosis in the puerperium 
OBSTEnUCPULMONARY EMBOLISM 
Obstetric pulmonary embolus 
OBSTEnUC AIR PULMONARY EMBOLISM 
OBSTEnUC AIR PULMONARY EMBOLISM UNSPEOFlED 
OBSTEnUC AIR PULMONARY EMBOLISM - DELIVERED 
OBSTEnUC AIR PULMONARY EMBOLISM WITH NN COMPLICATION 
OBSTETRlC AIR PULMONARY EMBOLISM WITH PIN COMPLICATION 
OBSTEnUC AIR PULMONARY EMBOLISM NOS 
AMNIOTIC FWID PULMONARY EMBOLISM 
AMNIOTIC FWID PULMONARY EMBOLISM UNSPEOFlED 
NIOTIC FWID PULMONARY EMBOLISM - DELIVERED 
NIOTIC FWID PULMONARY EMBOLISM V'ffiH NN COMPLICATIO 
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L431400 
L431z00 
L432.00 
L432000 
L432100 
L432300 
L432400 
L432z00 
L433.00 
L433000 
L433100 
L433z00 
L43y.OO 
L43yOOO 
L43yl00 
L43y200 
L43y300 
L43y400 
L43yzOO 
L43z.00 
L43zDOO 
L43z100 
L43z200 
L43z.300 
L43z400 
l43z:zOO 
SPl2200 
SP32100 
AMNIOTIC FLUID PULMONARY EMBOUSM WITH PIN COMPUCATION 
AMNIOTIC FLUID PULMONARY EMBOUSM NOS 
OBSTETRIC BLOOD-CLOT PULMONARY EMBOUSM 
OBSTETRIC BLOOD-CLOT PULMONARY EMBOUSM UNSPECIFIED 
OBSTETRIC BLOOD-CLOT PULMONARY EMBOUSM - DEUVERED 
OBSTETRIC BLOOD-CLOT PULMONARY EMBOUSM + AIN COMPUCATION 
OBSTETRIC BLOOD-CLOT PULMONARY EMBOUSM + PIN COMPUCATION 
OBSTETRIC BLOOD-CLOT PULMONARY EMBOUSM NOS 
OBSTETRIC PYAEMIC AND SEPTIC PULMONARY EMBOliSM 
OBSTETRIC PYAEMIC AND SEPTIC PULMONARY EMBOliSM UNSPECIFIED 
OBSTETRIC PYAEMIC AND SEPTIC PULMONARY EMBOliSM - DEUVERED 
OBSTETRIC PYAEMIC AND SEPTIC PULMONARY EMBOliSM NOS 
OTHER OBSTETRIC PULMONARY EMBOUSM 
OTHER OBSTETRIC PULMONARY EMBOUSM UNSPEOFIED 
OTHER OBSTETRIC PULMONARY EMBOUSM - DEUVERED 
OTHER OBSTETRIC PULMONARY EMBOUSM - DEUVERED + PIN COMP 
OTHER OBSTETRIC PULMONARY EMBOUSM WITH ANTENATAL COMP 
OTHER OBSTETRIC PULMONARY EMBOUSM WITH POSTNATAL COMP 
OTHER OBSTETRIC PULMONARY EMBOUSM NOS 
OBSTETRIC PULMONARY EMBOUSM NOS 
OBSTETRIC PULMONARY EMBOUS 
OBSTETRIC PULMONARY EMBOUS 
OBSTETRIC PULMONARY EMBOUS 
OBSTETRlC PULMONARY EMBOUS 
Y EMBOUS 
OS, UNSPEOFIED 
OS - OEUVERED 
OS - DEUVEREO WITH PIN COMP 
'OS WITH ANTENATAL COMPUCATION 
OS YIITli POSTNATAL COMPUCATION 
Y EHBOUSH NOS 
basis 
rh 
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Appendix 5: Anticoagulant prescription codes (multilex) 
Miltllex code generic_name 
Unfractionated heparin 
85596998 Heparin calcium inj 12500 iu/0.5ml 10 pre-filled syringe 
93267990 HEPARIN SODIUM pf inj 5000 i.u./5ml 
85583998 
93363990 
93388996 
93387998 
96836992 
96246990 
93387997 
96246988 
93360990 
85590998 
87599998 
98265996 
97531996 
Heparin sodium preservative free inj 5000 i.u./1ml 10 ampoule(s) 
HEPARIN SODIUM pf inj 10000 Lu./10ml 
Heparin sodium inj 10000 iu/ml 10 1ml ampoule(s) 
Heparin sodium inj 25000 i.u./ml 0.2ml ampoule(s) 10 
HEPARIN Ca 12,500iu/0.5mL syr 
HEPARIN SODIUM pf inj 1000 i.u./ml 
Heparin sodium se inj 25000 i.u./ml 50 0.2ml pre-filled syringe 
HEPARIN SODIUM inj 25000 Lu./ml 
HEPARIN SODIUM pf inj 25000 Lu./5ml 
Heparin sodium inj 5000 Lu./5ml 10 v ial(s) 
Heparin sod ium preservative free inj 5000 i.u./ml 0.2ml ampoule(s) 10 
HEPARIN SODIUM inj 10000 iu/ml 
HEPARIN SODIUM inj 25000 Lu./ml 
97531998 HEPARIN SODIUM inj 1000 Lu./ml 
85582998 Heparin sodium preservative free inj 25000 Lu./5ml 10 ampoule(s) 
95012990 HEPARIN SODIUM inj 125000 i.u./5ml 
93387996 
96678992 
98265998 
93385992 
~ 2 0 9 9 8 8
97530996 
98826998 
933 
85585998 
Heparin sodium soln 10 units/ml 10 5rnl ampoule(s) 
Heparin sod. 25000u/rnl 0.2m1 pt inj 0 
HEPARIN SODIUM inj 1000 i.uJ ml 
EPARmCALOU 
EPARlN SODIUM se inj 25000 i.u./rnl 
EPAAn, SODIUM of inj 25000 i.u./rnl 
EP, 
H5'ARIU SOD 
inj 25000 i.u./mJ 
25000 l.uJ5rnl 
PRESERVATIVE E 
HEPARIN SODIUM pf inj 1000 i.u./1ml 
HEPARIN SODIUM inj 25000 i.u./5ml 
93365990 
95013990 
85581998 
93266990 
93359990 
93355990 
95288992 
95957992 
93362990 
93358990 
98539990 
98264998 
85593998 
97759992 
96339992 
93361990 
85584998 
93932998 
85597998 
98541990 
95091992 
Heparin sodium preservative free inj 5000 i.u./0.2ml ampoule(s) 10 
HEPARIN SODIUM pf inj 10000 Lu./10ml 
HEPARIN SODIUM pf inj 25000 i.u./1ml 
HEPARIN SODIUM inj 125000 i.u./5ml 
HEPARIN Na 5000iu/0 .2mL syrng 
HEPARIN Na 5000 iu/0.2mL syrng 
HEPARIN SODIUM pf inj 20000 i.u ./20ml 
HEPARIN SODIUM pf inj 5000 i.u./0.2ml 
Heparin sod ium inj 25000 i.u./ml 1ml ampoule(s) 5 
HEPARIN SODIUM inj 25000 i.u./ml 
HEPARIN CALCIUM inj 5000 i.u./0.2ml 
HEPARIN Na 5000 iu/0.2mL syrng 
HEPARIN Na 5000iu/0.2mL inj 
HEPARIN SODIUM pf inj 5000 Lu./1ml 
HEPARIN SODIUM PRESERVATIVE FREE 
HEPARIN CALCIUM inj 25000 i.u./ml 
Heparin calcium inj 5000 i.u./0.2ml 10 pre-filled syringe 
HEPARIN SODIUM inj 25000 i.u./ml 
HEPARIN SODIUM 
98540990 Heparin calcium inj 25000 Lu./ml 0.5ml syringe(s) 15 
93354990 HEPARIN CALCIUM inj 5000 i.u./0 .2ml 
97530998 HEPARIN SODIUM pf inj 1000 Lu./ml 
97531997 HEPARIN SODIUM inj 5000 i.u./ml 
93388997 Heparin sodium inj 5000 i.u./ml 0.2ml ampoule(s) 10 
97573992 Heparin caldum b.p. inj 0 
98542990 HEPARIN CALOUM inj 25000 i.u.fml 
93388998 Heparin sodium inj 1000 Lu./ml 5ml vial (s) 10 
94950998 HEPARIN CALOUM inj 25000 i.u./ml 
93357990 HEPARIN SODIUM inj 5000 i.u./5ml 
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HEPARIN SODIUM PRESERVATIVE FREE 
HEPARIN SODIUM se inj 25000 i.u./ml 
Hepari n sodium inj 125000 i.u./5ml 10 vial(s) 
HEPARIN SODIUM inj 5000 i.u./ml 
Heparin sod ium inj 25000 i.u./Sml 10 vial(s) 
85586998 
97529998 
85588998 
98265997 
85589998 
90388998 
85580998 
93265990 
97530997 
Heparin calcium inj 25000 Lu./ml O.5ml syringe(s) 15 
Heparin sodium preservative free inj 25000 i.u./1ml ampoule(s) 10 
HEPARIN SODIUM pf inj 20000 i.u./20ml 
HEPARIN SODIUM pf inj 5000 i.u./ml 
95014990 HEPARIN SODIUM inj 5000 i.u./Sml 
94842998 HEPARIN SODIUM sc inj 25000 i.u./ml 
HEPARIN CALOUM inj 25000 i.u./ml 
HEPARIN SODIUM PRESERVATIVE FREE 
97412998 
85587998 
87600998 
87598998 
96236998 
Heparin sod ium preservative free inj 1000 i.u./ml 20ml ampoule(s) 10 
HEPARIN SODIUMPRESERVATIVE FREE 
HEPARIN SODIUM inj 1000 i.u./ml 
96677992 Heparin sodium b.p. 5000 i/u inj 0 
93364990 HEPARIN SODIUM pf inj 5000 i.u./Sml 
96246989 HEPARIN SODIUM inj 5000 i.u./ml 
85592998 HEPARIN CALGUM inj 12500 iu/O.Sml 
Low Molecul.ar weight heparin 
93400998 DALTEPARIN inj soln 10000 iU/4ml 
87267998 DALTEPARlN inj soln 10000 iU/OAml 
87633998 
93180997 
lied syringe 
92739998 
87265998 
87630998 
9 J 3 ~ ~
.aJteoarin inj soln SOOOiu/O.2m1 10 O. 2ml synnge 
.5000 iU/O.6ml 
'ICtGHT 
93179998 
87631998 
87271998 
87841998 
87273998 
93870996 
98287996 
87584998 
90543998 
Enoxaparin inj 100mg/ml 1ml pre-filled syringe (lS0mg) 10 
Tinzaparin inj 18000 i.u./0.9ml 6 0.9ml pre-filled syringe 
Dalteparin inj soln 1250{) iu/O .Sml S O.Sml pre-filled syringe 
Bemiparin sodium inj soln 3S00 iu 10 pre-filled syringe 
Dalteparin inj soln 7500 iu/0.3ml 10 0.3ml pre-filled syringe 
HEPARIN LOW MOLECULAR WEIGHT 
Dalteparin inj soln 2S00iu/0.2ml 10 0.2ml syringe 
ENOXAPARIN inj 120mg/0.8ml 
TINZAPARIN sterile soln 5000 i.u./Sml 
87842998 Bemiparin sod ium inj soln 2500 iu 10 pre-filled syringe 
97660996 TINZAPARIN inj 10000 IU/ml 
87627998 
92739996 
98287998 
92647998 
87264998 
87628998 
87591998 
87639998 
93870998 
85809998 
87586998 
93179997 
93865998 
84428998 
TINZAPARIN inj 18000 i.u./0.9ml 
Dalteparin inj soln 25000 iu/ml 0.3ml pre-filled syringe 10 
Dalteparin inj soln 10000 iu/4ml 10 ampoule(s) 
TINZAPARIN inj 20000 iu/ml 
DALTEPARIN inj soln 18000 iu/O.72ml 
TINZAPARIN inj 14000 i.u./0.7ml 
Enoxaparin inj 60mg/0.6ml 10 pre-filled syringe 
TINZAPARIN inj 20000 i.u./2ml 
HEPARIN LOW MOLECULAR WEIGHT 
Enoxaparin inj lS0mg/1ml 10 pre-filled syringe 
ENOXAPARlN inj GOmg/O.Gml 
Enoxaparin inj 150mg/ml pre-filled syringe 10 
DALTEPARIN inj soln 5000iu/0.2ml 
DALTEPARlN inj soln 10000 iu/ lml 
92967998 Danaparoid sodium inj 750 iu/0.6ml 10 ampoule(s) 
87270998 Dalteparin inj soln 15000 iu/0.6ml 5 O.Gml pre-filled syringe 
93180998 ENOXAPARlN inj 100mg/ml 
87585998 ENOXAPARIN Inj 80mg/0.8ml 
87642998 Tinzaparin inj 3500 i.u./0.3Sml 10 0.35ml prefilled unit dose syringe 
87635998 nNZAPARlN inj 2500 i.u./0.2Sml 
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93865997 DALTEPARIN inj soln 100,000 iu/4ml 
93400997 DALTEPARIN inj soln 10000 iu/lml 
87594998 Enoxaparin inj 20mg/0.2ml 10 pre-filled syringe 
97666997 TINZAPARIN sterile soln 3500 IU/0.3ml 
87592998 Enoxaparin inj 40mg/OAml 10 pre-filled syringe 
87590998 Enoxaparin inj 80mg/0.8ml 10 pre-filled syringe 
92739997 
87636998 
93865996 
87588998 
Dalteparin inj soln 100,000 iu/4ml 1 4ml multidose vial 
TINZAPARIN inj 4500 Lu./OA5ml 
DALTEPARIN inj soln 25000 iu/ml 
ENOXAPARIN inj 20mg/0 .2ml 
87643998 TInzaparin inj 20000 i.u./2mll0 2ml v ial(s) 
90544998 TInzaparin sterile soln 5000 i.u./5ml 10 5ml ampoule(s) 
87589998 Enoxaparin inj 120mg/0.8ml 10 pre-fi lled syringe 
87641998 TInzaparin inj 4500 i.u./ 0.45ml 10 OA5ml prefilled unit dose syringe 
97627998 HEPARINLOW MOLECULAR WEIGHT 
87795998 
98287997 
87840998 
87632998 
9 1404998 
97660998 
Bemiparin sod ium inj soln 7500 iu 2 pre-filled syringe 
Dalteparin inj soln 10000 iu/1ml I ml graduated syringe 5 
Bemiparin sodium inj soln 5000 iu 10 pre-filled syringe 
TInzaparin inj 14000 i.u./O.7ml 6 0 .7ml pre-filled syringe 
TInzaparin inj 20000 iu/ml 0.9ml pre-filled syringe 6 
llNZAPARlN sterile soln 3500 IU/0.3ml 
87793998 BEMIPARlN SODIUM inj soln 7500 iu 
94154998 ENOXAPARlN inj lSOmg/ml 
84607998 ENOXAPARlN inj 300mg!3rnl 
87629998 llNZAPARIN inj 10000 i.u./O.Srnl 
85807998 ENOXAPARlN inj lSOmg/lrnl 
93398997 
87587998 
87837998 
97633996 
872n998 
rnl unit dose synnge 
I ore-fiIIed synllQe 
85810998 
99021997 
99021998 
84427998 
Enoxaparin inj 100rng/1ml 10 pre-filled syringe 
Tinzaparin inj 10000 iu/ml 0.25ml prefilled unit dose syringe 10 
Tinzaparin sterile soln 4500 iu/0.39ml 5 0.39ml unit dose syringe 
DALTEPARIN inj soln 10000 iu/1ml 
97633997 Tinzaparin sterile soln 5000 i.u./0.5ml 10 0.5ml ampoule(s) 
87637998 TINZAPARIN inj 3500 i.u./0.35ml 
HEPARINLOW MOLECULAR WEIGHT 93398998 
97627997 
92966998 
87838998 
Heparin low molecular wei9ht sterile soln 4500 iu/0.39ml 5 0.39ml unit dose syri 
DANAPAROID SODIUM inj 750 iu/0.6ml 
BEMIPARIN SODIUM inj soln 3500 iu 
87634998 TInzaparin inj 40000 i.u./2ml 1 2ml vial(s) 
97666998 llNZAPARIN sterile soln 2500 IU/0.21ml 
97633998 Tinzaparin sterile soln 3500 iu/0.3ml 10 0.3ml unit dose syringe 
93045992 llNZAPARIN 20,000iu/2mL inj 
93870997 HEPARINLOW MOLECULAR WEIGHT 
87640998 
93400996 
87268998 
85808998 
87266998 
87269998 
97666996 
84608998 
97660997 
87839998 
87792998 
87794998 
Tinzaparin inj 2500 i.u./0.25mI10 0.25ml prefilled unit dose syringe 
DALTEPARIN inj soln 2500iu/0.2ml 
DALTEPARIN inj soln 7500 iu/0.3ml 
ENOXAPARIN inj 100mg/ lml 
DALTEPARIN inj soln 12500 iu/ 0.5ml 
Dalteparin inj soln 18000 iu/ 0.72ml 5 O.72ml pre-filled syringe 
llNZAPARIN sterile soln 4500 IU/0.39ml 
Enoxaparin inj 300mg/3ml 1 multi-dose vial(s) 
llNZAPARIN sterile soln 5000 Lu./0.5ml 
BEMIPARIN SODIUM inj soln 2500 iu 
BEMIPARIN SODIUM inj soln 10000 iu 
Bemiparin sodium inj soln 10000 iu 2 pre-filled syringe 
Oral anticoagulants 
95630990 WARfARIN SODIUM tabs 500 micrograms 
96318989 WARfARIN SODIUM tabs 3rng 
83976998 WARfARIN SODIUM 
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95234990 WARFARIN SODIUM tabs 3mg 97941989 WARFARIN SODIUM tabs 3mg 
99331989 WARFARIN SODIUM tabs 3mg 96308988 WARFARIN SODIUM tabs 5mg 
96163990 WARFARIN SODIUM tabs 1mg 99034990 WARFARIN SODIUM tabs 1mg 
83977998 WARFARIN SODIUM 98289998 WARFARIN SODIUM tabs 1mg 
94877990 WARFARIN SODIUM tabs 5mg 98031990 WARFARIN SODIUM tabs 1mg 
97089989 WARFARIN SODIUM tabs 3mg 98906996 WARFARIN SODIUM tabs smg 
97941990 WARFARIN SODIUM tabs 1mg 93532990 WARFARIN SODIUM tabs 500 micrograms 
97089988 WARFARIN SODIUM tabs smg 99034989 WARFARIN SODIUM tabs 3mg 
97711989 WARFARIN SODIUM tabs 3mg 98014989 WARFARIN SODIUM tabs 3mg 
96161990 WARFARIN SODIUM tabs smg 93227990 WARFARIN SODIUM tabs 500 micrograms 
96318988 WARFARIN SODIUM tabs smg 93575990 WARFARIN SODIUM tabs smg 
95617998 Warfarin sod ium tabs 1mg 28 tablet(s) 95232990 WARFARIN SODIUM tabs smg 
99331990 WARFARIN SODIUM tabs 1mg 84565998 WARFARIN SODIUM 
98906998 WARFARIN SODIUM tabs 1mg 99035990 WARFARIN SODIUM tabs 1mg 
98014988 WARFARIN SODIUM tabs 5mg 94878990 WARFARIN SODIUM tabs 3mg 
92245998 WARFARIN SODIUM tabs 500 microgra ms 95741992 WARFARIN 
98289996 WARFARIN SODIUM tabs smg 98014990 WARFARIN SODIUM tabs 1mg 
9 5513990 WARFARIN SODIUM tabs 3mg 93576990 WARFARIN SODIUM tabs 3mg 
9 5512990 WARFARIN SODIUM tabs 5mg 95243992 WARFARIN SODIUM 
98031989 WARFARIN SODIUM tabs 3mg 94879990 WARFARIN SODIUM tabs 1mg 
97089990 WARFARIN SODIUM tabs 1mg 93577990 WARFARIN SODIUM tabs 1mg 
95514990 WARFARIN SODIUM tabs 1mg 94106990 WARFARIN SODIUM tabs 5mg 
98031988 WARFARIN SODIUM tabs 5mg 95617997 Warfarin sodium tabs 3mg 28 tablet (s) 
86425998 WARFARIN SODIUM 94108990 WARFARIN SODIUM tabs 1mg 
95237990 WARFARIN SODIUM tabs 1mg 96308989 WARFARIN SODIUM tabs 3mg 
96162990 WARFARIN SODIUM tabs 3mg 99331988 WARFARIN SODIUM tabs 5mg 
96308990 WARFARIN SODIUM tabs 1mg 95617996 Warfarin sod ium tabs 5mg 28 tablet(s) 
98906997 VlARFARIfl SODIUM tabs 3mg 97711990 WARFARIN SODIUM tabs 1mg 
88944998 Warfarin sodium tabs 500 mic:rograms 28 tablet(s) 97941988 WARFARIN SODIUM tabs Smg 
99035989 WARFARIN SODIUM tabs Smg 94107990 WARFARIN SODIUM tabs 3mg 
98289997 WARFARIN SODIUM tabs 3mg 97711988 WARFARIN SODIUM tabs 5mg 
99034988 WARFARIN SODIUM tabs 5mg 
96318990 WARFARIN SODIUM tabs 1mg 
95556997 Phenind ione tabs 25mg tablet(s) 28 
99138998 ACENOCOUMAROL tabs 1mg 
96447989 PHENINDIONE tabs 25mg 
91984998 Fondaparinux sod ium inj 2.5mg/0.5mI1O O.5ml pre-filled syringe (2 .5mg) 
88070998 LEPIRUDIN inj 50mg 
86850998 FONDAPARINUX SODIUM inj 7.5mg/0.6ml 
96749997 Acenocoumarol tabs 4mg 100 tablet(s) 
86853998 Fondaparinux sod ium inj 7 .5mg/0.6mll0 0.6ml pre-filled syringe 
84390998 FONDAPARINUX SODIUM inj 1.5mg/0.3ml 
99138997 ACENOCOUMAROL tabs 4mg 
86849998 FONDAPARINUX SODIUM inj 10mg/0 .8ml 
95556996 Phenindione tabs 50mg tablet(s) 28 
98293998 PHENINDIONE tabs 10mg 
84391998 Fondaparinux sodium inj 1.5mg/O.3ml 
88073998 Lepirudin inj 50mg 1 vial(s) 
96749998 Acenocoumarol tabs Img 100 tablet(s) 
86854998 Fondaparinux sodium inj 5mg/0.4ml 10 O.4ml pre-filled syringe 
98293997 PHENINDIONE tabs 25mg 
95556998 Phenindione tabs 10mg tablet(s) 28 
96447988 PHENINDIONE tabs SOmg 
96447990 
88974998 
86851998 
98293996 
86852998 
E tabs 10mg 
UX SODIUM inj 2.5mg/ 0.5ml 
UX SODIUM inj 5mg/0.4ml 
E tabs SOmg 
sodium inj 10mglO.8ml 10 O.8ml pre-fiUed syringe 
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Appendix 6: Medical codes indicating anticoagulant 
therapy 
Readcode Description 
14LP.00 H/ O : warfarin allergy 
14P1.00 
42P8.00 
42Q7.00 
66Q .. 00 
66Q .. ll 
66Q1.00 
66Q2.00 
66Q3.00 
66Q4.00 
66Q5.00 
66Q6.00 
66Q9.00 
66QA.00 
66QB.OO 
66QZ.OO 
66c1.00 
7U0400 
7U04OO 
7U9BOO 
7U9BOO 
88A5.00 
SB2K.OO 
S661.00 
S66X.OO 
SBG7.00 
SBP7.00 
H/ O : anticoagulant therapy 
Heparin induced t hrombocytopenia screening test 
Heparin assay 
Warfarin monitor ing 
Anticoagulant monitoring 
I nitial warfarin assessment 
Follow-up warfa rin assessment 
Warfarin side effects 
Warfarin dose changed 
Warfa rin therapy stopped 
Warfarin therapy started 
Warfarin dose unchanged 
Warfarin treatment plan 
Annual warfarin assessment 
arfarin monitoring NOS 
Anticoagulant therapy stopped 
Continuous infusion of heparin 
Continuous infusion of heparin 
Subcutaneous injection of heparin 
Subcutaneous injection of heparin 
ticoaqulant therapy 
AntX:oaaulant prescribed by third party 
hytaxis 
Duration of antJcoa(julant the.ra 
8CAu.00 
8HH W.00 
8125.00 
8I3E.00 
8165.00 
8171.00 
9NiJ .00 
9k23 .00 
9k23 .11 
9k24.11 
0305.00 
0305100 
0 305z00 
PK82.00 
SL42.00 
SL42100 
SL42300 
SL42400 
SL42z00 
SL45 .00 
SL45z00 
T937300 
TJ42.00 
D42000 
2000 
TJ42100 
2z00 
U604200 
U604211 
U604212 
U604213 
Patient advised of anticoagulant dose 
Referral for warfarin monitoring 
Warfarin contraindicated 
Warfarin declined 
Warfarin not ind icated 
Warfarin not tolerated 
Did not attend general practit ioner anticoagulant clin ic 
Pt held anticoagulant therapy record updatd - enh serv admin 
Patient held anticoagulant therapy record updated 
Date of next anticoagulant cl inic appointment 
Haemorrhagic disorder due to Circulating anticoagulants 
Haemorrhag ic disorder due to hyperheparinaemia 
Heamorrhag ic d isorder due to circulating anticoagulants NOS 
Dysmorphism due to warfarin 
Anticoagulant poisoning 
Hepar in poisoning 
Warfarin sod ium po isoning 
Warfarin poisoning 
Anticoagulant poisoning NOS 
Anticoagulant agonist poisoning 
Anticoagulant agonist poisoning NOS 
Accidental poisoning by warfarin 
Adverse reaction to anticoagulants 
Adverse reaction to heparin 
Adverse reaction to heparin 
Adverse reaction to warfarin sodium 
Adverse reaction to anticoagulants NOS 
[XlAnticoagulant causing adverse effects in therapeutic use 
[Xl Adverse reaction to anticoagulants 
[Xl Adverse reaction to heparin 
[Xl Adverse reaction to warfarin sodium 
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U604216 
U604314 
U604318 
ZlQ2COO 
[X] Adverse reaction to anticoagulants NOS 
[X] Adverse reaction to anticoagulant antagonists 
[X] Adverse reaction to anticoagulant antagonist NOS 
Giving anticoagulant therapy 
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Appendix 7: Derivation of date of death 
Although deaths recorded in the primary care data are accurate, It Is 
important to know how these data are recorded In the Vision practice 
management software by General Practitioner (GP). When a patient dies, a 
GP should record a Read code for death known as the Statement of Death In 
the medical record. However there Is often a delay between the actual date of 
the patient's death and the recorded transfer out date Indicating transfer out 
reason as death (the median delay Is 19 days). Whilst THIN provides data on 
date of death which is the last date associated with death administration or 
medical codes Indicating death, there are Inconsistencies In the recorded 
codes for deaths and transfer out dates. Furthermore, there may be Instances 
where a practice might not update the registration status of patients, In which 
case patients who have died will appear to be alive In the dataset. Mortalitles 
and dates of death were also Identified using combinations of medical and 
death administration codes (presented below). The following steps were 
taken to ensure that the date of death recorded Is accurate and consistent 
with the transfer out date and that there are no Immortal persons In the data 
In addition to the Information on deaths provided by THIN. 
Step 1: 
A patient was considered to be dead, If she had medical or death 
administration codes which Indicated unequivocally that the patient has died. 
The date of the medical/death administration code was used as date of death 
If It preceded the transfer out date by 9S days. In cases where there was no 
date of death, a medical code Indicating death or death administration record, 
the transfer out date was used as date of death If patient registration status 
Indicated that the patient has died. 
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Step 2 
For medical codes or death administration codes recorded after the transfer 
out date, the latter date was used as the date of death. For patients with 
medical codes or death administration record which preceded the transfer out 
date by more than 95 days, prescription records were explored. A patient was 
only considered dead, it she had no prescription record for two years after the 
code for death. Date of medical/dead administration codes was used as the 
date of death. The same was done for those with medical codes Indicating 
death but no transfer out date. For patients with no transfer out date but with 
medical/death administration code, these were only considered dead If they 
had no prescription records two years after the date of death. In this Instance 
date of medical/death administration code was used as date of death. 
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Appendix 8: Body mass index codes 
Medcode 
22K1.00 
22K2.00 
22K3.00 
22K4.00 
22K5.00 
22K6.00 
22K7.00 
22KB.OO 
Ahdcode 
1005010200 
Description 
Body Mass Index normal K/M2 
Body Mass Index high K/M2 
Body Mass Index low K/M2 
Body mass Index Index 25-29 - overweight 
Body mass Index 30+ - obesity 
Body mass index less than 20 
Body mass index 40+ - severely obese 
Body mass Index 20-24 - normal 
Description 
Weight 
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Appendix 9: Smoking codes 
Medcode 
137 .. 11 
1371.00 
1371.11 
1372.00 
1372.11 
1373.00 
1374.00 
1375.00 
1376.00 
1377.00 
137S.00 
1379.00 
137A.00 
137B.00 
137C.00 
137F.00 
137G.00 
37H.00 
137J.00 
137K.OO 
37KOOO 
37LOO 
37H.00 
37N.00 
70.00 
37P.00 
37P. 
37Q.00 
Description 
Smoker - amount smoked 
Never smoked tobacco 
Non-smoker 
Trivial smoker - < 1 cig/day 
Occasional smoker 
Ught smoker - 1-9 cigs/ day 
Moderate smoker - 10-19 cigs/d 
Heavy smoker - 20·39 cigs/day 
Very heavy smoker - 40+cigs/d 
Ex-trivial smoker « l/day) 
Ex-light smoker (1 -9/day) 
Ex-moderate smoker (10-l9/day) 
Ex-heavy smoker (20-39/day) 
Ex-very heavy smoker (40+/ day) 
Keeps trying to stop smoking 
Ex-smolcer - amount unknown 
rying to give up smoking 
.er 
Ex ciga.r smoker 
Ogarenesmo 
SmoIcer 
S 
137Q.ll 
137R.00 
1375.00 
137T.00 
137V.OO 
137X.OO 
137Y.00 
137b.OO 
137c.00 
137d.00 
137e.00 
137f.00 
137g.00 
137h.00 
137j.00 
1371.00 
13pO.OO 
13p4.00 
13p5.00 
IVOS.OO 
lV09.00 
6791.00 
671(3.00 
67Hl.OO 
67H6.00 
74SH.00 
745HOOO 
74SHIOO 
745H200 
74SH300 
74SH400 
Smoking restarted 
Current smoker 
Ex smoker 
Date ceased smoking 
Smoking reduced 
Cigarette consumption 
Cigar consumption 
Ready to stop smoking 
Thinking about stopping smoking 
Not interested in stopping smoking 
Smoking restarted 
Reason for restarting smoking 
Cigarette pack-years 
Minutes from waking to first tobacco consumption 
Ex-cigarette smoker 
Ex roll-Up cigarette smoker 
Negotiated date for cessation of smoking 
Smoking free weeks 
Smoking cessation programme start date 
Smokes drugs in cigarette form 
Smokes drugs through a pipe 
Health ed . - smoking 
Pregnancy smoking advice 
Ufestyle advice regard ing smoking 
Brief intervention for smoking cessation 
Smoking cessation therapy 
Nicotine replacement therapy using nicotine patches 
Nicotine replacement therapy using nicotine gum 
Nicotine replacement therapy using nicotine inhalator 
Nicotine replacement therapy using nicotine lo,enges 
Smoking cessation drug therapy 
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745HyOO 
745HzOO 
BB2B.00 
BB3Y.00 
BB3f.00 
BBP3.00 
BCAL.OO 
BCAg.OO 
BH7i.00 
BHTK.OO 
8HkQ.00 
8121.00 
8139.00 
81Aj.00 
9N2k.00 
9N4M.00 
9001.00 
9002.00 
9003.00 
9007.00 
9008.00 
9km .. 00 
9km .. 11 
9kn .. OO 
9kn .. 
9ko .. OO 
9ko .. 
E251.00 
E251100 
E251300 
E251 zOO 
Other specified smoking cessation therapy 
Smoking cessation therapy NOS 
Nicotine replacement therapy 
Over the counter nicotine replacement therapy 
Nicotine replacement therapy provided free 
Nicotine replacement therapy provided by community pharmacis 
Smok ing cessation advice 
Smoking cessation advice prov ided by community pharmacist 
Referral to smoking cessation adv isor 
Referral to stop-smoking clinic 
Referral to NHS stop smoking service 
Nicotine replacement therapy contraindicated 
Nicotine replacement therapy refused 
Smoking cessation advice declined 
Seen by smoking cessation advisor 
DNA - Did not attend smoking cessation cl inic 
Attends stop smoking monitor. 
Refuses stop smoking monitor 
Stop smoking monitor default 
Stop smoking monitor verb.inv. 
Stop smoking monitor phone inv 
Ex-smoker annual review - enhanced services administration 
Ex-smoker annual revieY, 
annual review - enhanced services administration 
- enhanced services admin 
annual review 
obaaD dependenc:e in ISsion 
Tobacr.o 
H310100 
ZG23300 
ZRBm200 
ZRBm211 
ZRaM.OO 
ZRaM.ll 
ZRao.OO 
ZRao.ll 
ZRh4.00 
ZRh4.11 
ZV6DBOO 
Ahdcode 
1003040000 
Smokers' cough 
Advice on smoking 
Fagerstrom test for nicotine dependence 
FTND - Fagerstrom test for nicotine dependence 
Motives for smoking scale 
MFS - Motives ,for smoking scale 
Occasions for smoking scale 
OFS - Occasions for smoking scale 
Reasons for smoking scale 
RFS - Reasons for smoking scale 
[V]Tobacco abuse counsell ing 
Description 
Smoking 
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Appendix 10: Obstetric haemorrhage Read codes 
Read code 
7F22700 
7F227ll 
7F22712 
7F22713 
7F24100 
851..00 
851Z.00 
G8yO.OO 
K55y300 
K56ylOO 
K59yxOO 
K59yyOO 
L040100 
L041100 
L042100 
L043111 
L044111 
L050100 
L051100 
L052100 
L060100 
L061100 
L062100 
L070100 
L071100 
description 
Pack to control postnatal vaginal bleed ing 
Pack to control postnatal vaginal bleed ing 
Pack to control postnatal haemorrhage 
Pack to cont rol postpartum haemorrhage 
Obstetric uterine tamponade 
Haemorrhage control by packing 
Haemorr. control by pack NOS 
Haemorrhage NOS 
Haemorrhage of cervix 
Haemorrhage of vag ina 
Dysfunctional uterine haemorrhage NOS 
Functional uterine haemorrhage NOS 
Unspec spontaneous abortion + delayed/ excessive haemorrhage 
Incomp spontaneous abortion + delayed/ excessive haemorrhage 
Complete spontaneous abortion +delayed/excessive haemorrhage 
Unsp inevitable mis c:omp by delayed or excessive haemorrhage 
Incomplete inev mis comp by delayed or excessive haemorrhage 
UnspeOfJed le9al abortion + delayed/excessive haemorrhage 
ncomplete legal abortion + delayed or excessive haemorrhage 
Complete legal abortion with delayed/excessive haemorrhage 
Unspec illegal abortion + delayed or excessive haemorrhage 
ncomplete illegal abortion + delayed/ excessive haemorrhage 
Complete illegal abortion + delayed or excessive haemorrhage 
Unspecified abortion with delayed or excessIVe haemorrhage 
Unsoedfied incomolete abortion + delayed/ excess haemorrhage 
L072100 
L081.00 
L091.00 
L091z00 
LIO .. OO 
LlOy.OO 
LIOyOOO 
LIOylOO 
LlOy200 
LlOyzOO 
LlOz.OO 
LIOzOOO 
LlOzIOO 
LlOz200 
LIOzzOO 
LI1..00 
Ll1..11 
Ul1.00 
LlllOOO 
Llll100 
Ll11200 
UllzOO 
U12.1 2 
U13.00 
U13.1l 
Ll13.12 
U 13 .13 
U13000 
U13100 
U13200 
U13z00 
Unspecified complete abortion +delayed/excessive haemorrhage 
Failed attempted abortion + delayed or excessive haemorrhage 
Delayed/excessive haemorrhage following abortive pregnancy 
Delayed/excess haemorrhage NOS following abortive pregnancy 
Haemorrhage in early pregnancy 
Other haemorrhage in early pregnancy 
Other haemorrhage in early pregnancy unspecified 
Other haemorrhage in early pregnancy - delivered 
Other haemorrhage in early pregnancy - not delivered 
Other haemorrhage in early pregnancy NOS 
Early pregnancy haemorrhage NOS 
Early pregnancy haemorrhage NOS unspecified 
Early pregnancy haemorrhage NOS - delivered 
Early pregnancy haemorrhage NOS - not delivered 
Early pregnancy haemorrhage NOS 
Antepartum haemorrhage, abruptio placentae, placenta praev ia 
Antepartum haemorrhage 
Placenta praevia with haemorrhage 
Placenta praevia with haemorrhage unspecified 
Placenta praevia with haemorrhage - delivered 
Placenta praevia with haemorrhage - not delivered 
Placenta praevia with haemorrhage NOS 
Couvelaire uterus 
Antepartum haemorrhage with coagulation defect 
Antepartum haemorrhage with afibrinogenaemia 
Antepartum haemorrhage with hyperfibrinolysis 
Antepartum haemorrhage with hypofibrinogenaemia 
Antepartum haemorrhage with coagulation defect unspecified 
Antepartum ha.emorrhage with coagulation defect - delivered 
Antepartum haemorrhage with coagulation defect - not deliv 
Antepartum haemorrhage with coagulation defect NOS 
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1114.00 
1114000 
1114100 
1114200 
1114z00 
111S.00 
L11S.11 
111S.12 
L11S000 
L11S100 
111S200 
L11Sz00 
L11y.00 
L11yOOO 
L11y100 
Llly200 
LllyzOO 
L11z.00 
Ulz000 
U1z100 
L11zl00 
U1ZZ00 
L260.00 
L260000 
1260100 
1260200 
1260z00 
l36 .. 00 
l360.00 
l360000 
l360100 
Antepartum haemorrhage with trauma 
Antepartum haemorrhage with trauma unspecified 
Antepartum haemorrhage with trauma - delivered 
Antepartum haemorrhage with trauma - not delivered 
Antepartum haemorrhage with trauma NOS 
Antepartum haemorrhage with uterine leiomyoma 
Antepartum haemorrhage with fibroid 
Antepartum haemorrhage with uterine fibroid 
Antepartum haemorrhage with uterine leiomyoma unspecified 
Antepartum haemorrhage with uterine leiomyoma - delivered 
Antepartum haemorrhage with uterine leiomyoma - not deliv 
Antepartum haemorrhage with uterine leiomyoma NOS 
Other antepartum haemorrhage 
Other antepartum haemorrhage unspecified 
Other antepartum haemorrhage - delivered 
Other antepartum haemorrhage - not delivered 
Other antepartum haemorrhage NOS 
Antepartum haemorrhage NOS 
Antepartum haemorrhage NOS, unspecified 
Antepartum haemorrhage NOS - delivered 
Antepartum haemorrhage NOS - not deliv 
Antepartum haemorrhage NOS 
Fetal-maternal haemorrhage 
Fetal-maternal haemorrhage unspecified 
Fetal-maternal haemorrhage - delivered 
Fetal-maternal haemorrhage with antenatal problem 
Fetal-materna.1 haemorrhage NOS 
Postpartum haemorrhage ( PPH) 
-staae m haemorrhage 
m haemorrhage unspedfied 
DDStDartlJm haemorrhage - deJiv with pIn oroblem 
L360200 
L360z00 
L361.00 
L361000 
L361100 
L361200 
L361z00 
L362.00 
L362000 
L362100 
L362200 
L362z00 
L363100 
L36z.00 
L37 .. 00 
L37 .. 11 
L37 .. 12 
L370.00 
L370.11 
L370000 
L370100 
L370200 
L370z00 
L370z11 
L371.00 
L371000 
L371100 
L371200 
L371z00 
L37z.00 
L3A .. OO 
Third-stage postpartum haemorrhage with postnatal problem 
Third-stage postpartum haemorrhage NOS 
Other immediate postpartum haemorrhage 
Other immediate postpartum haemorrhage unspecified 
Other immediate postpartum haemorrhage - deliv with pin prob 
Other immediate postpartum haemorrhage with postnatal prob 
Other immediate postpartum haemorrhage NOS 
Secondary and delayed postpartum haemorrhage 
Secondary postpartum haemorrhage unspecified 
Secondary postpartum haemorrhage - deliv with postnatal prob 
Secondary postpartum haemorrhage with postnatal problem 
Secondary and delayed postpartum haemorrhage NOS 
Postpartum coagulation defects - delivered with pin problem 
Postpartum haemorrhage NOS 
Retained placenta or membranes with no haemorrhage 
Retained membrane without haemorrhage 
Retained placenta without haemorrhage 
Retained placenta with no haemorrhage 
Placenta accreta without haemorrhage 
Retained placenta with no haemorrhage unspecified 
Retained placenta with no haemorrhage - deliv with pin prob 
Retained placenta with no haemorrhage with postnatal problem 
Retained placenta with no haemorrhage NOS 
Retained placenta without haemorrhage 
Retained portion of placenta or membranes - no haemorrhage 
Retained products with no haemorrhage unspecified 
Reta ined products with no haemorrhage - deliv with pIn prob 
Retained products with no haemorrhage with postnatal problem 
Retained products with no haemorrhage NOS 
Retained placenta or membranes with no haemorrhage NOS 
Intrapartum haemorrhage with coagulation defect 
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L3X .. OO 
Lyu2000 
Lyu3EOO 
Lyu4700 
Lyu4DOO 
Lyu4MOO 
Q021.00 
Q021000 
Q021011 
Q021yOO 
Q021z00 
Q413.00 
Q413000 
Q413yOO 
Q413z00 
Ryu7300 
SK02.00 
SK02.11 
SK02.12 
SP21.00 
SP21. 12 
SP21000 
SP21100 
TAO .. ll 
Intrapartum haemorrhage, unspecified 
[X]Other haemorrhage in early pregnancy 
[X]Other antepartum haemorrhage 
[X]Other intrapartum haemorrhage 
[X1Other immediate postpartum haemorrhage 
[X]Intrapartum haemorrhage, unspecified 
Fetus/neonate affect other placental separation/haemorrhage 
Fetus/neonate affected by antepartum haemorrhage unspecified 
Fetus affected by APH - antepartum haemorrhage 
Fetus/neonate affected placental separation/haemorrhage OS 
Fetus/neonate affected placental separation/haemorrhage NOS 
Umbilical haemorrhage after birth 
Umbilical haemorrhage after birth, unspecified 
Other specified umbilical haemorrhage after birth 
Umbilical haemorrhage after birth NOS 
[X]Haemorrhage, not elsewhere classified 
Secondary and rec1.lrrent haemorrhage 
Secondary and reOJrrent haemorrhage 
Secondary and rec1.lrrent haemorrhage 
Peri-operative haemorrhage or haematoma 
Haemorrhage - postDperative 
Intra-opercitive haemorrhage 
Post-operative haemorrhage 
Accidental haemorrhage during medical care 
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Appendix 11: Eclampsia and preeclampsia Read codes 
Readcode 
L124.00 
L124.11 
L124000 
L124100 
L124200 
L124300 
L124400 
L124500 
L124600 
L124z00 
L125.00 
L125000 
L125100 
L125200 
L125300 
L125400 
L125z00 
L126.00 
L126000 
L126100 
L126200 
L126300 
L126400 
L126500 
L126600 
L126z00 
L127.00 
L127000 
L127100 
L127200 
L127300 
L127400 
L127z00 
L129.00 
description 
Mild or unspecified pre-eciampsia 
Mild pre-eciampsia 
Mild or unspecified pre-eciampsia unspecified 
Mild or unspecified pre-eclampsia - delivered 
Mild or unspecified pre-eciampsia - delivered with pIn comp 
Mild or unspecified pre-eclampsia - not delivered 
Mild or unspecified pre-eciampsia with pIn complication 
Mild pre-eclamps ia 
Pre-eclampsia, unspecified 
Mild or unspecified pre-eciampsia NOS 
Severe pre-eclampsia 
Severe pre-eclampsia unspecified 
Severe pre-eclampsia - delivered 
Severe pre-eclampsia - delivered with postnatal complication 
Severe pre-eciampsia - not delivered 
Severe pre-eclampsia with postnatal complication 
Severe pre-eciampsia NOS 
Eciampsia 
Eciampsia unspecified 
Eclampsia - delivered 
Eciampsia - delivered with postnata l complication 
Eciampsia - not delivered 
Eciampsia with postnatal complication 
Eciampsla in pregnancy 
Eciampsia in labour 
Eciampsia NOS 
Pre-eciampsla or eciampsia with pre-existlng hypert nslon 
Pre-eclampsia or eclampsia with hypertension unsp cln d 
Pre-eclampsia or eclampsia with hypertension - delivered 
Pre-eclampsia or eciampsla with hypertension - d I pIn comp 
Pre-eclampsia or eclampsia with hypertension - not d liv r d 
Pre-eclampsia or eclampsia with hypertension + pIn comp 
Pre-eclampsia or eclampsia + pre-exlst lng hyp rt nslon NOS 
Moderate pre-eclampsia 
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Appendix 12: Read codes for acute respiratory tract 
infection 
Readcode 
43eG.00 
43eH.OO 
43jQ.OO 
43jx.OO 
43jy.00 
43jz.OO 
43n1.00 
43n7.00 
4JUO.00 
4JU1.00 
4JU2.00 
4JU3.00 
4JU4.00 
4JUS.OO 
4JUF.OO 
4JUK.OO 
A022200 
A116.00 
A380300 
A3BS.OO 
A3BXAOO 
A3BXBOO 
A3BXOOO 
A3B' 
A54x 
AS51.00 
description 
Chlamydia pneumoniae IgG level 
Chlamydia pneumoniae IgM level 
Avian influenza virus nucleic acid detection 
Parainfluenza type I nucleic acid detection 
Parainfluenza type 2 nucleic acid detection 
Parainfluenza type 3 nucleic acid detection 
Mycoplasma pneumoniae antibody level 
Chlamyd ia pneumoniae IgA level 
Influenza HI v irus detected 
Influenza H2 v irus detected 
I nfluenza H3 virus detected 
I nfluenza HS virus det ected 
I nfluenza A virus, other or untyped strain detected 
Influenza B virus detected 
Human parainfluenza v irus detected 
Mycoplasma pneumoniae detected 
Salmonella pneumonia 
TuberClllous pneumonia 
Septicaemia due to streptocoCCllS pneumoniae 
Haemophilus influenzae infection 
Mycoplasma pneumoniae [PPLO) causetdis dassifd/oth chaptr 
Klebsiella pneumoniae/cause/disease classifd/oth chapters 
H infJuenzae as cause/diseases classified/other chapters 
Herpes simpleX pneumo 
Postmeasles pneumonia 
'LO) infection 
A730.00 
A789300 
AB24.11 
AB40S00 
AB41S00 
AB4zS00 
Ayu3UOO 
AyuK900 
AyuKAOO 
AyuKCOO 
FOOy400 
F030800 
F030AOO 
GS20300 
H040400 
H06 .. 00 
H060.00 
H060.11 
H060000 
H060100 
H060 200 
H060300 
H060400 
H060S00 
HOG0600 
HOG0700 
H060800 
H060900 
H060AOO 
HOGOBOO 
H060COO 
Ornithosis with pneumonia 
HIV d isease resulting in Pneumocystis carinii pneumonia 
Pneumonia - candidal 
Histoplasma capsulatum with pneumonia 
Histoplasma duboisii with pneumonia 
Histoplasmosis with pneumonia 
[X]Haemophilus influenzae infection, unspecified 
[X]Mycoplasma pneumoniae [PPLO]cause/dis classifd/oth chaptr 
[X]Klebsiella pneumoniae/cause/disease classifd/oth chapters 
[X]H influenzae as cause/diseases classified/other chapters 
Mening itis due to klebsiella pneumoniae 
Encephalitis due to influenza-specific virus not identified 
Encephalitis due to influenza-virus identified 
Acute myocarditis - influenzal 
Acute haemophilus influenzae laryngitis 
Acute bronchitis and bronchiolitis 
Acute bronchit is 
Acute wheezy bronchit is 
Acute fibrinous bronchitis 
Acute membranous bronchit is 
Acute pseudomembranous bronchit is 
Acute purulent bronchit is 
Acute croupous bronchitis 
Acute tracheobronchitis 
Acute pneumococcal bronchitis 
Acute streptococcal bronchit is 
Acute haemophilus influenzae bronchit is 
Acute neisseria catarrhalis bronchit is 
ACllte bronchitis due to mycoplasma pneumoniae 
ACllte bronchitis due to coxsackievirus 
Arute bronchitis due to parainfluenza virus 
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H060DOO 
H060EOO 
H060FOO 
H060vOO 
H060wOO 
H060xOO 
H060z00 
H06z.00 
H06z000 
H06z011 
H06z200 
H2 ••. 00 
H20 .• 00 
H20 •• 11 
H200.00 
H201.00 
H202.00 
H2Oy.OO 
H20z.00 
H21..00 
H2l.. 
H22 •• 00 
H22 .• 1 
H220.00 
221.00 
H222.00 
222. 
H223.00 
223000 
H224.00 
lly.OO 
Acute bronchitis due to respiratory syncytial v irus 
Acute bronchit is due to rhinovirus 
Acute bronchitis due to echovirus 
Subacute bronchitis unspecified 
Acute viral bronchitis unspecified 
Acute bacterial bronchitis unspecified 
Acute bronchitis NOS 
Acute bronchitis or bronchio litis NOS 
Chest infection NOS 
Chest infection 
Recurrent chest infection 
Pneumonia and influenza 
Viral pneumonia 
Chest infection - viral pneumonia 
Pneumonia due to adenovirus 
Pneumonia due to respiratory syncytial v irus 
Pneumonia due to parainHuenza virus 
ViraJ pneumonia NEe 
Viral pneumonia NOS 
Lobar (pneumocxx:x::al) pneumo 
Chest infection - pneumococcal 
Other bacterial pneumonia 
Chest infection - other bacterial 
Pneumonia due to kJebsieAa 
Pneu nas 
neumonia 
neumonia 
ue to su epmal!(XJlS, 9 
ue to s:aphylococa IS 
8 
Pneu ue l e d ~ ~
H22yOOO 
H22yOll 
H22ylOO 
H22y200 
H22yXOO 
H22yzOO 
H22z.00 
H23 .• 00 
H23 .• 11 
H230.00 
H231.00 
H232.00 
H233 .00 
H23z.00 
H24 .. 00 
H24 •. 11 
H240.00 
H241.00 
H242.00 
H243.00 
H243.11 
H244.00 
H24S.00 
H246.00 
H247.00 
H247000 
H247100 
H247200 
H247z00 
H24y.OO 
H24yOOO 
Pneumonia due to escherichia coli 
E.coli pneumonia 
Pneumonia due to proteus 
Pneumonia - Leg ionella 
Pneumonia due to other aerobic gram-negative bacteria 
Pneumonia due to bacteria NOS 
Bacterial pneumonia NOS 
Pneumonia due to other specified organisms 
Chest infection - pneumonia organism OS 
Pneumonia due to Eaton's agent 
Pneumonia due to mycoplasma pneumoniae 
Pneumonia due to pleuropneumonia like organ isms 
Chlamydial pneumonia 
Pneumonia due to specified organism NOS 
Pneumonia wit h infectious diseases EC 
Chest infection with infectious disease EC 
Pneumonia with measles 
Pneumonia with cytomegalic indusion dise.ase 
Pneumonia with ornithosis 
Pneumonia with whooping cough 
Pneumonia with pertussis 
Pneumonia with tularaemia 
Pneumonia with anthrax 
Pneumonia with aspergillosis 
Pneumonia with other systemic mycoses 
Pneumonia with candidiasis 
Pneumonia with coccidioidomycosis 
Pneumonia with histoplasmosis 
Pneumonia with systemiC mycosis NOS 
Pneumonia with other infectious diseases EC 
Pneumonia with actinomycosis 
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H24yl00 
H24y200 
H24y300 
H24y400 
H24ySOO 
H24y600 
H24y700 
H24yzOO 
H24z.00 
H2S .. 00 
H2S .. 11 
H26 •. 00 
H26 .. 11 
H260.00 
H261.00 
H262.00 
H27 .• 00 
H270.00 
H270.1l 
H270000 
H270100 
H270z00 
271.00 
H271000 
271100 
27lzOO 
27v.00 
H27_ 
27ylOO 
27yzOO 
27z.00 
Pneumonia with nocardiasis 
Pneumonia with pneumocystis carin ii 
Pneumonia w ith Q-fever 
Pneumonia with salmonellosis 
Pneumonia with toxoplasmosis 
Pneumonia with typhoid fever 
Pneumonia with varicella 
Pneumonia with other infectious d iseases EC NOS 
Pneumonia with infectious diseases EC NOS 
Bronchopneumonia due to unspecified organism 
Chest infection - unspecified bronchopneumonia 
Pneumonia due to unspecified organism 
Chest infection - pnemonia due to unspecified organism 
lobar pneumonia due to unspecified organism 
Basal pneumonia due to unspecified organism 
Postoperative pneumonia 
Influenza 
Influenza yrith pneumonia 
Chest infection - influenza Ylith pneumonia 
Influenza with bronchopneumonia 
I 
manifestaoon 
:nr"""-rv manifestations NOS 
emen 
H28 .. 00 
H29 .. 00 
H2y .. OO 
H2z .• 00 
H30 .. 00 
H30 •. 11 
H30 •. 12 
H300.00 
H301.00 
H302.00 
H30z.00 
H470312 
H471000 
HS30200 
HS30300 
HS40000 
H540100 
HS64 .00 
HS6yOOO 
HS6y l OO 
HS7 1.00 
HyuOSOO 
Hyu0700 
Hyu0800 
Hyu0900 
HyuOAOO 
HyuOBOO 
HyuOCOO 
HyuODOO 
HyuOEOO 
HyuOFOO 
Atypical pneumonia 
Avian influenza 
Other specified pneumonia or influenza 
Pneumonia or influenza NOS 
Bronchitis unspecified 
Chest infection - unspecified bronchitis 
Recurrent wheezy bronchitis 
Tracheobronchitis NOS 
Laryngotracheobronchitis 
Wheezy bronchit is 
Bronchit is NOS 
Aspiration pneumonia due to vomit 
Upoid pneumonia (exogenous) 
Gan9renous pneumonia 
Abscess of lung with pneumonia 
Hypostatic pneumonia 
Hypostatic bronchopneumonia 
Bronchiolitis obliterans organising pneumonia 
Endogenous lipoid pneumonia 
Interstitial pneumonia 
Rheumatic pneumonia 
[X1I nfluenza+other manifestations,influenza virus identified 
[X1Influenza+other manifestations, virus not identified 
[X10ther v iral pneumonia 
[X1Pneumonia due to other aerobic gram-negative bacteria 
[X10ther bacterial pneumonia 
[X1Pneumonia due to other specified infectious organisms 
[X1Pneumonia in bacterial diseases classified elsewhere 
[X1Pneumonia in viral diseases dassified elsewhere 
[ X1Pneumonia in mycoses dassified elsewhere 
[X1Pneumonia in parasitic diseases dassified elsewhere 
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HyuOGOO 
HyuOHOO 
SP13200 
U60K400 
ZV04800 
ZV04811 
[ X]Pneumonia in other diseases classified elsewhere 
[X]Other pneumonia, organism unspecified 
Post operative chest infection 
[X)Influenza vaccine causing adverse effects therapeutic use 
[V] Influenza vaccination 
[V)Flu - influenza vaccination 
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Appendix 13: Read codes for urinary tract infection 
Readcode description 
1AG .. 00 
K101.00 
K101000 
KIOllOO 
KIOlzOO 
K1 5 .. 00 
K1 50.00 
K151.00 
K151200 
K1 51z00 
K152.00 
K152000 
K1 52yOO 
K152z00 
K1 53.11 
Kl54.00 
54000 
1<154100 
1 
154500 
54600 
54700 
54800 
zOO 
55.00 
5v.00 
Recurrent urinary tract infections 
Acute pyelonephritis 
Acute pyelonephritis without medullary necrosis 
Acute pyelonephritis w ith medullary necrosis 
Acute pyelonephritis NOS 
Cystitis 
Acute cystitis 
Chronic interstitial cystitis 
Submucous cystitis 
Chronic interstitial cystitis NOS 
Other chronic cystitis 
SUbaaJte cystitis 
Chronic cystitis unspecified 
Other chronic cystitis NOS 
FolliaJlar cystitis 
Cystitis in diseases EC 
Cystitis in actinomycosis 
Cystitis in amoebiasis 
Cystitis in biJharziasis 
Cystitis in echinocxx:cus infestation 
Cystitis in diphtheria 
Cystitis in gonorrhoea 
Cystitis in moniliasis 
C y s t i t i i i n u x n o r n o n i a s ~ ~
CYStitis in bJbercuIosis 
iseases EC NOS 
K15yOOO 
K15y100 
K15yzOO 
K15z.00 
K190.00 
K190.11 
K190200 
K190300 
K190500 
K190z00 
Kyu5100 
L09y400 
L166.00 
L166.11 
L166000 
L166100 
L166200 
L166300 
U66400 
L166600 
L166800 
U66z00 
U66z11 
lyu2400 
lyu6100 
ZG44100 
Cystitis cystica 
Irradiation cystitis 
Other cystitis NOS 
Cystitis NOS 
Urinary tract infection, site not specified 
Recurrent urinary tract infection 
Post operative urinary tract infection 
Recurrent urinary tract infection 
Urinary tract infection 
Urinary tract infection, site not specified NOS 
[X]other cystit is 
Urinary tract infection following abortive pregnancy 
Genitourinary tract infections in pregnancy 
CystitiS of pregnancy 
Genitourinary tract infection in pregnancy unspecified 
Genitourinary tract infection in pregnancy - delivered 
Genitourinary tract infection in pregnancy - deliv +p/n comp 
Genitourinary tract infection in pregnancy - not delivered 
Genitourinary tract infection in pregnancy with pi n comp 
Urinary tract infection following delivery 
Urinary tract infection complicating pregnancy 
Genitourinary tract infection in pregnancy NOS 
UTI - urinary tract infection in pregnancy 
[XJ0ther+unspd genitourinary tract infection in pregnancy 
[XJ0ther genitourinary tract infections following delivery 
Advice on avoiding reaJrrent urinary tract infection 
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Appendix 14: Read codes for medical co-morbidities 
Inflammatory bowel disease 
medcode 
J08z900 
J40 .. 00 
J40 .. 11 
J400 .00 
J400000 
J400100 
J400200 
J400300 
J400400 
J400500 
J400z00 
J401.00 
J401000 
J401100 
J401200 
J401z00 
J401z11 
J40z.00 
J40z.11 
Jyu4000 
N031100 
N045300 
ZR3S.00 
ZR3S.1l 
14C4.11 
J41..12 
J41O.00 
J410100 
J410300 
J410400 
J410z00 
Jyu4100 
N031000 
N045400 
J4 ... 12 
J41..00 
J41y.00 
J41yzOO 
J41z.00 
description 
Orofacial Crohn's disease 
Regional enteritis - Crohn's disease 
Crohn's disease 
Regional enteritis of the small bowel 
Regional enteritis of the duodenum 
Regional enteritis of the jejunum 
Crohn's disease of the terminal Ileum 
Crohn's disease of the ileum unspecified 
Crohn's disease of the ileum NOS 
Exacerbation of Crohn's disease of small Intestine 
Crohn's disease of the small bowel NOS 
Regional enteritis of the large bowel 
Regional enteritis of the colon 
Regional enteritis of the rectum 
Exacerbation of Crohn's disease of large Intestine 
Crohn's disease of the large bowel NOS 
Crohn's colitis 
Regional enteritis NOS 
Crohn's disease NOS 
[X]Other Crohn's disease 
Arthropathy In Crohn's disease 
Juvenile arthritis in Crohn's disease 
Crohn's disease activity Index 
CDAI - Crohn's disease activity Index 
H/O: ulcerative colitis 
Ulcerat ive colitis and/or proctitis 
Ulcerative proctocolitis 
Ulcerative colitis 
Ulcerative proctitis 
Exacerbation of ulcerative colitis 
Ulcerative proctocolitis NOS 
[X]Other ulcerative colitis 
Arthropathy In ulcerative colitis 
Juvenile arthritis In ulceratlv coli tis 
Inflammatory bowel disease 
Idiopathic proctocolitis 
Other Idiopathic proctocolitis 
Other Idiopathic proctocolitis NOS 
Idiopathic proctocolitis NOS 
27 
Nephrotic syndrome 
medcode 
KO ... OO 
KO 1..00 
KOlO.OO 
KOl1.00 
KOl2.00 
K013 .00 
K013 .l2 
KOl4.00 
KOlS .OO 
KOl6.00 
KOlA.OO 
KOlB.OO 
KOlw.OO 
KOlwOll 
KOlwzOO 
KOlx.OO 
KOlxOOO 
KOlxlOO 
KOlx200 
KOlx300 
KOlx400 
KOlxzOO 
KOly.OO 
KOlz.OO 
KOy .. OO 
KOz .. OO 
description 
Nephritis, nephrosis and nephrotic syndrome 
Nephrotic syndrome 
Nephrotic syndrome with proliferative glomerulonephritis 
Nephrotic syndrome with membranous glomerulonephrit is 
Nephrotic syndrome+membranoproliferatlve glomerulonephritis 
Nephrotic syndrome with minimal change glomerulonephritis 
Steroid sensitive nephrotic syndrome 
Nephrotic syndrome, minor glomerular abnormality 
Nephrotic syndrome, foca l and segmental glomerular lesions 
Nephrotic syndrome, diffuse membranous glomerulonephritis 
Nephrotic syndrome, dense deposit disease 
Nephrotic syndrome, diffuse crescentlc glomerulonephritis 
Congenital nephrotic syndrome 
Microcystic type congenital nephrotic syndrome 
Congenital nephrotic syndrome NOS 
Nephrotic syndrome In diseases EC 
Nephrotic syndrome In amyloidosis 
Nephrotic syndrome In diabetes mellltus 
Nephrotic syndrome In malaria 
Nephrotic syndrome In polyarteritis nodosa 
Nephrotic syndrome In systemic lupus ryth matQSus 
Nephrotic syndrome In dlseas s EC NOS 
Nephrotic syndrome with other pathological kldn y I Ions 
Nephrotic syndrome NOS 
Other specified nephritis, nephrosis or n phrotlc syndrom 
Nephritis, nephrosis and nephrotic syndrom NOS 
o 
Systemic lupus erythematosus 
medcode description 
HS7y400 Lung disease with systemic lupus erythematosus 
KOlx400 Nephrotic syndrome in systemic lupus erythematosus 
NOOO.OO Systemic lupus erythematosus 
N000200 Drug-induced systemic lupus erythematosus 
N000300 Systemic lupus erythematosus with organ or sys Involv 
N000400 Systemic lupus erythematosus with pericarditis 
NOOOzOO Systemic lupus erythematosus NOS 
Nyu4300 [X]Other forms of systemic lupus erythematosus 
ZRq9.00 Systemic lupus erythematosus disease activity Index 
2 1 
Cardiac disease 
Readcode 
P54 .. 00 
P6z .. 00 
G580.00 
G577.00 
G581.00 
GS8 .. 11 
GS73200 
GS70000 
G340.12 
GS72z00 
G33z300 
G33 .. 00 
G311.13 
GS7z.00 
GS7y900 
7L1Hl 00 
GS73000 
GS73100 
P511.00 
G58 •• 00 
GS73.00 
P735.00 
P70 .• 00 
7AOlzOO 
51..00 
7936000 
GS8O. 
G55 .• 00 
7U 
description 
Ventricular septal defect 
Congenital heart anomaly NOS 
Congestive heart failure 
Sinus arrhythmia 
Left ventricular failure 
Cardiac failure 
Paroxysmal atrial fibrillation 
Paroxysmal atrial tachycard ia 
Coronary artery disease 
Paroxysmal tachycard ia NOS 
Angina on effort 
Angina pectoris 
Unstable angina 
Cardiac dysrhythmia NOS 
SupraventriaJlar tachycardia NOS 
External cardioversion NEC 
Atrial fibrillation 
Atrial flutte 
Double outlet right ventride 
Heart failure 
Atrial fibrillation and flutte, 
Stenosis of pulmonary arteIy 
Patent ductus arteriosus 
Open mrrection of patent ductus arteriosus NOS 
Transposition of great vesseJs 
lrnDiantation of intravenous cardiac pacemaker system 
'ailure 
Cardiomyopathy 
o· ioversion 
PSSO.OO 
P641.00 
P71..00 
GS71.00 
GS54300 
3272.00 
P6y6000 
GS7yOOO 
P601.00 
P6z3.00 
7908z00 
GS8z.00 
GS7 .. 00 
GS74.00 
GS7y.14 
G311. 11 
GS74000 
PS2 .. 00 
GS5S .00 
3282.00 
G570.00 
PSO .. OO 
AAl..OO 
GSS4000 
G58 1000 
790 2.00 
GS74100 
GS7y300 
P6 ... 00 
7936.00 
G581.13 
Atrial septal defect NOS 
Bicuspid aortic valve 
Coarctation of aorta 
Paroxysmal ventricular tachycardia 
Hypertrophic non-obstructive cardiomyopathy 
ECG: atrial fibrillation 
Dextroca rd ia 
Persistent sinus bradycardia 
Congenital atresia of the pulmonary valve 
Cyanotic congenital heart disease NOS 
Closure of defect of interventricular septum NOS 
Heart failure NOS 
Card iac dysrhythmias 
Ventricular f ibrillation and flutter 
Heart beats irregular 
Crescendo ang ina 
Ventricular fibrillation 
Tetralogy of Fallot 
Alcoholic card iomyopathy 
ECG : ventricular tachycardia 
Paroxysmal supraventricular tachycard ia 
Common aorto-pulmonary trunk 
Vincent's ang ina 
Congestive card iomyopathy 
Acut e left ventricular fa ilure 
Correction of tetralogy of Fa"ot 
Ventricular flutter 
Sick sinus syndrome 
Other congenital heart anomalies 
Introduction of cardiac pacemaker system via vein 
Impaired left ventricular function 
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14AS.00 
14AN.00 
GS7 .. 11 
1454.00 
3273.00 
P64z.00 
P63 .. 00 
7903.00 
7UH.11 
P6z3.11 
G343.00 
7A01.11 
G311100 
7L1H200 
G57y400 
P55 .. 00 
G 5544 00 
GS75300 
GS7 1. 11 
GS7y.OO 
F2S6000 
G551.00 
P6z.. 
7936600 
•• 00 
GSS'Y' 
H/O: ang ina pectoris 
H/O: atrial fibrillation 
Card iac arrhythmias 
H/O: heart valve recipient 
ECG: atrial flutter 
Congenital aortic valve insufficiency NOS 
Congenital aortic valve stenosis 
Atrial inversion ops for transpOSit ion of great vessels 
Cardioversion and stimulation 
Blue baby 
lschaemic cardiomyopathy 
Open correction of patent ductJ.Js arteriosus (POA) 
Unstable angina 
Internal electrode cardioversion 
Sinoatri.al node dysfunction NOS 
Ostium secundum atrial septal defect 
Primary d ilated cardiomyopathy 
Electromechanical dissodation 
VentriaJlar tachycardia 
Other cardiac dysrhythmias 
Hypsarrhythmia 
Hvn..rtrnnhic obstructive cardiomyopathy 
n 
enous cardiac pacemalter 
1dency 
7936AOO 
G580.14 
G33zS00 
7AOllOO 
A740.00 
101..00 
P736.12 
G580.12 
G580 .13 
6620.11 
G331.11 
7936.11 
P73 .. 00 
P72z111 
GS80300 
P72zz00 
P6zz.00 
662T.00 
14AQ.OO 
G58z.11 
9NOk.00 
P61..00 
G33z700 
7A02000 
G331.00 
662K.00 
662g.00 
662)000 
329 .. 00 
662K200 
14A6.00 
Implant intravenous pacemaker for atrial fibrillation 
Biventricular failure 
Post infarct angina 
Ligation of patent ductus arteriosus 
Herpangina 
Heart failure confirmed 
Pulmonary arterio-venous malformation 
Right heart fa ilure 
Right ventricular failure 
Oigital ised 
Variant ang ina pectoris 
Introduction of intravenous cardiac pacemaker system 
Pulmonary artery anomalies 
Congen ital dilatation of aorta 
Compensated cardiac failure 
Other anomaly of aorta NOS 
Congenital heart anomaly NOS 
Congestive heart failure monitoring 
HiStory of supraventricular tachycard ia 
Weak heart 
Seen in heart failure clinic 
Congenital tricuspid atresia and stenosis 
Stable ang ina 
Percut transluminal prosth occlusion patent ductus arterios 
Prinzmetal's angina 
Angina control 
New York Heart Association classification - class IJ 
Digoxin monitoring 
ECG: heart block 
Angina control - improving 
H/O: heart failure 
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662KzOO 
662KlOO 
7907z00 
7902000 
P6yO.00 
P713.11 
14H1.11 
G58z.l2 
G31l200 
J421.11 
327 .. 00 
8H6E.OO 
7936.00 
G311400 
G330000 
GS7yl00 
3274.00 
P55y.l 
6625.00 
PS ... l3 
H1.00 
P733.00 
9Ulp.00 
662h.OO 
7A020 
66 
G3 
3 
3 .. 
Angina control NOS 
Angina control - poor 
Oosure of defect of interatrial septum NOS 
Correct Fallot tetralogy- valved right ventr outflow conduit 
Subaortic stenosis 
Stenosis of aortic arch 
H/O: heart anomaly 
Cardiac failure NOS 
Angina at rest 
Angina - abdominal 
ECG: supraventricular arrhythmia 
Heart fa ilure follow-up 
Implantation of intravenous dual chamber permanent pacemaker 
Worsening angina 
Nocturnal angina 
Severe sinus bradycardia 
ECG: paroxysmal atrial tachy. 
0theT spedTJed atrial septal defect 
- I fib -
artery 
~ l u r e e nurse 
Association dassdication - class HI 
uctus arteriosus ( PDA) 
,Ieted 
ECG: ~ ~ antwttunsa 
os 
G330.00 
PS4S.00 
G3 ... l2 
P6y6.11 
P6l .. 00 
lA01.00 
1]60.00 
P6l0 .00 
G232.00 
P603.00 
PS .. . ll 
GlyzlOO 
P602.00 
l4AD.00 
GSSz.OO 
G573z00 
G570100 
PS20 .11 
GS80000 
P62 .. 00 
P6yy900 
PS .•. 12 
PS11100 
A340000 
8629.00 
P6y5.00 
P6yyzOO 
P6y •• OO 
P6yy.OO 
GS72.00 
P6v4.00 
Angina decubitus 
Roger's disease 
Atherosclerotic heart disease 
Ectopic heart 
Hypoplastic left heart syndrome 
Open correction of patent ductus arteriosus 
Suspected heart failure 
Congenital tricuspid atresia 
Hypertensive heart&renal dis wth (congestive) heart failure 
Right hypoplastic heart syndrome 
Card iac septal defects 
Rheumatic left ventricular failure 
Congenital pulmonary stenosis 
H/O ventricular fibrillation 
Cardiomyopathy NOS 
Atrial fibrillation and flutter NOS 
Paroxysmal atrioventricular tachycardia 
Ventricular septal defect in Fallot's tetralogy 
Acute congestive heart fa ilure 
Ebstein's anomaly 
Congenital epicard ial cyst 
Congenital heart dise.ase, septal and bulbar anomalies 
Dextratransposition of aorta 
Streptococcal ang ina 
Cardiac failure therapy 
Congenital heart block 
Other specified heart anomalies NOS 
Other specified heart anomalies 
Other specified heart anomalies 
Paroxysmal tachycardia unspecified 
Coronary artery anomaly 
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G574011 
G33z.00 
8HHb.00 
ZRad.OO 
P6z0 .00 
G33z600 
329Z.00 
G5S81 00 
GS80200 
GS82.0 0 
7909300 
P5S0 .12 
7904.00 
7907300 
G33ttOO 
P6y4411 
7905.00 
212R.OO 
9 hFO.00 
793 
6621000 
328Z.00 
G570300 
6330z00 
7909.00 
.00 
'n21.00 
9h.'iO.00 
Cardiac arrest -ventricular fi brillat ion 
Angina pectoris NOS 
Referral to heart fa ilure nurse 
New York Heart Assoc classification heart fa ilure symptoms 
Unspecified anomaly of heart valve 
New onset ang ina 
ECG: heart block NOS 
Cardiomyopathy in myotonic dystrophy 
Decompensated card iac failure 
AOJte heart fa ilure 
Primary closure of defect of septum of heart NEC 
I nteratrial septal defect NEC 
Other correction of transposition of great vessels 
Primary closure of defect of interatrial septum NEC 
Angina pectoris NOS 
Congenital coronary arteria-venous fistula 
Correction of total anomalous pulmonary venous connection 
Atrial fibrillation resolved 
Except from atr fib quarlty indicators: Patient unsuitable 
Removal of intravenous cardiac pacemaker system 
ina oontrol - worsening 
ECG: ventricular a mia NOS 
Paroxysmal nodal tachycardia 
ina decubitus NOS 
Closure of defect of unspecified septum of hea 
tachvcard0 
unsu 
7903.11 
7907000 
P732.00 
GS7yzOO 
3283.00 
Ppy4400 
)083300 
PS ... OO 
GS7yAOO 
7906.00 
P738.00 
G580100 
P6y3000 
8H2S.00 
90r . . 00 
8CL3.00 
7936500 
7904000 
P60 2z00 
P6yy200 
PS4 z.00 
P721z00 
G311300 
P6y1.00 
7907.00 
G570z00 
G573300 
3293.00 
P737.1l 
7908.00 
P74z600 
Mustard interatrial tr venous return 
Closure defect of interatrial septum using prosthetic patch 
Pulmonary artery atresia 
other cardiac dysrhythmia NOS 
ECG : ventricular fibrillation 
Anomalous coronary artery communication 
Ludwig's angina 
Bulbus cordis and card iac septal closure anomalies 
Re-entry ventricular arrhythmia 
Closure of defect of atrioventricular septum 
Atresia of pulmonary artery with septal defect 
Chronic congestive heart fa ilure 
Uhl's disease 
Adm it heart fa ilu re emergency 
Heart fa ilu re monitoring administration 
Heart failure care plan discussed with pat ient 
Implantation of emergency intravenous card iac pacemaker 
RepOSitioning of transposed great vessels 
Congenital pulmonary stenosis NOS 
Congenital cardiomegaly 
Vent ricular septal defect NOS 
Aortic arch anomalies NOS 
Refractory angina 
Cor triatriatum 
Oosure of defect of interatrial septum 
Paroxysmal supraventriOJlar tachycardia NOS 
Non-meumatic atrial fibrillation 
ECG:complete sinu-atrial block 
Dilatation of pulmonary artery 
Oosure of defect of interventriOJlar septum 
Sdmitar syndrome 
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7A01200 
P713.00 
P50 .. 11 
P6yy700 
P722200 
7UHlll 
7936FOO 
P552.OO 
7936300 
7903.12 
7936600 
7936700 
7904 zOO 
7906zOO 
7UH300 
'721211 
7909y00 
520.00 
P6.z2.00 
9hfl.00 
Gyu3000 
3889.00 
7906500 
P60 .• 00 
32CJS.00 
3 ..00 
Oosure of patent ductus arteriosus NEC 
Interruption of aortic arch 
Aortic septal defect 
Atresia of heart valve NEC 
Hypoplasia of aorta 
External electrode cardiover.;ion 
Renewal of intravenous cardiac pacemaker system 
Persistent ostium secundum 
.intenance of intravenous cardiac pacemaker system NEC 
Senning correction for transposition of great vessels 
Implantation simpk! one w ire intravenous cardiac pacemak.e 
mplantation of intravenous fixed-rate cardiac pacemake 
Other correction of transposition of great vessels NOS 
entriaJlar se.pt1Jm NOS 
et'Sion 
heart se.pt1Jm 
le: Inform dlSSeO 
P550 .11 
G554z00 
P74z300 
P502.11 
G554100 
7936511 
G574z00 
G5Sy.00 
7909000 
P73z.00 
P54{).00 
7936yOO 
7906300 
711H.12 
7936100 
P74 .. 00 
P56z100 
7936900 
7907100 
F391600 
P721500 
P60z.oo 
P6yy.ll 
72z.00 
56z2oo 
SOO.12 
P74{).00 
7908300 
2100 
501.00 
9 .. 00 
Auricular septal defect NOS 
Other primary cardiomyopathy NOS 
Stenosis of superior vena cava 
Truncus arteriosus 
Constrictive card iomyopathy 
Implantation of temporary intravenous card iac pacemaker 
Ventricular fibrillation and flutter NOS 
Secondary cardiomyopathy NOS 
Closure of defect of heart sept1Jm using prosthetic patch NEC 
Pulmonary artery anomaly NOS 
Ventricular septal defect, unspecified 
Other specified cardiac pacemaker system introduced via vein 
Oosure of persistent ostium primum 
Direct current card iac shock 
cardiac pacemaker system introduced via vein NOS 
Anomalies of great veins 
Common atrioventricular canal 
Implantation of intravenous atrial overdrive pacemaker 
Oosure detect of Interatrial septum using pericardial patch 
cardiomyopathy in Dudlenne muscular dystrophy 
Persistent nght aortic arch 
Other pulmona.ry valve anomalies 
Hypoplastic aortic ontice or vaJve 
Other anomalies of aorta NOS 
Common atnoventnaJlar-type ventncular septal defect 
Truncus arteriosus 
Anomaly of great veirtS, unspeof1ed 
mary dosure of defect of lO1erventncular sept1Jm NEC 
erutal fusIOn of pulmonary valve segrnel 
septal defect 
286 
8627.00 
PS8 .. 00 
P742.00 
P721200 
68B6.00 
3880.00 
P6W .. 00 
14AM.00 
P736.11 
Ps"x •• OO 
7906400 
8HTLOO 
P6yy300 
P71 2.13 
P72z000 
P56z.00 
P721300 
PGy4500 
7AO 1 000 
P72 .. 00 
110.00 
PGy6300 
7909'zOO 
PG 
~ x x.. oo 
00 
Antiang inal therapy 
Double outlet left ventride 
Partial anomalous pulmonary venous return 
Double aortic arch 
Heart failure screen 
New Vone Heart Assoc classification heart failure symptoms 
Congenital malformation of aortic and m itral valves unsp 
HID: Heart failure in last yea 
Pulmonary arterio -venous fIStula 
Col19enital malforms of cardiac chambers+connections unsp 
Primary dosure of defect of atrioventricular septum NEC 
Referral to heart failure d inic 
Congenital left ventricular divertiOJlum 
Postductal aortic stenosis 
Analrysm of sinus of Valsalva 
Endocardial cushion defects NOS 
KommereJrs diverticulum 
Congenital coronary aneurysm 
ductus arteriosus 
C o ~ J J ma!fonnztIDn 
SIJCD5SIuI resusotabon 
Assoc21Jon das:sdic:a1Jon - das:s 
PS01.11 
7936200 
PS21.00 
P74z200 
GS70200 
PS44.00 
P74z800 
P741.00 
G211100 
7907200 
P6y5100 
7936100 
P73y.OO 
P60z1 00 
P6y7.00 
388E.00 
327Z.00 
7936800 
PSSy.OO 
PGy4z00 
GyuSaOO 
P722400 
PSz..OO 
PSSz.OO 
P734.00 
P601000 
y.OO 
562000 
l.R3P.OO 
GS58.00 
7AOOOOO 
Aortopulmonary window 
Maintenance of battery of intravenous card iac pacemaker syst 
Pentalogy of Fallot 
Stenosis of inferior vena cava 
Paroxysmal junctional tachycardia 
Gerbode's defect 
Atresia of pulmonary vein 
Total anomalous pulmonary venous return - TAPVR 
Benign hypertensive heart disease with CCF 
Closure defect of interatrial septum using tissue graft NEC 
Congenital complete atrio-ventricular heart block 
Resiting of lead of intravenous pacemaker system 
Other specified anomaly of pulmonary artery 
Fallot's tri logy 
Myocardial bridge of coronary artery 
Canadian Cardiovascular Society dassification of angina 
ECG : supraventric. arryth. NOS 
I mplantation of intravenous triggered card iac pacem aker 
Other specified ostium secundum atrial septal defect 
Coronary artery anomaly NOS 
[X10the.r specified cardiac arrhythmias 
Supra-valvular aortic stenosis 
Heart bulb or septal dosure defects NOS 
Ostium secvndum atrial septal defect NOS 
Hypoplasia of the pulmonary artery 
HypoplaSia of pulmonary valve 
Other specified ventricular septal defect 
Common atrium 
OA$P al19ina score 
Cardiomyopathy in dISease EC 
Correction of persistent truncus artenosus 
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P72z100 
P541.00 
7905100 
14AJ.00 
P6S .. 00 
7906000 
7906yOO 
790SyOO 
90s .. 00 
ZR3P.ll 
P710.00 
38SF.OO 
G234.00 
P722z00 
P72241 
P640.00 
7903zOO 
GSSyOOO 
7909100 
PSS3.00 
P722100 
ZR37.00 
P7ILOO 
G572000 
6 
P!:>ly. 
P66 .• 00 
Congenital aneurysm of aorta 
I nterventricular septal defect 
Correct total anomal pulm venous connect to coronary sinus 
H/O: Angina in last year 
Congenita l mitral stenosis 
aose defect atrioventric septum using dual prosthetic patch 
Other specified d osure of defect of atrioventriaJlar septum 
Other specified d osure of defect of interventricular septum 
Atrial fibrillation monitoring administration 
UASP angina score 
Hypoplasia of aortic arch, unspecified 
Cardiovascular Umitations and Symptoms Profile angina score 
Hyperten heart&renal dis+both(congestv)heart and renal fa il 
Atresia or stenosis of aorta NOS 
Congenital stenosis of ascending aorta 
Congenital aortic valve insufficiency, unspecified 
Atrial inversion op for transposition of great vessels NOS 
Cardiomyopathy due to drugs and other external agents 
Closure defect of heart septum using pericardial patch Nee 
lutemba 
angina 
P6y4100 
PSly.OO 
P720.00 
7A02.00 
P722S00 
7903000 
G21z100 
7AOOyOO 
P52z.00 
P6S2 .00 
7A0 1300 
P730 .00 
9 ROO.00 
PS6 .. 00 
9hF .. 00 
P512.00 
P742.11 
P722300 
7936000 
9hH1.00 
7904yOO 
G5S7z00 
P6z1100 
G5S8200 
P712.12 
P737.00 
7A02yOO 
PSllzOO 
P50 1.12 
7902yOO 
P502.00 
Single coronary artery 
Other specified transposition of great vessels 
Anomaly of aorta, unspecified 
Transluminal operations on abnormality of great vessel 
Atresia of aorta 
Atrium reconstruction atrial patch for transpos great vessel 
Hypertensive heart disease NOS with CCF 
Open operation for combined abnormality of great vessels OS 
Tetralogy of Fallot NOS 
Parachute deformity of the mitral valve 
Revision of correction of patent ductus arteriosus 
Pulmonary artery anomaly, unspecified 
Transfer of care from paediatric congenital heart service 
Endocardial cushion defects 
Exception reporting : atrial fibrillation quality ind icators 
Corrected great vessel transpOSit ion 
Anomalous termination of r ight pulmonary vein 
Stricture of aorta 
Implantation complex two wire intravenous cardiac pacemaker 
Excepted heart failure quality indicators: Informed d issent 
Other correction of transposition of great vessels OS 
Nutritional and metabolic cardiomyopathy NOS 
Anomalous ventricular bands 
Dystrophic cardiomyopathy 
Postductal interruption of aorta 
Pulmonary artery aneurysm 
Transluminal operation on abnormality of great vessel OS 
Double outlet right ventride NOS 
Aortic:opulmonary se.ptal defect 
Other speafied correcbon of tetralogy of Fallot 
Persistent trullOJS arteriosus 
288 
SPI I 11 I 
PSy . . OO 
P721000 
790 7yOO 
7908200 
P542.00 
P731.00 
P6yyI00 
P6ySOOO 
P722.00 
SPIll00 
G552.00 
G55401 
P74 1ZOO 
P65 .. 11 
P6yySOO 
P603.11 
7903100 
9r-l6T.OO 
P611.oo 
7903yOO 
P6y6 
pn 
P510.oo 
P6OO.00 
GS72100 
Heart fa ilure as a complication of care 
Other heart bulb and septal closure defect 
Anomalous orig in of t he aortic arch 
Other specified d osure of defect of interatrial septum 
Oose defect interventricular septum using tissue graft NEC 
left ventride to right atrial communication 
Pulmonary artery agenesis 
Hypoplasia of card iac vein 
Congenital heart block, unspecified 
Atresia and stenosis of aorta 
Cardia.c insufficiency as a complication ot care 
Obscvre African cardiomyopathy 
Congestive obstructive cardiomyopathy 
Total anomalous pulmonary venous return NOS 
Duroz.iez's disease 
Congenital anomaly of myocardium 
Pseudotruncus arteriosus 
. m reconstruction atrial wall for transpos great vessels 
Referred by heart failure nurse specialist 
ngenital tricuspid stenosis 
or transpositio great vessels OS 
t.aevoc:aroia 
ao 
~ s e p p
nrnnramrne 
GSS8000 
7902300 
P60zz00 
P6ySzOO 
8HkO.00 
PS20 .12 
P6y6 .00 
P74z700 
P6y4000 
AAl z.OO 
P6y6I00 
P71 1.00 
90r4.00 
P6y6200 
7936COO 
66g .. 00 
PS50.13 
PSOO.OO 
P74z100 
G2 10100 
90r3.00 
7902100 
P51z.00 
P74ZZ00 
P651.oo 
P74z.00 
PS6zz00 
79n6200 
79'OSZOO 
P7 
7936JOO 
Card iomyopathy in Friedreich's ataxia 
Revision of correction of tetralogy of Fallot 
Other pulmonary valve anomaly NOS 
Congenital heart block NOS 
Referred to heart fa ilure education group 
Dextraposit ion of aorta in Fallot's tetralogy 
Heart and card iac apex malposit ion 
Transposit ion of pulmonary veins 
Congenital absence of coronary artery 
Vincent 's angina NOS 
Levocard ia 
Preductal coarctation of aorta 
Heart fa ilure monito ring second letter 
Mesocard ia 
Implantation of complex 1 wire intravenous card iac pacemaker 
Congenita l heart cond ition monitoring 
I nterauricular septal defect 
Absent septum between aorta and pulmonary artery 
Absence of superior vena cava 
Malignant hypertenSive heart disease with CCF 
Heart failure monitoring fi rst letter 
Correct Fallot tetralogy- right ventric outflow conduit NEC 
Great vessel transposition NOS 
Other great vein anomaly NOS 
Fused commissure of the mitral valve 
Other great vein anomalies 
EndocardIal cushion defects NOS 
Oosure defect atrioventricular septum using tissue graft 
Correcbon total anomalous pulmonary venous connection NOS 
Anomaly of the pulmonary veins, unspecified 
ImDlantat intravenous biventricular cardiac pacemaker system 
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9N4w.00 
662p.00 
7936HOO 
7936GOO 
P68 .. 00 
90rS.00 
90sO.00 
90s 1. 00 
90s2.00 
90s3.00 
90 s4 .00 
90r2.00 
90r1.00 
P721600 
P650.oo 
3281.00 
9hH .. 00 
8Hg8.oo 
7AOO.00 
GyuS 
P6y6zOO 
PS6 • . 
3296.00 
P60lzOO 
7qnc;nnn 
'lUAs.OO 
Did not attend heart fa ilure clinic 
Heart fa ilure 6 month review 
I mplantat intravenous dual chamber card iac pacemaker system 
I mplantat intraven single chamber card iac pacemaker system 
Congenital heart d isease 
Heart fa ilure monitoring third letter 
Atrial fibrillation monitoring fi rst letter 
Atrial fibrillation monitoring second letter 
Atrial fibriUation monitoring third letter 
Atrial fibrillation monitoring verbal invite 
Atrial fibrillation monitoring telephone irrvite 
Heart fa ilure monitoring verbal invite 
Heart failure monitoring telephone invite 
VasaJlar ring, aorta 
Congenital mitral stenosis, unspecified 
ECG: no ventricular arrhythmia 
Exception reporting: heart failure quality indicators 
Discharge from practice nurse heart failure d inic 
Open operations for cnmbined abnormality of great vessels 
[ X ] ~ ~ restrictive cardiomyopathy 
or cardiac apex malposibon NOS 
aacvein 
essd 
P6yyAOO 
679X.00 
GS7y200 
GS73S00 
P736.00 
GS73400 
7L1H800 
GSy4z00 
7936KOO 
7AOOzOO 
GS59.00 
P6y3z00 
GSS8z00 
P6y8.00 
ZRB1.00 
P6yyCOO 
GyuSROO 
PSO .. 12 
7A02z00 
P6y3.00 
7902200 
7UH700 
P744.00 
P61z.00 
P6Sz.00 
PSlz . l1 
P74z .11 
743.00 
Pyu2100 
56y.00 
74zOoo 
Hemicardia 
Heart fa ilure education 
Brugada syndrome 
Persistent atrial fibrillation 
Pulmonary arterio-venous aneurysm 
Permanent atrial fibrillation 
Chemical card ioversion 
Post cardiac operation heart fa ilu re NOS 
Implantation of intravenous cardiac pacemaker system NEC 
Open operation for combined abnormality of great vessels NOS 
Arrhythmogenic right ventricular cardiomyopathy 
Obstructive heart anomaly NEC NOS 
Cardiomyopathy in diseases EC, NOS 
Congenital dextroposit ion of heart 
Euroscore for ang ina 
Fusion of m itral valve cusps 
[X]Card iomyopathy in metabolic diseases CE 
Common truncus 
Transluminal operation on abnormality of great vessel NOS 
Obstructive heart anomaly NEC 
Correct Fallot tetralogy- right ventricular outflow patch 
Extemal ventricular defibrillation 
Portal vein - hepatic artery fistula 
Congenital tricuspid atresia or stenosis NOS 
Congenital mitral stenosis NOS 
Transposition of arterial trunk NEC 
Persistent left posterior cardinal vein 
Anomalous portal vein terminabon 
[X]Other cnngenital malformations of cardiac septa 
Other specified endocardial cushion defects 
Absence of inferior vena cava 
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Varicose veins 
medcode 
24S2.00 
7A66112 
7A69311 
GS3 .. 00 
GS30.00 
GS31.00 
GS32.00 
GS33 .00 
GS34.00 
GS34000 
GS34100 
GS3z.00 
GSS .. OO 
GSSV·OO 
GS5z.00 
GvuS600 
L41..11 
L410.00 
L410000 
L410100 
L410200 
L410300 
L410400 
L410S00 
L410600 
L410z00 
L411.11 
L411.12 
L411z00 
description 
O/E - varicose veins 
Subfascial ligation of varicose veins 
Babcock subcutaneous enucleation of varicose veins 
Varicose veins of the legs 
Varicose veins of the leg with ulcer 
Varicose veins of the leg with eczema 
Varicose veins of the leg with ulcer and eczema 
Varicose veins of the leg with rupture 
Varicose veins of leg without mention of complications 
Varicose veins of leg with long saphenous vein distribution 
Varicose veins of leg with short saphenous vein distribution 
Varicose veins of the leg NOS 
Other varicose veins 
Other specified varicose veins 
Other varicose veins NOS 
[X]Varlcose veins of other specified sites 
Varicose veins - obstetric 
Varicose veins of legs In preg n ncv and th pu rp rlum 
Varicose veins of legs In pregnancv/pu rp rlum unsp clrl d 
Varicose veins of legs In pregnancV/pu rp rlum - d liv red 
Varicose veins of legs In pregnancv/pu rp rlum -d I+p/n camp 
Varicose veins of legs In pregnancy/puerp rlum /n COmp 
Varicose veins of legs In pregnancv/pu rp rlum pin camp 
Varicose veins of legs In pregn ncv 
Varicose veins of legs In the puerp rium 
Varicose veins of legs In pregn ncV nd pu rp rlum NOS 
Perinea l obstetric varicose v Ins 
Vulval obstetric varlcos v Ins 
Varicose veins of perineum/vulva In pr 9n ncy/pu rp rlum NO 
Appendix 15: leD-10 codes for birth outcomes and multiple 
gestations 
Live and stillbirths birth outcomes 
leD-IO 
P95X 
Z370 
Z371 
Z372 
Z373 
Z374 
Z375 
Z376 
Z377 
Z380 
Z381 
Z382 
Z383 
Z384 
Z385 
Z386 
Z387 
P95 
Description 
Fetal death of unspecified cause 
Single live birth 
Single stillbirth 
Twins, both Ilveborn 
Twins, one liveborn and one sti llborn 
Twins, both stillborn 
Other multiple births, all IIveborn 
Other multiple births, some IIveborn 
Other multiple births, all stillborn 
Singleton, born In hospita l 
Singleton, born outside hospital 
Singleton , unspecified as to place of birth 
Twin, born In hospita l 
Twin, born outside hospital 
Twin, unspecified as to place of birth 
Other multiple, born in hospita l 
Other multiple, born outside hospital 
Fetal death of unspecified cause 
Miscarriages and terminations 0042 Medical abortion 
0043 Medical abortion 
leD-lO Desc.ription 0044 Medical abortion 
000 Ectopic pregnancy 0045 Medical abortion 
0000 Abdominal pregnancy 0046 Medical abortion 
0001 Tubal pregnancy 0047 Med ical abortion 
0002 Ovarian pregnancy 0048 Medical abortion 
0008 Other ectopic pregnancy 0049 Medical abortion 
0009 Ectopic pregnancy, unspecified 005 Other abortion 
001 Hydatidiform mole 0050 Other abortion 
0010 Oassical hydatidiform mole 0051 Other abortion 
0011 Incomplete and partial hydatidiform mole 0052 Other abortion 
0019 Hydatidiform mole, unspecified 0053 Other abortion 
002 Other abnormal products of conception 0054 Other abortion 
0020 Blighted ovum and nonhydatidiform mole 0055 Other abortion 
0028 Other spedfted abnormal products of c o ~ t i o n n 0056 Other abortion 
0029 Abnormal product of conception, unspeafied 0057 Other abortion 
003 Spontaneous abortion 0058 Other abortion 
0030 Spontaneous abortion 0059 Other abortion 
0031 Spontaneous abortion 006 Unspecified abortion 
0032 Spontaneous abortion 0060 Unspecified abortion 
0033 Sporuaneous abortion 0061 Unspecified abortion 
0034 Spontaneous abortJon 0062 Unspecified abortion 
0035 Spontaneous aborbon 0063 Unspecified abortion 
0036 Spontaneous abortion 0064 Unspecified abortion 
0037 Spontaneous aboroon 0065 Unspecified abortion 
0038 Spontaneous abortJon 0066 Unspecified abortion 
0039 SPOntaneous aborUon 0067 Unspecified abortion 
0068 Unspeofied abortion 
0069 Unspeafied abortion 
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Appendix 16: Codes used to extract mode of delivery 
OPCS4 
RI71 
RI72 
RI78 
R179 
R18! 
R182 
RI88 
R189 
R19l 
R198 
RI99 
Description 
Elective upper uterine segment caesarean delivery 
Elective lower ute rine segment caesarean delivery 
Other specified elective caesarean delivery 
Unspecified elective caesarean delivery 
Upper uterine segment caesarean delivery NEe 
Lower uterine segment caesarean delivery NEe 
Other specified other caesarean delivery 
Unspecified other cae5<lrean delivery 
Breech extraction delivery with version 
Other specified breech extraction delivery 
Unspecified breech extraction delivery 
RlOl Spontaneous breedl delivery 
Rl02 Assisted breech delivery 
Rl08 other specffied other breech deJivery 
Rl09 Unspecified other breech delivery 
R211 High 
R212 
R213 
R21 
R215 
R218 
R219 
Rn 
R222 
R223 
'28 
High 
n 
BY 
R231 
R232 
R238 
R239 
R249 
R25l 
R252 
R258 
Rl59 
Manipulative cephal ic vaginal delivery with abnormal presentation of 
head at delivery without instrument 
Non-manipulative cephal ic vag inal delivery with abnormal 
presentation of head at delivery without instrument 
Other specified cephal ic vaginal delivery w ith abnormal presentation 
of head at del ivery without instrument 
Unspecified cephal ic vaginal delivery with abnormal presentation of 
head at delivery without instrument 
All normal delivery 
Caesarean hysterectomy 
Destructive operation to facilitate delivery 
Other specified other methods of delivery 
Unspecified other methods of delivery 
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opes codes used to facilitate delivery 
OPCS 
R271 
R278 
R279 
R281 
R288 
R289 
R291 
R298 
R299 
R301 
R302 
R303 
R304 
R308 
R309 
R321 
R322 
R323 
R324 
R325 
R328 
R329 
R348 
R349 
Description 
OTHER OPERATIONS TO FACILITATE DELIVERY 
OTHER OPERATIONS TO FACILITATE DELIVERY 
OTHER OPERATIONS TO FACILITATE DELIVERY 
INSTRUMENTAL REMOVAL/PRODUCTS/CONCEPTION FROM 
DEL.UTERU 
INSTRUMENTAL REMOVAL/PRODUCTS/CONCEPTION FROM 
DEL.UTERU 
INSTRUMENTAL REMOVAL/PRODUCTS/CONCEPTION FROM 
DEL.UTERU 
MANUAL REMOVAL/PRODUCTS/CONCEPTION FROM 
DELIVERED UTERU 
MANUAL REMOVAL/PRODUCTS/CONCEPTION FROM 
DELIVERED UTERU 
MANUAL REMOVAL/PRODUCTS/CONCEPTION FROM 
DELIVERED UTERU 
OTHER OPERATIONS ON DELIVERED UTERUS 
OTHER OPERATIONS ON DELIVERED UTERUS 
OTHER OPERATIONS ON DELIVERED UTERUS 
OTHER OPERATIONS ON DELIVERED UTERUS 
OTHER OPERATIONS ON DELIVERED UTERUS 
OTHER OPERATIONS ON DELIVERED UTERUS 
REPAIR OF OBSTETRIC LACERATION 
REPAIR OF OBSTETRIC LACERATION 
REPAIR OF OBSTETRIC LACERATION 
REPAIR OF OBSTETRIC LACERATION 
REPAIR OF OBSTETRIC LACERATION 
REPAIR OF OBSTETRIC LACERATION 
REPAIR OF OBSTETRIC LACERATION 
OTHER OBSTETRIC OPERATIONS 
OTHER OBSTETRIC OPERATIONS 
Appendix 17: Characteristics of the studies included in t he systematic review 
and meta-analysis 
Author 
Sul tanJ6 
VikrusJ7 
O'CornnorJ8 
LiU12 
l acobsenJ2 
LindqvistJ9 
Sharma40 
Larsen41 
lames7 
HeltJ1 
Haggaz9 
Country Study 
period 
United 1987-
Kingdom 2004 
Denmark 1995-
2005 
United 2003-
States 2008 
Canada 1991-
2006 
Norway 1990-
2003 
Sweden 1990-
2005 
Australia 1999-
2006 
Denmark 1980-
United 
States 
United 
States 
Sudan 
2001 
2000-
2001 
1966-
1995 
1999-
2000 
Study design and methodologV 
Population based retrospective 
cohort. Cases were Identified using 
primary care data which were 
validated 
Population based retrospective 
cohort. Cases were Identified from 
national registry using lCD-10 codes. 
Cross sectional study. Cases were 
identified from a single hospital. 
Cross sectional study. Cases wer 
Identified using hospital discharge 
database using lCD-10 codes. 
Cross sectional study. Cas s w re 
Identified from patient and birth 
register. 
Cross sectional study. C s s w re 
Identified from a single hospl t I. 
Cross sectional study . C s s w r 
Identified from a slngl hospl t I. 
Cross sectional study. C w 
Identified from slngl county. 
Cross-section I tudy. C w 
Identified from n tlon I Inp tl n 
sample which cov r round 100 
hosplt Is using l CD- 10 cod 
to 
Registry was 
va lldat d (or VTE 
during 
pr gn ncy with 
PPV of mor 
than 80% 
VTE cas sw r 
obJ ctl v Iy 
confirm db d 
on dl gnostic 
t sts' 
rm 
d 
Lindqvist44 
McColl 45 
Anderson6 
James48 
Lyall 123 
Sweden 
United 
Kingdom 
Denmark 
United 
States 
190-
1993 
1985-
1996 
1984-
1994 
1989-
1994 
United 1999-
Kingdom 2007 
Cross sectional study . C s w r 
Identified from Swedish birth nd 
patient registry 
Cross sectional study . C s w r 
Identified using nation I h 
service data. 
Cross sectional study. C 
Identified using Inp t l n 
Ith 
Cross section I study . C s w 
Identified from slngl unl 
ur 
m 
Appendix 18: Read codes for hyperemesis 
readcode 
L13 .. 11 
L130.00 
L130000 
L13 .. 12 
L131.00 
L130z00 
L130200 
L131z00 
L131000 
L131200 
L130100 
description 
Hyperemesis gravidarum 
Mild hyperemesis gravidarum 
Mild hyperemesis unspecified 
Hyperemesis of pregnancy 
Hyperemesis gravidarum with metabolic disturbance 
Mild hyperemesis gravidarum NOS 
Mild hyperemesis-not delivered 
Hyperemesis gravidarum with metabolic disturbance NOS 
Hyperemesis gravidarum with metabolic d isturbance unsp 
Hyperemesis gravidarum with metabolic d isturbance - not del 
Mild hyperemesis-delivered 
Appendix 19: leD-IO codes for hyperemesis, acute systemic infection 
and antepartum haemorrhage 
Antepartum haemorrhage leD-IO codes 
leD-IO 
0460 
0468 
0469 
0200 
0208 
0209 
Description 
Antepartum haemorrhage with coagulation defect 
Other antepartum haemorrhage 
Antepartum haemorrhage, unspecified 
Threatened abortion 
Other haemorrhage In early pregnancy 
Haemorrhage in early pregnancy, unspecified 
Hyperemesis leD-IO codes 
leD-IO 
0210 
0211 
Description 
Mild hyperemesis gravidarum 
Hyperemesis gravidarum with metabolic disturb nc 
Acute systemic infection leD-IO codes 
leD-IO 
JIOO 
JI01 
JI08 
J110 
J111 
J118 
JI20 
JI21 
JI22 
JI28 
JI29 
JI3X 
J14X 
JI50 
JI51 
JI52 
JI53 
JI54 
JI55 
JI56 
J157 
J158 
JI59 
JI60 
J168 
J170 
J171 
JI72 
J173 
JI78 
JI80 
Description 
Influenza with pneumonia, Influenz virus Id ntlfl d 
Influenza with oth resp manifest Influenza virus Id ntln d 
Influenza with other manifest Influ nza virus Id ntln d 
Influenza with pneumonia, virus not Id ntlfl d 
Influenza with oth resp manlf station virus not Id ntln d 
Influenza with other m nlf st tlons, virus not Id ntlfl d 
Adenovlra l pneumonia 
Respiratory syncytia l virus pn umonl 
Paralnfluenza virus pn umonl 
Other viral pneumonia 
Viral pneumonia, unsp clfl d 
Pneumonia due to Str ptococcus pn umonl 
Pneumonia due to H mophllus Inf!u n 
Pneumonia due to Klebsl 11 pn umonl 
Pneumonia due to Ps udomon 
Pneumonl due to st phylococcu$ 
Pneumonia due to str ptococcus, roup B 
Pneumonia due to oth r str ptococcl 
Pneumonia due to Esch rich I coil 
Pneumonia du to oth r a roblc Gr m·n 
Pneumonia du to Mycopl srn pn umonl 
Other bacterial pn umonl 
Bacterial pn umonla, unsp cif! d 
Chlamydl I pn umonl 
Pneumonia du to oth r sp cif! d Inf tloy 0 
Pneumonia In viral dls as s cl 
Pneumonia In mycos s 
Pneumonia In par sltlc dls as 
Wed I 
J181 
J182 
J188 
J189 
J200 
J201 
)202 
J203 
J204 
J205 
)205 
)207 
]208 
J209 
)210 
)218 
)219 
J22X 
0851 
0852 
0853 
0230 
0231 
0232 
0233 
0234 
0235 
Lobar pneumonia, unspecified 
Hypostatic pneumonia, unspecified 
Other pneumonia, organism unspecified 
Pneumonia, unspeci fied 
Acute bronchitis due to Mycoplasma pneumonlae 
Acute bronchitis due to Haemophllus Influenzae 
Acute bronchitis due to streptococcus 
Acute bronchitis due to coxsacklevlrus 
Acute bronchitis due to paralnfluenza virus 
Acute bronchitis due to respiratory syncytia l virus 
Acute bronchitis due to rhinovirus 
Acute bronchitis due to echovirus 
Acute bronchitis due to other specified organisms 
Acute bronch itis, unspecified 
Acute bronchio litis due to respiratory syncytia l virus 
Acute bronchiolitis due to other specified organisms 
Acute bronchio litis, unspecified 
Unspecified acute lower respiratory Inf ctlon 
Other Infection of genital tract following delivery 
Urinary tract Infection following delivery 
Other genltourlnary tract Infections following d IIv ry 
Infections of kidney In pregnancy 
Infections of bladder In preg nancy 
Infect ions of urethra In pregn ncy 
Infections of other parts of urinary tract In pregn ncy 
Unspecified Infection of urinary tr et In pr gnancy 
Infect ions of the genita l tract In pregn ncy 
0239 Other and unspec genltourln ry tr ct Inf ct lon In p gn ncy 
N390 Urinary tract Infection, site not sp cif! d 
N300 Acute cystitis 
N301 Interstitial cystitis (chron ic) 
Other chronic cystitiS 
Trigonitis 
Irradiation cystitis 
Other cystit is 
Cystitis, unspecl fl d 
Acute tubulo-Int rstltl I n phrltls 
N302 
N303 
N304 
N308 
N309 
N10X 
N110 
Nll1 
N1l8 
N119 
N12X 
N340 
N341 
N342 
Nonobstructlve r flux -assocl d chronic py Ion phrltJ 
Chronic obstructlv py Ion phrltls 
Other chronic tubulo -Int rstltl I n phrltl 
Chronic tubulo-Interstltl I n phrltls, unsp cln d 
Tubulo-Interstltlal n phrltls not sp C 
Urethral abscess 
Nonspecific ur thrltls 
Other urethritis 
or hronl 
o 
Appendix 20: ICD-lO codes for medical co-morbidities 
ICD-lO codes for diabetes 
ICD-10 
EIOO 
EIOl 
EI02 
EI03 
EI04 
EIOS 
EI06 
EI07 
EIOS 
EI09 
Ell0 
Elll 
E112 
El13 
E1l4 
EllS 
E1l6 
E1l7 
EllS 
E119 
E120 
El2 
EI22 
EI23 
El2 
El25 
Description 
Insulin-dependent diabetes melJitus with coma 
Insulin-dependent d iabetes melJitus with ketoacidosis 
Insulin-dependent d iabetes melJitus with renal compl ications 
Insulin-dependent d iabetes melJitus with ophthalmic comps 
Insulin-dependent diabetes melJitus w ith neurological comps 
Insulin-dependent diabetes melJitus w ith periph circ comps 
Insulin-dependent d iabetes melJitus w ith other spec comps 
Insulin-dependent d iabetes melJitus w ith multiple comps 
Insulin-dependent d iabetes melJitus with unspec comps 
Insulin-dependent d iabetes mell itus without compl ications 
Non-insulin-dependent diabetes mellitus with coma 
Non-insulin-dependent diabetes mellitus w ith ketoacidosis 
Non-insulin-dependent diabetes mellitus w ith renal comps 
Non-insulin-dependent diabetes mellitus with ophthalm comps 
Non-insulin-dependent diabetes mellitus with neuro comps 
Non-insulin-depend diabetes mellitus with periph cire camp 
Non-insulin-depend diabetes mellitus with other spec comp 
Non-insulin-dependent diabetes mellitus with multiple comps 
on-insulin-dependent diabetes mellitus with unspec comps 
on-insulin-depend diabetes mellitus without complication 
ialnutrition-related diabetes mellitus with coma 
nutrition-related diabetes mellitus with ketoaddosis 
lnutrition-related diabetes mellitus with renal romps 
n-related diabetes mellitus with ophthalmic romps 
n-related diabetes meDitus with IleUro comps 
n-reIat diabetes meffitus with periph drc romp 
E126 
E127 
E12S 
E129 
E130 
E131 
E132 
E133 
E134 
E13S 
E136 
E137 
E13B 
E139 
E140 
E141 
E142 
E143 
El44 
E14S 
E146 
E147 
E14S 
E149 
0240 
0241 
0242 
0 243 
0244 
0249 
0244 
Malnutrit ion-relat diabetes mellitus with other spec comps 
Malnutrition-related diabetes mell itus with multiple comps 
Malnutrition-related diabetes mellitus with un spec comps 
Malnutrition-related diabetes mellitus without complications 
Other specified diabetes mellitus with coma 
Other specified diabetes mellitus with ketoacidosis 
Other specified diabetes mellitus with renal compl ications 
Other specified diabetes mellitus with ophthalmic comps 
Other specified d iabetes mellitus with neurological comps 
Other specified diabetes mellitus with periph circ comps 
Other specified diabetes mellitus with other spec comps 
Other specified d iabetes mellitus with multiple comps 
Other specified diabetes mellitus with unspecified comps 
Other specified d iabetes mellitus without complications 
Unspecified d iabetes mellitus with coma 
Unspecified diabetes mellitus with ketoacidosis 
UnspeCified d iabetes mell itus with renal compl ications 
Unspecified d iabetes mellitus with ophthalmic compl ications 
Unspecified diabetes mellitus with neurolog ical comps 
UnspeCified diabetes mellitus with periph Circulatory comps 
Unspecified diabetes mellitus with other specified comps 
UnspeCified diabetes mellitus with multiple compl ications 
Unspecified diabetes mellitus with unspecified compl ications 
Unspecified diabetes mellitus without complications 
Pre-existing diabetes mellitus, insulin-dependent 
Pre-existing diabetes mellitus, non-insulin-dependent 
Pre-existing malnutrition-related diabetes mellitus 
Pre-existing diabetes mell itus, unspecified 
Diabetes meJlitus arising in pregnancy 
Diabetes meJlitus in pregnancy, unspecified 
Gestational diabetes mellitus NOS 
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leD-10 codes for cardiac disease 
ICD-10 
1420 
1421 
1422 
1423 
1424 
1425 
1426 
1427 
1428 
1429 
1430 
1431 
1432 
1438 
1500 
150 
1509 
2 00 
120 
2. 
[2 
12 
Description 
Dilated card iomyopathy 
Obstructive hypertrophic cardiomyopathy 
Other hypertrophic cardiomyopathy 
Endomyocard ial (eosinophilic) d isease 
Endocardial fibroelastosis 
Other restrictive cardiomyopathy 
Alcoholic cardiomyopathy 
Cardiomyopathy due to drugs and other external agents 
Other cardiomyopathies 
Cardiomyopathy, unspectfied 
Cardiomyopathy in infectious & parasitic diseases CE 
Cardiomyopathy in metabolic diseases 
ed elsewhere 
documented spasm 
1221 Subsequent myocard ial infarction of inferior wall 
1228 Subsequent myocardial infarction of other sites 
1229 
1230 
1231 
1232 
1233 
1234 
1235 
1236 
1238 
1240 
1241 
1248 
1249 
1250 
1251 
1252 
1253 
1254 
1255 
1256 
1.258 
1259 
Q200 
Q20 1 
Q202 
Q203 
Q 
Q20S 
Q206 
Subsequent myocardial infarction of unspecified site 
Haemopericard ium as curr comp folow acut myocard infarct 
Atral sept defect as curr comp folow acut myocardal infarct 
Ventric sep defect as curr comp fol acut myocardal infarc 
Rup cardac wal withou haemopercard as cur comp fol ac MI 
Rup chordae tend inae as curr comp fol acut myocard infarct 
Rup papilary muscle as curr comp fol acute myocard infarct 
Thromb atrium/auric append/vent as curr comp foil acute MI 
Oth current comp following acute myocard ial infarction 
Coronary thrombosis not resulting in myocardial infarction 
Dressier's syndrome 
Other forms of acute ischaemic heart d isease 
Acute ischaemic heart disease, unspecified 
Atherosclerotic card iovascular d isease, so described 
Atherosclerotic he.art disease 
Old myocardial infarction 
Aneurysm of heart 
Coronary artery aneurysm 
Ischaemic cardiomyopathy 
Silent myocardial ischaemia 
Other forms of chronic ischaemic heart disease 
Chronic ischaemic heart disease, unspecified 
Common arterial trunk 
Double outlet right ventride 
Double outlet left ventricle 
Discordant ventriaJloarterial connection 
Double inlet ventnde 
Discordant atrioventriaJlar connection 
lsomensm of atnal appendages 
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Q208 Other cong malforms of cardiac chambers and connections Q246 Congenital heart block 
Q209 Cong malforms of cardiac chambers and connections unspec Q248 Other specified cong enital malformations of heart 
Q210 Ventricular septal defect Q249 Congenital malformation of heart, unspecified 
Q211 Atrial septal defect Q250 Patent ductus arteriosus 
Q212 Atrioventricular septal defect Q251 Coarctation of aorta 
Q213 Tetralogy of Fallot Q252 Atresia of aorta 
Q214 Aortopulmonary septal defect Q253 Stenosis of aorta 
Q218 Other congenital malformations of cardiac septa Q254 Other congenital malformations of aorta 
Q219 Congenital malformation of card iac septum, unspecified Q255 Atresia of pulmonary artery 
Q220 Pulmonary valve atresia Q256 Stenosis of pulmonary artery 
Q221 Congenital pulmonary valve stenosis Q257 Other congenital malformations of pulmonary artery 
Q222 Congenital pulmonary valve insufficiency Q258 Other congenital malformations of great arteries 
Q223 Other congenital malformations of pulmonary valve Q259 Congenital malformation of great arteries, unspecified 
Q224 Congenital tricusp id stenosis Q260 Congenital stenosis of vena cava 
Q225 Ebstein's anomaly Q261 Persistent left superior vena cava 
Q226 Hypoplastic right heart syndrome Q262 Total anomalous pulmonary venous connection 
Q228 Other congenital malformations of tricuspid valve Q263 Partial anomalous pulmonary venous connection 
Q229 Congenital malformation of tricuspid valve, unspecified Q264 Anomalous pulmonary venous connection, unspecified 
Q230 Congenital stenosis of aortic valve Q265 Anomalous portal venous connection 
Q231 Congenital insufficiency of aortic valve Q266 Portal vein-hepatic artery f istula 
Q232 Congenital mitral stenosis Q268 Other congenital malformations of great veins 
Q233 Congenital mitral insufficiency Q269 Congenital malformation of great vein, unspecified 
Q234 Hypoplastic left heart syndrome 148X Atrial fibrillation and flutter 
Q238 Other congenital malformations of aortic and mitral valves 1490 Ventricular fibrillation and flutter 
Q239 Congenital malformation of aortic and mitral valves unspec 1491 Atrial premature depolarization 
Q240 Dextrocardia 1492 Junctional premature depolarization 
Q241 Laevocard ia 1493 Ventricular premature depolarization 
Q242 Cor triatriatum 1494 Other and unspecified premature depolarization 
Q243 Pulmonary infundibular stenosis 1495 Sick sinus syndrome 
Q244 Congenital subaortic stenosis 1498 Other specified card iac arrhythmias 
Q245 Malformation of coronary vessels 1499 Card iac arrhythmia, unspecified 
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leD-10 codes for hypertension 
ICD-lO 
1110 
1119 
I120 
I129 
I130 
I131 
I132 
I139 
I1S0 
I151 
I152 
I1S8 
I1S9 
0100 
0101 
0102 
0103 
0104 
0109 
OUX 
013 
0140 
0141 
0142 
0149 
Description 
Hypertensive heart disease with (congestive) heart failure 
Hypertensive heart disease without (conges) heart failure 
Hypertensive renal disease with renal failure 
Hypertensive renal disease without renal failure 
Hypertens heart and renal dis with (conges) heart failure 
Hypertensive heart and renal disease with renal failure 
Hyper heart and renal dis both (cong) heart and renal fail 
Hypertensive heart and renal disease, unspeci fied 
Renovascular hypertension 
Hypertension secondary to other renal disorders 
Hypertension secondary to endocrine disorders 
Other secondary hypertension 
Secondary hypertension, unspecified 
Pre-exist essen hypertens comp preg childbirth and puerp 
Pre-exist hyperten heart dis comp preg childbth and puerp 
Pre-exist hyperten renal dis comp preg childbth and puerp 
Pre-exist hyperten heart renal dis comp preg chdbth/puerp 
Pre-exist sec hypertens comp preg childbth and puerprum 
Unspec pre-exist hypertens compl pregn childbth puerprum 
Pre-exist hypertens disorder with superimposed proteinuria 
Gest [pregnancy-induced] hypertens without sig proteinuria 
Moderate pre-eclampsia 
Severe pre-eclampsia 
HELLP syndrome 
Pre-eclampsia, unspecified 
leD-10 codes for IBD 
ICD-lO 
K500 
KS01 
KS08 
KS09 
KSlO 
KSll 
KS12 
KS13 
KS14 
KS1S 
KS18 
KS19 
Description 
Crohn's disease of small intestine 
Crohn's disease of large intestine 
Other Crohn's disease 
Crohn's disease, unspecified 
Ulcerative (chronic) enterocolitis 
Ulcerative (chronic) ileocolitis 
Ulcerative (chronic) proctitis 
Ulcerative (chronic) rectosigmoiditis 
Pseudopolyposls of colon 
Mucosal proctocolitis 
Other ulcerative colitis 
Ulcerative colitis, unspecified 
leD-10 codes for varicose veins 
ICD-lO 
1830 
1831 
1832 
1839 
0220 
Description 
Varicose veins of lower extremities with ulcer 
Varicose veins of lower extremities with inflammation 
Varicose veins low extremities with both ulcer and inflamm 
Varicose veins lower extremities without ulcer or inflamm 
Varicose veins of lower extremity in preg nancy 
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Appendix 21: leD-10 codes for delivery related complications 
Postpartum and intra-partum haemorrhage 
ICD-lO 
0720 
0721 
0722 
0723 
0670 
0678 
0679 
Description 
Third -stage haemorrhage 
Other immediate postpartum haemorrhage 
Delayed and secondary postpartum haemorrhage 
Postpartum coagulation defects 
Intrapartum haemorrhage with coagulation defect 
Other intrapartum haemorrhage 
Intrapartum haemorrhage, unspecified 
Eclampsia/pre-eclampsia 
ICD-I0 
0150 
0151 
0152 
0159 
011 
0140 
0141 
0149 
Description 
Eclampsia in pregnancy 
Eclampsia in labour 
Eclampsia in the puerperium 
Eclampsia, unspecified as to time period 
Pre-exist hypertens disorder with superimposed proteinuria 
Moderate pre-eclampsia 
Severe pre-eclampsia 
Pre-eclampsia, unspecified 
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